

MD/MS

MANDATORY ESSENTIALS

For Amrita Postgraduate Medical Students

BASIC LIFE SUPPORT • ADVANCED CARDIAC LIFE SUPPORT

GOOD CLINICAL PRACTICE • GOOD LABORATORY PRACTICE

RESEARCH METHODOLOGY & BIOSTATISTICS

A focused guide for mandatory postgraduate competencies





AMRITA
VISHWA VIDYAPEETHAM
DEEMED TO BE UNIVERSITY UNDER SECTION 3 OF UGC ACT, 1956

**SCHOOL OF
MEDICINE**



MD/MS MANDATORY ESSENTIALS

For Amrita Postgraduate Medical Students

BASIC LIFE SUPPORT • ADVANCED CARDIAC LIFE SUPPORT
GOOD CLINICAL PRACTICE • GOOD LABORATORY PRACTICE
RESEARCH METHODOLOGY & BIostatISTICS

Authors and Editors



Dr Gireesh Kumar K. P.

Principal, Amrita School of Medicine
Head and Professor, Emergency Medicine



Dr Sajitha Krishnan

Professor
Department of Biochemistry, School of Medicine,
Kochi



Dr Princy Louis Palatty

Head and Professor
Department of Pharmacology, School of Medicine,
Kochi



**Dr Anagani Hrushikesh
Yadav, PhD**

AHA Training Centre Faculty
Emergency Medicine, AIMS Kochi



Dr Arun Vivek Kochan

Utilization Review Medical Officer
and Academic Quality
Principal Office, AIMS Kochi



Ms Anusree

Biostatistician
Biostatistics, AIMS Kochi



Ms Devika

Biostatistician
Biostatistics, AIMS Kochi

NMC Mandate for Postgraduate Students

Regulatory basis

The National Medical Commission Post-Graduate Medical Education Regulations 2023, Chapter V, Regulation 5.2, prescribe common training requirements for postgraduate medical students alongside specialty-specific academic and clinical training.

Operative wording of Regulation 5.2 (xi)-(xiii)

(xi) Course in Research Methodology

- All post-graduate students shall complete an online course in Research Methodology.
- Students shall register on the portal of the designated training institutions and are expected to complete the course in the first year.
- The online certificate generated after successful completion of the course and examination is acceptable evidence; this certification is mandatory for eligibility to appear in the final examination.

(xii) Course in Ethics

- All post-graduate students shall complete a course in ethics, including Good Clinical Practices and Good Laboratory Practices, whichever is relevant to them, conducted by the institution or University.
- The course is expected to be completed in the first year. No post-graduate student shall be permitted to appear in the examination without certification.

(xiii) Course in Cardiac Life Support Skills

- All post-graduate students shall complete a course in Basic Cardiac Life Support (BCLS) and Advanced Cardiac Life Support (ACLS) skills conducted by the institution.
- The course is expected to be completed in the first year. No post-graduate student shall be permitted to appear in the examination without certification.

Editorial note

Biostatistics is included in this book as an essential analytical component of Research Methodology; it is not listed as a separate certified course in these clauses.

Foreword

Postgraduate medical education requires more than mastery of a specialty. The final MD/MS examination also expects candidates to understand the ethical, scientific, laboratory and emergency-care principles that support safe clinical practice. This book brings those essential areas together in one focused resource for Amrita postgraduate medical students.

The chapters begin with Basic Life Support and Advanced Cardiac Life Support, followed by Good Clinical Practice, Good Laboratory Practice, research methodology and biostatistics. These subjects may appear separate, yet they meet in everyday patient care. Structured resuscitation skills help teams respond effectively when minutes matter; ethical conduct protects participants and patients; reliable laboratory systems protect the validity of clinical decisions; and research methods and statistics help clinicians interpret evidence.

The material is arranged for examination-oriented study without losing its practical purpose. Core concepts, algorithms, tables, process charts, common pitfalls and rapid-revision points help readers move from understanding to recall and application. Candidates can use the book for systematic preparation, focused revision before the final examination and reinforcement of principles relevant to ward, laboratory, research and emergency settings.

It is hoped that this volume will support confident examination performance while strengthening the habits of responsible, evidence-based and patient-centred practice expected of every postgraduate medical professional.

Editorial Team

Amrita School of Medicine, Kochi

About the Book

MD/MS Mandatory Essentials is a concise, integrated study guide developed for postgraduate medical students completing the common training and certification requirements associated with their MD/MS programme and final examination. It consolidates cross-cutting competencies that complement specialty knowledge and support safe, ethical and scientifically sound medical practice.

- **Basic Life Support and Advanced Cardiac Life Support**

systematic assessment, high-quality cardiopulmonary resuscitation, rhythm-based algorithms, defibrillation, emergency drugs, teamwork and post-resuscitation priorities.

- **Good Clinical Practice**

ethical principles, informed consent, participant safety, documentation, protocol compliance and responsible conduct of clinical research.

- **Good Laboratory Practice**

quality systems, standard operating procedures, sample integrity, equipment control, biosafety, documentation and dependable laboratory results.

- **Research Methodology and Biostatistics**

study designs, bias, data collection, statistical reasoning, selection of tests, interpretation of results and critical appraisal of medical evidence.

Designed for both structured learning and rapid revision, the book uses clear explanations, comparison tables, algorithms, quick-reference summaries and examination-focused guidance. Readers may study it chapter by chapter or use individual sections to revise a specific competency before theory, practical or viva-voce assessment.

Contents

Section	Page
Authors and Editors	2
NMC Mandate for Postgraduate Students	3
Foreword	4
About the Book	5
Chapter 1 Advanced Cardiac Life Support	9
Chapter 2 Good Clinical Practice	71
Chapter 3 Good Clinical Laboratory Practice	98
Chapter 4 Basics of Clinical Research	126
Chapter 5 Biostatistics	157
Index	194

Page numbers exclude the front cover and follow the continuous digital edition.

MD/MS MANDATORY ESSENTIALS

A Concise Study Guide for Medical & Nursing Students and Clinicians

Basic Life Support • Advanced Cardiac Life Support
Good Clinical Practice • Good Laboratory Practice • Research Methodology & Biostatistics

Amrita School of Medicine

TABLE OF CONTENTS

- Chapter 1 — Advanced Cardiac Life Support (ACLS)**
- Chapter 2 — Good Clinical Practice (GCP)**
- Chapter 3 — Good Clinical Laboratory Practice (GCLP)**
- Chapter 4 — Basics of Clinical Research**
- Chapter 5 — Biostatistics**

How to use this book: Each chapter follows a consistent structure — core concepts, classification/comparison tables, drug or process charts, at least one flow diagram for the chapter's key algorithm or pathway, a "Common Pitfalls" box, and a closing quick-reference box for rapid revision before exams or practice.

Amrita School of Medicine

CHAPTER 1 — ADVANCED CARDIAC LIFE SUPPORT (ACLS)

Introduction and the Chain of Survival

Advanced Cardiac Life Support, commonly abbreviated ACLS, is a systematic, evidence-based framework for recognizing and treating life-threatening cardiovascular emergencies, most notably cardiac arrest, symptomatic bradycardia, and unstable tachycardia. Built upon the foundation of Basic Life Support, ACLS integrates high-quality cardiopulmonary resuscitation with advanced airway management, rhythm recognition, electrical therapy, pharmacologic intervention, and post-resuscitation care. This chapter follows the 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, the framework used in virtually all accredited ACLS certification courses and clinical practice in the United States. The 2025 update introduced a substantial structural change: the historical split between an Out-of-Hospital Cardiac Arrest (OHCA) chain and an In-Hospital Cardiac Arrest (IHCA) chain has been retired in favour of one unified, six-link Chain of Survival that applies across adult and paediatric patients and across every care setting.

Survival from cardiac arrest depends on the rapid, coordinated execution of a sequence of time-critical actions known as the Chain of Survival. Beginning with the 2025 American Heart Association Guidelines, the Chain of Survival is unified into a single six-link sequence that applies whether the arrest occurs in the community or inside a hospital, and whether the patient is an adult or a child — replacing the previous model of two parallel, setting-specific chains. Every minute without defibrillation or effective CPR decreases the probability of survival with good neurological outcome by roughly seven to ten percent when no bystander CPR is performed, making early recognition and action the single greatest determinant of outcome regardless of setting.

Link	What it means
1	Recognition and Emergency Activation of EMS — recognizing cardiac arrest (or, in hospital, a deteriorating patient) and immediately activating the emergency response system or code team.
2	High-Quality CPR — early, continuous, high-quality chest compressions with minimal interruption, started by whoever is present, lay rescuer or healthcare provider.
3	Defibrillation — rapid rhythm assessment and early defibrillation of a shockable rhythm, using a public-access AED or a hospital defibrillator as soon as one is available.
4	Advanced Resuscitation — ACLS-level care layered on top of BLS: advanced airway management, IV/IO drug therapy, and treatment of reversible causes by trained providers.
5	Post-Cardiac Arrest Care — structured critical care after return of spontaneous circulation (ROSC), including haemodynamic optimisation, targeted temperature management, and early diagnostic evaluation.
6	Recovery and Survivorship — a link new to the unified chain, formally recognising physical, cognitive, emotional, and social recovery, rehabilitation, and long-term follow-up for survivors and their families.

Unifying the chain reflects a change in emphasis rather than a change in the underlying science: every arrest, wherever it occurs, still depends on the same weakest-link principle — a delay or failure at any single step substantially reduces the likelihood of survival to hospital discharge with

favourable neurological function. What changes under the unified model is that hospital teams are now explicitly held to the same recognition-to-defibrillation urgency as out-of-hospital responders, and out-of-hospital systems are expected to extend their responsibility through recovery and survivorship rather than considering their role complete at hospital handover. The addition of Recovery and Survivorship as a formal sixth link reflects growing recognition that outcomes are not fully determined at ROSC or at hospital discharge, and that structured rehabilitation and follow-up meaningfully affect a survivor's long-term function and quality of life.

Epidemiologically, cardiac arrest remains one of the leading causes of death in industrialized nations. In the United States, well over 350,000 out-of-hospital cardiac arrests and roughly 290,000 in-hospital cardiac arrests are treated by emergency medical services and hospital code teams each year. Survival to hospital discharge for out-of-hospital arrest historically hovers around 10 percent overall, but rises dramatically — often to 30 to 45 percent — when the arrest is witnessed, an initial shockable rhythm is present, and bystander CPR and early defibrillation occur promptly. In-hospital arrest survival to discharge is somewhat higher, generally 20 to 25 percent, reflecting continuous monitoring and immediate access to trained personnel and equipment. These statistics underscore why every provider, not just specialists, must be fluent in the Chain of Survival: laypeople and first responders control the earliest, most time-sensitive links, while hospital-based providers control the links that determine long-term neurological recovery.

ACLS training exists because outcomes from cardiac arrest are exquisitely time-dependent and protocol-driven. Unlike many areas of medicine where a single expert can deliberate over the best course of action, resuscitation succeeds through rapid, algorithmic, team-based execution of well-rehearsed steps performed simultaneously by multiple providers. This chapter presents each component of that system in turn — basic life support mechanics, the systematic ACLS assessment, rhythm recognition, electrical and pharmacologic therapy, reversible-cause identification, the bradycardia and tachycardia algorithms, post-arrest care, airway management, special populations, and team dynamics — but in practice these elements are executed concurrently by a coordinated team, not as an isolated checklist performed by one person.

Because certification examinations frequently test the precise sequence and terminology used by the American Heart Association, students should be comfortable distinguishing the vocabulary used across this chapter: BLS refers to the foundational skills of recognition, compressions, ventilation, and AED use, performed by both laypersons and healthcare providers; ACLS layers advanced airway management, rhythm interpretation, IV/IO pharmacology, and electrical therapy on top of BLS and is performed by trained healthcare providers; and post-cardiac-arrest care refers specifically to the structured critical care management that begins once ROSC is achieved. Understanding this hierarchy clarifies why BLS skills are never abandoned once ACLS providers arrive on scene — rather, high-quality compressions and ventilation, the core BLS skills, remain the foundation upon which every subsequent ACLS intervention is built.

BLS Primary Assessment and High-Quality CPR

Adult* BLS in 5 Steps

Healthcare provider • one glance, one sequence

NUMBERS TO REMEMBER

10 s

max pulse check

30 : 2

compressions : breaths

1 / 6 s

rescue breath (10/min)

2 min

CPR before each rhythm check

1

SAFE

Scene safe?

2

CALL

Unresponsive → shout for help, activate EMS

Send someone for the AED / defibrillator

3

CHECK

Breathing + pulse together, ≤ 10 s**NORMAL + PULSE**

Monitor till advanced care arrives

ABNORMAL + PULSE

1 breath / 6 s • pulse check every 2 min • opioid? → naloxone

NONE / GASPING, NO PULSE

Start CPR ▼

4

CPR

30 : 2 • attach AED as soon as it arrives

Suspected opioid overdose → consider naloxone

5

AED

Rhythm check

SHOCKABLE

1 shock → CPR 2 min

NOT SHOCKABLE

CPR 2 min

↻ Repeat every 2 min until ALS team takes over or the person moves

DON'T MISS IN THE EXAM

- Pulse not **definitely** felt within 10 s → treat as no pulse, start CPR.
- Gasping is **not** normal breathing.
- After a shock, resume CPR **immediately** — no pulse check.
- Keep going until ALS arrives or the person starts to move.

* Signs of puberty → treat as adult

Redrawn from the 2025 AHA Guidelines for CPR & ECC

Figure — Adult Basic Life Support: revision card (adapted from the 2025 AHA Guidelines)

rescuer first ensures scene safety, then checks for responsiveness by tapping and shouting. If the patient is unresponsive, the rescuer simultaneously assesses for absent or abnormal breathing

(agonal gasps count as absent breathing) and palpates a carotid pulse for no more than ten seconds. If no definite pulse is felt within that window, or if there is uncertainty, the rescuer must assume cardiac arrest and begin chest compressions immediately. Activation of the emergency response system and retrieval of a defibrillator/AED should occur in parallel with, not before, the start of compressions whenever a second rescuer or means of activation (such as a mobile phone) is available.

The quality of CPR delivered is the single most modifiable determinant of outcome in cardiac arrest and is emphasized heavily on certification examinations. High-quality CPR requires attention to rate, depth, recoil, minimization of interruptions, and avoidance of excessive ventilation.

The physiology underlying these targets is straightforward but critical to understand rather than simply memorize. Chest compressions generate forward blood flow through a combination of direct cardiac compression and generalized intrathoracic pressure changes; even optimally performed compressions typically produce only 25 to 33 percent of normal cardiac output. Compression rates below 100 per minute or depths shallower than 5 cm generate inadequate coronary and cerebral perfusion pressure, while rates faster than 120 per minute do not allow adequate time for the chest wall and ventricles to recoil and refill between compressions, likewise reducing forward flow. Full chest recoil is essential because incomplete recoil (leaning on the chest) sustains intrathoracic pressure and impairs venous return to the heart during the relaxation phase, meaningfully lowering coronary perfusion pressure over the course of a resuscitation. Every pause in compressions, even a brief one, causes coronary perfusion pressure to fall rapidly, and it takes multiple subsequent compressions to rebuild that pressure back to its prior level — which is why minimizing the frequency and duration of interruptions has as much impact on outcome as the compressions themselves.

Providers should also be alert to signs of fatigue, which begins to degrade compression depth and rate within about two minutes even when the compressor feels capable of continuing; this is the physiologic basis for the recommended two-minute rotation schedule. Feedback devices, when available, that provide real-time audio or visual guidance on rate and depth have been shown to improve CPR quality and are increasingly used in both training and clinical settings. Mechanical CPR devices may be considered in specific circumstances, such as prolonged resuscitation or transport, where manual compressions cannot be sustained safely, though they have not been shown to improve outcomes over well-performed manual CPR in routine use.

- Compression rate: 100 to 120 compressions per minute, maintained throughout the resuscitation.
- Compression depth: at least 2 inches (5 cm) in adults, but not exceeding 2.4 inches (6 cm), delivered on a firm surface.
- Allow complete chest wall recoil between compressions; do not lean on the chest.
- Minimize interruptions in compressions; keep pauses under 10 seconds whenever possible, and target a chest compression fraction greater than 60 percent, ideally above 80 percent.
- Avoid excessive ventilation — deliver breaths just enough to produce visible chest rise, roughly 1 second per breath.

- Compression-to-ventilation ratio of 30:2 for a single rescuer or two-rescuer CPR without an advanced airway, regardless of patient age (adult BLS).
- Once an advanced airway (endotracheal tube or supraglottic device) is in place, compressions become continuous at 100 to 120 per minute with asynchronous ventilations delivered every 6 seconds (10 breaths per minute), without pausing compressions for breaths.
- Rotate the compressor role every 2 minutes (or sooner if fatigued) to prevent degradation in compression quality, ideally during a scheduled rhythm check to avoid additional interruption.
- Use an Automated External Defibrillator (AED) as soon as it is available: apply pads, allow the device to analyze the rhythm, clear the patient, and deliver a shock if advised, resuming compressions immediately afterward.

The AED deserves specific attention because it is frequently the only tool available to a lay rescuer before EMS arrival, and its design deliberately removes the need for rhythm interpretation skill from the operator. Once pads are applied to the bare chest in the positions indicated by the diagram on the pads themselves (or the anterolateral position if unlabeled), the device analyzes the rhythm automatically and will only permit a shock to be delivered if it detects a shockable rhythm; if it detects a non-shockable rhythm, it will advise 'no shock indicated' and prompt the rescuer to resume CPR immediately. This built-in safety feature means that AEDs cannot be used to inappropriately shock a non-shockable rhythm, which is why their use is encouraged even by minimally trained bystanders and is a core, non-negotiable link in the out-of-hospital Chain of Survival. Special AED considerations include using pediatric pads/dose-attenuating systems when available for children under 8 years or under 25 kg, quickly drying the chest if the patient is wet, and removing (not shaving around, unless it interferes with pad contact) transdermal medication patches before pad placement.

High-Quality CPR — Core Metrics

1. Rate 100-120/min
2. Depth at least 2 inches (5 cm), not over 2.4 inches (6 cm)
3. Full chest recoil after every compression
4. Minimize interruptions; pauses under 10 seconds
5. Avoid excessive ventilation (visible chest rise only)
6. 30:2 ratio without advanced airway; continuous compressions with 1 breath/6 sec once an advanced airway is placed

The ACLS Systematic Approach

Once BLS is underway, ACLS providers layer a systematic assessment on top of ongoing resuscitation. This begins with the Primary Survey, an ABCDE framework that identifies and treats immediately life-threatening problems in priority order, followed, when time and clinical circumstance permit, by a Secondary Survey that gathers focused history and searches for reversible causes.

The ABCDE framework is deliberately ordered by the speed with which each category of problem can kill the patient: an obstructed airway causes death within minutes, inadequate breathing shortly thereafter, and circulatory collapse can be immediate, whereas disability and exposure findings, while important, are rarely as acutely lethal. This ordering means that if a life-threatening problem is identified at any step, it should be corrected before moving to the next letter — for example, an obstructed airway is cleared before assessing breathing, and a tension pneumothorax identified during the breathing assessment is decompressed before proceeding further. In cardiac arrest specifically, the primary survey is performed continuously and iteratively alongside CPR, rather than as a discrete one-time assessment performed before treatment begins.

Primary survey element	Key actions
A — Airway	Assess patency; open the airway using head-tilt/chin-lift or jaw thrust if trauma suspected; consider basic or advanced airway adjunct as needed.
B — Breathing	Assess ventilation and oxygenation; give supplemental oxygen; monitor with pulse oximetry and waveform capnography; avoid hyperventilation.
C — Circulation	Monitor CPR quality and rhythm; establish IV/IO access; give indicated drugs and fluids; identify and treat hemorrhage or shock.
D — Disability	Perform a rapid neurologic assessment (level of consciousness, pupils, gross deficits, blood glucose check).
E — Exposure	Fully expose the patient to identify trauma, bleeding, rash, track marks, medical alert jewelry, or signs suggesting a specific etiology.

Primary Survey in Detail

A — Airway. Confirm the airway is patent and will remain so: look inside the mouth for blood, vomitus, a foreign body or loose dentures, and listen for stridor or gurgling. A patient speaking normally has, by definition, a patent airway. Open the airway with head-tilt/chin-lift in a patient without suspected trauma, or jaw-thrust if cervical spine injury is a concern. If positioning alone is insufficient, insert a basic adjunct — an oropharyngeal airway in an unconscious patient with no gag reflex, or a nasopharyngeal airway in a more responsive patient — and escalate to a supraglottic device or endotracheal intubation when basic measures fail or definitive airway protection is needed.

B — Breathing. Assess rate, depth, symmetry and effort of breathing; expose the chest to look for paradoxical movement, and auscultate for equal, bilateral breath sounds. Apply supplemental oxygen and monitor continuously with pulse oximetry; once an advanced airway is placed, confirm and continuously monitor it with waveform capnography. Actively look for and treat immediately life-threatening breathing problems — tension pneumothorax, massive haemothorax, flail chest — before moving on. Avoid excessive ventilation rate or volume during CPR, since hyperventilation raises intrathoracic pressure, reduces venous return, and measurably worsens coronary and cerebral perfusion.

C — Circulation. Palpate a central pulse, monitor cardiac rhythm continuously, and assess skin colour, temperature and capillary refill as bedside markers of perfusion. In arrest, this step means

monitoring the quality of ongoing chest compressions (rate, depth, recoil, minimal interruption) and the rhythm displayed on the monitor. Establish IV or IO access without delaying compressions, control any visible haemorrhage, and give indicated fluids, blood products or vasoactive drugs. In a perfusing patient, obtain a blood pressure and 12-lead ECG as part of this step.

D — Disability. Perform a rapid neurologic assessment: level of consciousness (AVPU or GCS), pupillary size and reactivity, gross focal motor deficits, and a bedside glucose check, since hypoglycaemia is a rapidly reversible cause of altered consciousness that is easy to miss under time pressure. In the post-arrest patient, disability assessment also flags a clinical seizure or a persistently unresponsive patient who requires EEG evaluation.

E — Exposure. Fully expose the patient (while maintaining dignity and preventing heat loss) to look for trauma, external haemorrhage, rash, needle marks, a medical-alert bracelet, or an implanted device pocket that might identify a specific cause. Exposure also includes a core temperature check, since unrecognised hypothermia changes the entire resuscitation approach, and inspection for signs pointing to a toxidrome or an occult injury sustained during the collapse itself.

The Secondary Survey focuses on obtaining a focused history and physical, and on actively searching for and treating underlying causes of arrest or hemodynamic instability. History is efficiently obtained using the SAMPLE mnemonic, typically gathered from family, EMS personnel, or the medical record while resuscitation continues.

SAMPLE element	Information sought
S — Signs and symptoms	What symptoms preceded the event (chest pain, dyspnea, palpitations, syncope)?
A — Allergies	Known drug or other allergies.
M — Medications	Current medications, including anticoagulants, antiarrhythmics, insulin, and recreational or illicit substances.
P — Past medical history	Prior cardiac disease, diabetes, renal disease, prior arrests, implanted devices.
L — Last oral intake	Relevant for airway management and aspiration risk.
E — Events	Events leading up to the arrest or emergency, including witnessed collapse, downtime, and bystander CPR.

Integrated throughout the secondary survey is the search for reversible causes of arrest, traditionally organized as the H's and T's, which is previewed here and detailed fully later in this chapter. Systematically considering these causes during every arrest — particularly during the non-shockable rhythm pathway — differentiates a resuscitation attempt that merely follows the algorithm from one that gives the patient a genuine chance at survival, since electrical therapy and epinephrine alone cannot correct an underlying tension pneumothorax, tamponade, or profound hyperkalemia.

It is worth emphasizing the distinction between the primary and secondary surveys as a matter of timing and priority rather than strict sequence: in a witnessed cardiac arrest, the primary survey's life-saving interventions (compressions, defibrillation, airway support) always take precedence and begin immediately, while secondary-survey elements such as detailed history-taking are woven in opportunistically as additional providers arrive and information becomes available, rather than

delaying resuscitation until a complete history is obtained. In a peri-arrest patient who is still responsive with a pulse — for example, someone with unstable bradycardia or tachycardia rather than full arrest — the two surveys are often performed nearly simultaneously by different team members, since there is more opportunity to gather history and perform a physical examination without interrupting life-saving compressions.

Cardiac Arrest Rhythms: Shockable vs Non-Shockable

All cardiac arrest rhythms are classified into two categories that determine the immediate treatment pathway: shockable rhythms, which respond to defibrillation, and non-shockable rhythms, which do not. Correct, rapid rhythm identification at each rhythm check is therefore the pivotal decision point of the Cardiac Arrest Algorithm.

Ventricular fibrillation arises when multiple re-entrant electrical wavelets circulate chaotically through the ventricular myocardium, most often triggered by acute myocardial ischemia or infarction, structural heart disease, severe electrolyte derangement, or inherited channelopathies. Because there is no coordinated depolarization wavefront, the ventricles quiver rather than contract, and cardiac output falls to zero almost instantly. Pulseless ventricular tachycardia, in contrast, still involves an organized (though abnormal) depolarization sequence originating from a single ventricular focus or re-entrant circuit, producing a wide, rapid QRS complex; whether it generates a pulse depends on the rate and the heart's mechanical reserve, and when it does not, it is treated identically to VF. Both rhythms respond to defibrillation because a sufficiently large shock depolarizes the entire myocardium simultaneously, extinguishing the abnormal circuits and creating a brief period of electrical silence from which the sinoatrial node, as the fastest intrinsic pacemaker, can resume control.

Pulseless electrical activity and asystole, by contrast, do not arise from a primary electrical malfunction that a shock can correct; rather, they typically reflect a failure of the heart to generate adequate mechanical contraction despite (in PEA) organized electrical activity, or complete absence of electrical activity altogether (asystole), usually as the end stage of prolonged hypoxia, severe metabolic derangement, or a mechanical/obstructive process such as tamponade or tension pneumothorax. Delivering a shock to these rhythms provides no benefit and only delays effective therapy — namely, high-quality CPR, epinephrine, and correction of the underlying reversible cause. This distinction is the conceptual foundation for why the Cardiac Arrest Algorithm splits into two separate pathways immediately after the first rhythm check.

Rhythm	Category	Mechanism	Key ECG features
Ventricular fibrillation (VF)	Shockable	Chaotic, disorganized ventricular electrical activity with no coordinated contraction or cardiac output	No identifiable P waves, QRS, or T waves; irregular undulating baseline of varying amplitude
Pulseless ventricular tachycardia (pVT)	Shockable	Rapid, organized ventricular depolarization without effective mechanical contraction/pulse	Wide QRS complexes (>0.12 sec) at a rapid, often regular rate, no discernible pulse on palpation

Rhythm	Category	Mechanism	Key ECG features
Pulseless electrical activity (PEA)	Non-shockable	Organized electrical activity on the monitor without a palpable pulse; caused by an underlying reversible condition	Variable — may appear narrow or wide, normal-looking or bizarre; defined by absence of pulse despite organized rhythm
Asystole	Non-shockable	Complete absence of ventricular electrical activity	Flat line; must confirm in a second lead and check that leads/gain are correct to rule out fine VF

Approximately 20 to 25 percent of adult in-hospital cardiac arrests present with an initially shockable rhythm, while the majority present with PEA or asystole, particularly when the underlying cause is respiratory failure, sepsis, or a metabolic derangement rather than a primary arrhythmic event. Out-of-hospital arrests of cardiac etiology are more likely to present initially as VF or pVT, especially when witnessed. Because rhythm can evolve during resuscitation — VF may deteriorate into asystole, or successful defibrillation may transiently produce PEA before return of spontaneous circulation — the rhythm must be reassessed at every scheduled rhythm check, roughly every two minutes.

ECG Rhythm Recognition Basics for ACLS

Rapid, confident rhythm recognition on the cardiac monitor is a foundational ACLS skill that must become almost reflexive, since the entire treatment pathway pivots on correctly distinguishing a handful of rhythm patterns within seconds during a rhythm check. Rather than attempting detailed 12-lead interpretation during an arrest, providers rely on a rapid single-lead pattern-recognition approach: is there organized electrical activity or not, is the QRS narrow or wide, is the rate fast, slow, or normal, and is a pulse present.

Normal sinus rhythm serves as the baseline against which all other rhythms are compared, and recognizing it quickly is what allows an abnormal rhythm to stand out. Sinus rhythm shows a consistent upright P wave preceding every narrow QRS complex in a regular pattern, at a rate typically between 60 and 100 beats per minute, with a constant, physiologically appropriate PR interval. Any deviation from this pattern — an absent P wave, an irregular R-R interval, a widened QRS, or an inappropriate rate — signals that further systematic evaluation, and possibly immediate intervention, is required.

Rhythm	Rate	P waves	QRS width	Regularity	Bedside recognition tip
Normal sinus rhythm	60-100/min	Present, upright, one before each QRS	Narrow (<0.12 sec)	Regular	The baseline healthy pattern; a pulse should be palpable and correlate with each QRS.
Sinus tachycardia	>100/min	Present, normal morphology	Narrow	Regular	Rate varies with underlying cause (fever, pain, hypovolemia); treat the cause, not the rate.

Rhythm	Rate	P waves	QRS width	Regularity	Bedside recognition tip
Sinus bradycardia	<60/min	Present, normal morphology	Narrow	Regular	Often normal in athletes; assess for hemodynamic symptoms before treating.
Ventricular fibrillation (VF)	Not measurable (chaotic)	Absent	No identifiable complexes	Chaotic, irregular	Coarse (larger amplitude, easier to see) vs fine (low amplitude, may mimic asystole) — confirm in a second lead if unsure.
Pulseless VT (pVT)	Usually 150-250/min	Absent (buried)	Wide (≥ 0.12 sec)	Regular	Looks like a fast, wide, sine-wave-like pattern; no pulse on palpation confirms pulseless VT.
PEA (example: sinus-appearing PEA)	Variable	May be present	Variable (narrow or wide)	May be regular	The monitor may look deceptively normal — PEA is defined clinically by the ABSENCE of a palpable pulse, not by the ECG appearance.
Asystole	None	Usually absent	No QRS complexes	Flat line	Always confirm in a second lead, check that all leads are connected, and increase the gain to exclude fine VF before declaring asystole.

Lead selection and monitor gain also influence rhythm recognition and are worth brief mention. Most code carts and defibrillators default to a single monitoring lead (often lead II or a pads-based lead) during resuscitation, which is adequate for the gross pattern recognition needed to distinguish shockable from non-shockable rhythms, but is not intended for detailed ST-segment or interval analysis; a full 12-lead ECG should be obtained once the rhythm is organized and a pulse is present, particularly after ROSC. If a flat or near-flat tracing is seen, providers should always briefly confirm that all leads/pads are properly attached and that the gain (amplitude) setting on the monitor has not been turned down, since either of these technical issues can make a shockable fine VF rhythm falsely resemble asystole.

A practical bedside habit taught in ACLS courses is the 'quick look' — glancing at the overall pattern on the monitor before analyzing individual waveform components in detail. A chaotic, disorganized tracing with no discernible complexes at any amplitude is almost always VF; a fast, wide, regular tracing is almost always VT; a flat or near-flat line, once confirmed in a second lead with adequate gain, is asystole; and any other organized-appearing tracing in a pulseless patient is, by definition, PEA. This simplified approach is deliberately designed to be fast and reliable under the time pressure of a resuscitation, rather than requiring detailed interval measurement, which is appropriate for calmer, non-emergent 12-lead interpretation but impractical during an active arrest.

Rhythm Recognition — Fast Pattern Cues

1. Chaotic baseline, no complexes at any amplitude = VF (coarse if large amplitude, fine if low amplitude).
2. Fast, wide, regular = ventricular tachycardia (check pulse to distinguish pVT from VT with a pulse).
3. Flat line, confirmed in a second lead with adequate gain = asystole.
4. Organized rhythm on the monitor but no palpable pulse = PEA, regardless of how normal the tracing looks.
5. When in doubt about fine VF vs asystole, treat as a non-shockable rhythm but continue to reassess, since escalating amplitude may reveal VF.

Defibrillation and Cardioversion

Defibrillation delivers an unsynchronized high-energy shock intended to depolarize a critical mass of myocardium simultaneously, terminating VF or pVT and allowing the sinus node to resume normal pacemaker activity. Because there is no organized rhythm to synchronize to, the shock is delivered as soon as the operator confirms the rhythm and clears the patient — it is not timed to any point in the cardiac cycle.

Synchronized cardioversion, by contrast, delivers a lower-energy shock timed to the R wave to avoid the vulnerable period of the T wave, which could otherwise induce VF. It is used for hemodynamically unstable patients who still have an organized rhythm with a pulse, such as unstable atrial fibrillation, atrial flutter, SVT, or monomorphic VT with a pulse. Polymorphic (irregular) VT is treated as if pulseless VF-equivalent and requires unsynchronized high-energy defibrillation, since synchronization may not reliably capture an irregular waveform.

Therapy	Indication	Initial energy (biphasic)	Initial energy (monophasic)	Notes
Defibrillation	VF / pulseless VT	120-200 J (per manufacturer; 200 J if unknown)	360 J	Unsynchronized; escalate to maximum device energy for subsequent shocks if unsuccessful.
Cardioversion — AFib	Unstable atrial fibrillation	120-200 J	200 J	Synchronized; may require escalation.
Cardioversion — Atrial flutter / SVT	Unstable narrow regular tachycardia	50-100 J	100 J	Often converts at lower energy than AFib.
Cardioversion — Monomorphic VT with pulse	Unstable, organized wide-complex tachycardia	100 J	100 J	Synchronized; escalate if unsuccessful.
Defibrillation — Polymorphic VT	Irregular wide-complex tachycardia, unstable/pulseless	Treat as VF: 120-200 J	360 J	Use unsynchronized (high-energy) shock; synchronization may fail to capture.

Pad or paddle placement matters clinically as well as for exam purposes. The anterolateral position places one pad at the right upper sternal border below the clavicle and the second pad over the left

anterolateral chest at the cardiac apex (roughly the fifth-sixth intercostal space, midaxillary line); this is the default position taught in most courses. The anteroposterior position places one pad over the left precordium and the second pad on the back below the left scapula, and may be preferred in patients with an implanted pacemaker or defibrillator on the left chest, or in some cardioversion cases. Pads should be placed at least one inch away from an implanted device generator when possible, and away from medication patches, which should be removed and the skin wiped before pad placement to prevent skin burns and energy attenuation.

Successful defibrillation depends heavily on transthoracic impedance, which is reduced by firm pad contact, appropriately sized pads, shaving excessive chest hair if it prevents good contact, and avoiding pad placement directly over pooled water or excessive diaphoresis. If the initial shock fails to terminate VF/pVT, subsequent shocks are typically delivered at the same or an escalating energy level depending on the specific defibrillator, with most modern biphasic devices allowing escalation to their maximum output for refractory rhythms. Manufacturers' specific energy recommendations should always be followed when known; 200 J is a reasonable default when the specific device's recommended energy is unknown.

Safety during shock delivery is essential and is a frequent examination and simulation focus: the operator must loudly and clearly announce that a shock is being delivered ("Charging — everybody clear"), visually confirm that no team member is in contact with the patient, bed, or attached equipment, ensure supplemental oxygen is not flowing directly across the chest, and ensure pads are properly placed (anterolateral or anteroposterior) with good skin contact, away from implanted devices and medication patches. Chest compressions should continue right up until the shock is delivered and should resume immediately afterward without pausing to check a rhythm or pulse, since even a successful shock rarely restores an immediate perfusing rhythm.

The Cardiac Arrest Algorithm

Adult Cardiac Arrest — 2 Lanes

Start CPR • bag-mask + O₂ • attach monitor/defib → check rhythm

Shockable

VF / pVT

⚡ Shock

CPR 2 min
IV / IO

⚡ Shock

CPR 2 min
Epinephrine
Airway + ETCO₂

⚡ Shock

CPR 2 min
Amiodarone / lidocaine
Treat H's & T's

Keep cycling shock → CPR. **Not shockable at a check** → no ROSC: switch to non-shockable lane • ROSC: post-cardiac arrest care.

Non-shockable

Asystole / PEA

📈 Epinephrine ASAP

CPR 2 min • IV / IO
Epi every 3–5 min • airway + ETCO₂

CPR 2 min

Treat H's & T's

Shockable at any check → shock lane (shock + CPR with epinephrine). Consider whether continued resuscitation is appropriate.

DRUG & SHOCK NUMBERS (IV / IO)

1 mg

Epinephrine every 3–5 min

300 → 150 mg

Amiodarone, 1st → 2nd dose

1–1.5 → 0.5–0.75

Lidocaine mg/kg, 1st → 2nd

120–200 J

Biphasic (or device max)

360 J

Monophasic

ETCO₂

Low / falling → improve CPR

HIGH-QUALITY CPR

≥ 5 cm

depth • full recoil

100–120

compressions / min

30 : 2

no advanced airway

1 / 6 s

with advanced airway

Minimise pauses • avoid over-ventilation • swap compressor every 2 min

REVERSIBLE CAUSES — 5 H'S & 5 T'S

Hypovolemia • Hypoxia • H⁺ (acidosis) •
Hypo/hyperkalemia • Hypothermia

Tension pneumothorax • Tamponade • Toxins •
Thrombosis (pulmonary, coronary)

DON'T MISS IN THE EXAM

- Epinephrine: **ASAP** in asystole/PEA, but only after the **2nd shock** in VF/pVT.
- Amiodarone / lidocaine: after the **3rd shock**.
- Rhythm check every **2 min** — never interrupt CPR longer than needed.

Advanced airway: ETT or SGA; confirm with waveform capnography

Redrawn from the 2025 AHA Guidelines for CPR & ECC


Figure — Adult Cardiac Arrest (two-lane): revision card (adapted from the 2025 AHA Guidelines)

The 2-Minute ALS Loop

Adult cardiac arrest, circular view — the same care as Card B, drawn as a repeating cycle

NUMBERS TO REMEMBER

2 min CPR between rhythm checks	1 mg epinephrine every 3–5 min	120–200 J biphasic (or device max)	1 / 6 s breaths with advanced airway
---	--	--	--



🔄 Back to step 2 · monitor CPR quality the whole time

HIGH-QUALITY CPR	REVERSIBLE CAUSES
• ≥ 5 cm deep, 100–120/min, full recoil • Minimise pauses; avoid over-ventilation • Swap compressor every 2 min • No advanced airway 30:2 • Low / falling ETCO₂ → improve CPR	Hypovolemia · Hypoxia · H⁺ Tension pneumothorax · (acidosis) · Tamponade · Toxins · Hypo/hyperkalemia · Thrombosis (pulmonary, Hypothermia coronary)

DON'T MISS IN THE EXAM

- Circular and linear algorithms carry the **same** content — only the drawing differs.
- The rhythm check is the **only** exit point: shock, ROSC, or keep going.
- Compressions continue **throughout** — drugs and airway fit around them.


ROSC, return of spontaneous circulation

Redrawn from the 2025 AHA Guidelines for CPR & ECC

Figure — Adult Cardiac Arrest, circular view: revision card (adapted from the 2025 AHA Guidelines)

repeating cycle. After recognition of arrest and initiation of high-quality CPR, the monitor/defibrillator is attached and the rhythm is checked at the earliest opportunity, and then

approximately every two minutes thereafter. The subsequent pathway diverges based on whether the rhythm is shockable or non-shockable, but both pathways share the same underlying two-minute cycle of CPR, rhythm check, and drug administration, and both converge on the same goals: achieve return of spontaneous circulation (ROSC) or, if resuscitative efforts are unsuccessful despite adequate treatment of reversible causes, consider termination of efforts.



It is helpful to think of the algorithm as a continuously repeating loop rather than a linear checklist that is completed once. Each loop consists of the same core elements — two minutes of high-quality CPR, a brief rhythm check, a pulse check if the rhythm appears organized, a decision about whether a shock is indicated, and consideration of whether a drug dose is due — and the resuscitation may cycle through this loop many times before ROSC is achieved, the rhythm changes pathway, or the

team decides to stop. Recognizing this cyclical structure helps students avoid a common misconception: the algorithm is not a race to reach a final box, but a sustained, repeatable process whose quality must be maintained consistently over what may be twenty minutes or more of resuscitation.

Two structural principles govern the algorithm and are commonly tested: first, epinephrine should be given as early as possible in non-shockable rhythms (as soon as IV/IO access allows) because early administration correlates with improved ROSC rates, whereas in shockable rhythms epinephrine is typically given after the second shock has failed; second, drug administration should never require pausing or delaying chest compressions or defibrillation — medications are pushed during ongoing compressions, and a rhythm/pulse check should never exceed 10 seconds.

ACLS Resuscitation Drug Chart

A limited set of medications forms the pharmacologic backbone of ACLS. Precise dosing, route, and indication are frequently tested and must be committed to memory, since drug errors during a code are common and consequential.

Drug class	Drug	Dose	Route / Duration / Notes
Vasopressor	Epinephrine	1 mg IV/IO push	Every 3-5 minutes during arrest; follow with 20 mL saline flush and limb elevation.
Antiarrhythmic	Amiodarone	First dose 300 mg IV/IO bolus; second dose 150 mg IV/IO	For refractory VF/pVT after defibrillation and epinephrine; given during CPR, not to interrupt compressions.
Antiarrhythmic	Lidocaine	First dose 1-1.5 mg/kg IV/IO; second dose 0.5-0.75 mg/kg	Alternative to amiodarone for refractory VF/pVT; max total dose ~3 mg/kg.
Anticholinergic	Atropine	1 mg IV push, may repeat every 3-5 minutes, maximum 3 mg total	Indicated for symptomatic bradycardia; NOT recommended for PEA or asystole (removed from arrest algorithm).
Antiarrhythmic (nodal)	Adenosine	First dose 6 mg rapid IV push; second dose 12 mg rapid IV push if needed	For stable, regular, monomorphic narrow-complex (SVT); give via large proximal vein followed by rapid saline flush; may briefly cause asystole/flushing.
Electrolyte	Magnesium sulfate	1-2 g IV/IO diluted, over 5-20 minutes (or rapid push in arrest)	For torsades de pointes and known/suspected hypomagnesemia; use with caution in renal failure.
Buffer	Sodium bicarbonate	1 mEq/kg IV (institution-dependent)	Selected use: known pre-existing metabolic acidosis, hyperkalemia, tricyclic antidepressant overdose; not routine in arrest.

Drug class	Drug	Dose	Route / Duration / Notes
Electrolyte	Calcium chloride	500-1000 mg (10 mL of 10% solution) IV/IO	Selected use: hyperkalemia, hypocalcemia, hypermagnesemia, calcium channel blocker toxicity; not routine in arrest.
Opioid antagonist	Naloxone	0.4-2 mg IV/IM/IN, may repeat	For suspected opioid-associated life-threatening emergency; does not replace CPR/ventilation.
Vasopressor (bradycardia)	Dopamine infusion	5-20 mcg/kg/min IV infusion	Second-line for symptomatic bradycardia refractory to atropine, titrated to response.
Vasopressor (bradycardia)	Epinephrine infusion	2-10 mcg/min IV infusion	Alternative to dopamine for symptomatic bradycardia refractory to atropine.
Antiarrhythmic	Procainamide	20-50 mg/min infusion until arrhythmia suppressed, hypotension develops, QRS widens >50%, or 17 mg/kg given	For stable wide-complex tachycardia/VT; avoid combining with amiodarone; avoid in prolonged QT or heart failure.
Vasopressor (shock/post-ROSC)	Norepinephrine infusion	0.01-1 mcg/kg/min IV infusion, titrated to MAP	First-line vasopressor for post-ROSC hypotension/shock and for maintaining MAP $\geq$ 65 mmHg.
Vasopressor (peri-arrest)	Push-dose epinephrine	10-20 mcg IV every 2-5 minutes (diluted 'cardiac' concentration)	Bridges hypotension in the peri-arrest period before an infusion is running; requires careful dilution to avoid dosing error.
Antiarrhythmic (historical)	Vasopressin	40 units IV/IO (historically as a one-time substitute for the first or second epinephrine dose)	Removed from the 2020 AHA arrest algorithm in favor of epinephrine alone; included here for recognition on legacy materials/exams.

Vascular access is a prerequisite for most of these medications and should be established early without interrupting compressions. Peripheral intravenous access in an antecubital or larger proximal vein is preferred when it can be obtained quickly; each dose should be followed by a 20 mL saline flush and brief limb elevation to promote central delivery. When peripheral IV access is difficult or delayed — a common scenario in cardiac arrest due to peripheral vasoconstriction — intraosseous (IO) access should be obtained without delay, typically at the proximal tibia or proximal humerus, since IO access provides comparably rapid and reliable drug delivery. Central venous access, while providing the fastest onset of drug effect, is not recommended as a first-line route during active resuscitation because cannulation requires interrupting compressions and carries procedural risk; it may be pursued after ROSC or by a highly experienced provider if peripheral and IO access both fail. The endotracheal route for drug administration is no longer recommended except as a last resort, since absorption and resulting plasma concentrations are unpredictable.

Drug Timing Pearls

1. Epinephrine every 3-5 minutes throughout arrest, regardless of rhythm pathway.
2. In shockable rhythms, give amiodarone or lidocaine only after the second (or third) unsuccessful shock — never as a substitute for defibrillation.
3. Atropine has no role in pulseless arrest (PEA/asystole); it is reserved for symptomatic bradycardia with a pulse.
4. Adenosine is only for stable, regular, narrow-complex tachycardia — never push adenosine into an irregularly irregular or wide, unstable rhythm without careful consideration.

Vascular Access in Resuscitation

Every resuscitation drug in the ACLS armamentarium depends on timely, reliable vascular access, and choosing the right access strategy under time pressure is itself a tested skill. The guiding principle is simple: use whichever route can be obtained fastest and most reliably without interrupting chest compressions, escalating from peripheral IV to intraosseous access without hesitation when the peripheral attempt is difficult or delayed.

Peripheral intravenous access remains the preferred first attempt in most patients because it is familiar to virtually all providers, carries minimal complication risk, and, when placed in a large proximal vein such as the antecubital fossa or external jugular, delivers drugs to the central circulation almost as quickly as a central line once followed by an adequate saline flush and brief limb elevation. However, cardiac arrest produces profound peripheral vasoconstriction and often long-standing venous access difficulty in critically ill patients, so peripheral attempts should not be allowed to consume excessive time; most protocols recommend moving to intraosseous access after one or two unsuccessful peripheral attempts, or immediately if peripheral access is expected to be difficult based on the patient's history or body habitus.

Intraosseous access exploits the fact that the medullary cavity of long bones contains a rich vascular plexus that drains directly into the central venous circulation and does not collapse during shock the way peripheral veins do, making it strikingly fast and reliable even in profound hypotension or arrest. Modern spring-loaded or battery-powered IO drivers allow placement within seconds by providers with only brief training, and drugs, fluids, and even blood products can be administered through an IO line at rates approaching those achieved through a peripheral IV, particularly when a pressure bag or manual push is used. The proximal tibia (2 cm below and 1-2 cm medial to the tibial tuberosity) is the most commonly used and easiest site to locate, followed by the proximal humerus (greater tubercle), which offers faster flow rates to the central circulation but requires correct arm positioning and is technically slightly more difficult to landmark; the distal tibia and sternum are alternative sites used in some protocols and devices.

Access route	Typical time to establish	Reliability in arrest/shock	Notes
Peripheral IV (antecubital/forearm)	Seconds to a few minutes	Reduced in profound shock/vasoconstriction	First choice when quickly obtainable; flush 20 mL and elevate limb after each drug.

Access route	Typical time to establish	Reliability in arrest/shock	Notes
Intraosseous — proximal tibia	Under 60 seconds with a driver	High, largely unaffected by peripheral vasoconstriction	Most common IO site; easy landmarks; avoid if fracture, prior orthopedic hardware, or infection at site.
Intraosseous — proximal humerus	Under 60 seconds with a driver	High; faster flow to central circulation than tibial site	Requires correct arm/hand position (hand on abdomen, elbow adducted); slightly more technically demanding.
Central venous catheter	Several minutes, requires procedural pause	High once placed, but placement is slow and interrupts care	Not first-line during active arrest; reserve for post-ROSC or when other routes fail.
Endotracheal drug administration	Immediate if tube already placed	Unreliable, unpredictable absorption	Last resort only (e.g., naloxone, epinephrine, atropine, lidocaine — 'NAVEL' mnemonic); doses typically 2-2.5x IV dose.

Indications. IO access is indicated whenever peripheral IV access cannot be obtained quickly (generally within 2 attempts or 90 seconds) in a patient who needs urgent drugs, fluids, or blood — cardiac arrest is the single most common indication, since IV attempts should never be allowed to delay epinephrine or amiodarone administration during a shockable-rhythm pause.


Contraindications. Avoid IO placement through fractured bone, an area of prior orthopaedic hardware or recent IO attempt at the same site, overlying infection or burns, or a limb with known vascular injury proximal to the site; osteogenesis imperfecta and severe osteoporosis are relative contraindications because of the fracture risk.

Technique. Identify landmarks, prep the skin, and insert the needle perpendicular to the bone surface using a manual, spring-loaded, or drill-powered device until a give/pop is felt as the cortex is penetrated. Confirm placement by aspirating marrow (not always possible), and by a needle that stands firmly without support. Flush briskly with 5-10 mL of normal saline before starting an infusion or drug administration — this flush is essential, since the medullary space must be hydraulically cleared before drugs will reach the central circulation at a clinically useful rate.

Complications. Extravasation and compartment syndrome are the complications of greatest concern, so the limb should be reassessed periodically for swelling, and the line should be removed as soon as IV access is secured. Other complications include pain on infusion (treat with slow preservative-free lidocaine through the IO line before infusing in a conscious patient), fracture, and, rarely, osteomyelitis or fat embolism.

Common Pitfalls — IO Access

1. Delaying the first drug dose while making repeated peripheral IV attempts instead of moving to IO after 1-2 failed tries.
2. Forgetting the saline flush before infusion, leaving the drug sitting in the medullary space rather than reaching the circulation.
3. Missing early extravasation because the limb was not re-examined after placement.



Regardless of route, every medication delivered peripherally or via IO should be followed by a 20 mL rapid saline flush and, when the site allows, brief elevation of the extremity for 10 to 20 seconds; this practical step is easy to forget under stress but meaningfully speeds central delivery of the drug and is frequently tested. Providers should also periodically reassess any vascular access site during a prolonged resuscitation for signs of infiltration, dislodgement, or extravasation, since a line that has failed silently can lead to a period of ineffective drug administration that goes unnoticed until the team wonders why the patient is not responding to appropriately dosed medications.

Reversible Causes: The H's and T's

Cardiac arrest, particularly presenting as PEA or refractory VF/pVT, is frequently driven by an identifiable and potentially reversible underlying process. The mnemonic H's and T's organizes ten such causes into two groups of five, and systematically working through this differential during every arrest — especially each two-minute CPR cycle — is essential, since no amount of high-quality compressions or epinephrine will restore circulation if, for example, a tension pneumothorax is not decompressed or severe hyperkalemia is not corrected.

Cause	Clinical clue	Management
Hypovolemia	History of hemorrhage, trauma, vomiting/diarrhea, flat neck veins, narrow pulse pressure	IV/IO crystalloid or blood product resuscitation; control hemorrhage source.
Hypoxia	Cyanosis, poor oxygen saturation prior to arrest, airway obstruction, respiratory failure	Ensure airway patency, effective ventilation, and 100% supplemental oxygen; consider advanced airway.
Hydrogen ion (acidosis)	Known severe metabolic/respiratory acidosis, renal failure, prolonged arrest	Optimize ventilation; treat underlying cause; consider sodium bicarbonate in select cases.
Hypo/hyperkalemia	Renal failure, dialysis patient, peaked T waves or widened QRS (hyperK), flattened T/U waves (hypoK)	Hyperkalemia: calcium chloride/gluconate, insulin + glucose, sodium bicarbonate, albuterol; Hypokalemia: potassium and magnesium replacement.
Hypothermia	Cold exposure history, low core temperature	Rewarm (passive/active); may require prolonged resuscitation; withhold repeat drug doses if core temp very low per protocol.
Tension pneumothorax	Unilateral absent breath sounds, tracheal deviation, jugular venous distension, difficulty ventilating	Immediate needle decompression followed by tube thoracostomy.
Tamponade (cardiac)	Jugular venous distension, muffled heart sounds, history of trauma/effusion, pulseless electrical activity	Emergent pericardiocentesis or surgical decompression.
Toxins	Overdose history, medication bottles at scene, known ingestion, characteristic toxidrome	Specific antidote if available (e.g., naloxone for opioids, lipid emulsion for local anesthetics); supportive care, consider toxicology consult.
Thrombosis — pulmonary	Sudden collapse, known DVT/risk factors, hypoxia, right heart strain, distended neck veins	Consider fibrinolytics, embolectomy, or extracorporeal support if massive PE strongly suspected.
Thrombosis — coronary	History/ECG suggestive of acute MI preceding arrest	Consider emergent reperfusion (PCI or fibrinolysis) once ROSC achieved and coronary occlusion confirmed/suspected.

In practice, experienced resuscitation teams assign one member specifically to think through the H's and T's aloud during each two-minute cycle, drawing on the patient's known history, physical examination findings gathered during the primary and secondary surveys, point-of-care ultrasound when available and feasible without interrupting compressions, and any available laboratory or imaging data. Point-of-care cardiac ultrasound performed during a brief compression pause (ideally coordinated with a scheduled rhythm check) can rapidly identify pericardial effusion/tamponade, right ventricular strain suggesting massive pulmonary embolism, or global hypokinesis, though its use must never be allowed to prolong the pause beyond the standard 10-second limit. Certain causes cluster with certain clinical contexts: hyperkalemia and hypothermia are more common in dialysis and environmental exposure patients respectively; tension pneumothorax and tamponade are more common after trauma or recent cardiothoracic procedures; and pulmonary and coronary

thrombosis should be strongly considered in patients with known risk factors or a clinical story consistent with sudden collapse preceded by chest pain or dyspnea.

Worked Case Scenario: VF Arrest Walkthrough

Applying the concepts above to a concrete scenario helps consolidate the algorithm into clinical practice. The following narrative walks through a typical in-hospital VF arrest from recognition through ROSC, explicitly naming each decision point and the reasoning behind it.

A 62-year-old man with a history of coronary artery disease is found unresponsive in his hospital bed by a nurse making rounds. The nurse taps his shoulder and shouts his name; there is no response. She simultaneously looks for chest rise and palpates a carotid pulse for no more than ten seconds — she finds no pulse and no normal breathing (only occasional agonal gasps). She immediately calls for help and activates the hospital's code system, then begins high-quality chest compressions at a rate of 100-120 per minute and a depth of at least 5 cm, allowing full recoil between compressions.

Within about ninety seconds, the code team arrives with a code cart and monitor/defibrillator. A second provider takes over compressions to allow rotation, while a third applies defibrillator pads and briefly pauses compressions to check the rhythm. The monitor shows a chaotic, disorganized waveform with no identifiable QRS complexes: ventricular fibrillation. The team leader announces the rhythm aloud, confirms the defibrillator is charged to 200 J biphasic, loudly calls 'charging, everybody clear,' visually confirms no one is touching the patient or bed, and delivers an unsynchronized shock. Compressions resume immediately, without pausing to check a pulse, since even a successful shock rarely restores an immediate perfusing rhythm.

During this first two-minute CPR cycle, a nurse obtains intraosseous access at the proximal tibia after a rapid failed attempt at peripheral IV access, and the airway provider begins bag-mask ventilation with two-person technique, delivering breaths only enough to produce visible chest rise without interrupting compressions. At the two-minute mark, compressions pause briefly for a rhythm check: the monitor again shows VF. A second shock is delivered at the same or an escalated energy per the device's protocol, and CPR resumes immediately. Because the rhythm remains shockable after this second shock, the team leader now directs epinephrine 1 mg IV/IO to be given, followed by a 20 mL flush, and notes the time so the next dose can be given in 3 to 5 minutes.

At the next two-minute rhythm check, VF persists. A third shock is delivered, and because this is now the second or third unsuccessful shock, the team leader calls for amiodarone 300 mg IV/IO, pushed during ongoing compressions rather than during the brief rhythm-check pause. Throughout these cycles, the team leader periodically prompts the team to consider the H's and T's aloud — reviewing the patient's chart, which shows no evidence of hemorrhage, electrolyte disturbance, or recent procedures, but does show a known history of coronary artery disease, raising strong suspicion for coronary thrombosis as the underlying cause. A 12-lead ECG will be prioritized once ROSC is achieved.

At the fourth rhythm check, the monitor now shows an organized, narrow-complex rhythm at a rate of approximately 90 beats per minute. The team leader immediately calls for a pulse check, which reveals a strong, palpable carotid pulse: return of spontaneous circulation. The team transitions immediately into post-cardiac-arrest care — obtaining a 12-lead ECG, which shows ST-segment

elevation consistent with an acute anterior myocardial infarction, prompting an emergent call to the cardiac catheterization laboratory. The patient remains comatose, so targeted temperature management is initiated, oxygenation is titrated to an SpO₂ of 94 to 98 percent, and a mean arterial pressure above 65 mmHg is maintained with fluids and a norepinephrine infusion while he is transported for emergent catheterization.

This scenario illustrates several principles discussed throughout the chapter operating together: compressions were never delayed for anything other than a brief, necessary rhythm/pulse check or shock delivery; epinephrine and amiodarone were timed correctly relative to shocks; vascular access was obtained via IO without interrupting care; the team searched for reversible causes throughout rather than only after multiple failed shocks; and the transition into structured post-arrest care, including immediate 12-lead ECG and consideration of emergent reperfusion, began the moment ROSC was confirmed.

The Bradycardia Algorithm

Adult Bradycardia With a Pulse

Decide on compromise, not on the number alone

NUMBERS TO REMEMBER

< 50/min
typical
bradyarrhythmia

1 mg
atropine, repeat 3–5
min

3 mg
atropine maximum
total

5–20
dopamine
mcg/kg/min

2–10
epinephrine mcg/min

1

ASSESS

Is the heart rate appropriate for the clinical condition?

2

SIGNS

Cardiopulmonary compromise?

Hypotension • acutely altered mental status • signs of shock • ischemic chest discomfort • acute heart failure

NO

Identify and treat causes: support ABCs, consider oxygen, 12-lead ECG • observe

YES

Support now ▼

3

SUPPORT

Airway + oxygen • assist breathing (PPV) if needed

Attach cardiorespiratory monitor • monitor pulse

4

TREAT

Still compromised? → Atropine**ATROPINE INEFFECTIVE**

Transcutaneous pacing and/or dopamine or epinephrine infusion

IMPROVED

Treat causes • observe

5

ESCALATE

Consider expert consultation • transvenous pacing**POSSIBLE CAUSES**Myocardial ischemia/infarction • drugs/toxins (eg, CCBs, β -blockers, digoxin) • hypoxia • electrolytes (eg, hyperkalemia)**INFUSIONS**

Titrate both to response; taper dopamine slowly

DON'T MISS IN THE EXAM

- The trigger to treat is **compromise**, not the heart rate alone.
- Atropine 1 mg, repeat every 3–5 min, **max 3 mg**.
- Atropine fails → pacing or infusion — do not keep repeating atropine.

PPV, positive-pressure ventilation

Redrawn from the 2025 AHA Guidelines for CPR & ECC

Figure — Adult Bradycardia With a Pulse: revision card (adapted from the 2025 AHA Guidelines)

not by the number alone, but by whether the bradycardia is causing hemodynamic instability. The

first and most important step is to determine whether the rate is adequate to maintain perfusion, and whether signs and symptoms are caused by the bradycardia itself.

It is important to recognize that many patients tolerate heart rates in the 40s or even 30s without symptoms, particularly well-conditioned athletes or patients on chronic AV-nodal blocking medications, and such patients require observation rather than aggressive intervention. Conversely, a rate in the 50s can be profoundly symptomatic in a patient with critical illness or limited cardiac reserve. The clinician must therefore always correlate the rate with the patient's clinical state rather than treating a number in isolation. Common causes include increased vagal tone, sinus node dysfunction, AV block (first, second, or third degree), medication effect (beta-blockers, calcium-channel blockers, digoxin), electrolyte disturbance, hypothyroidism, and inferior myocardial infarction, which classically affects the AV node given its blood supply from the right coronary artery in most individuals.

Atropine works by blocking vagal (parasympathetic) input to the sinoatrial and atrioventricular nodes, and is therefore most effective for sinus bradycardia and AV block at the level of the AV node itself (typically Mobitz type I / Wenckebach). It is generally ineffective, and should not delay definitive therapy, for high-grade or infranodal block (Mobitz type II or third-degree AV block with a wide escape QRS), since these blocks occur below the level of vagal influence; in these cases, transcutaneous pacing should be initiated promptly, with sedation and analgesia provided as the patient's hemodynamic status allows, since pacing is uncomfortable for an awake patient.


- Assess for signs/symptoms of instability caused by the bradycardia: hypotension, acutely altered mental status, signs of shock, ischemic chest discomfort, or acute heart failure.
- If the patient is stable, monitor and observe; identify and treat the underlying cause (e.g., medications, electrolyte disturbance, hypoxia, increased vagal tone).
- If the patient is unstable, give atropine 1 mg IV, repeated every 3-5 minutes to a maximum total dose of 3 mg.
- If atropine is ineffective or the block is unlikely to respond (e.g., Mobitz type II or third-degree AV block with a wide QRS), proceed to transcutaneous pacing without delay.
- Alternatively, or while awaiting pacing, start a dopamine infusion (5-20 mcg/kg/min) or an epinephrine infusion (2-10 mcg/min), titrated to patient response.
- Prepare for transvenous pacing and obtain expert/cardiology consultation if bradycardia is refractory to these interventions.
- Always search for and treat reversible causes (e.g., hyperkalemia, beta-blocker or calcium-channel-blocker toxicity, hypothyroidism, inferior MI, hypoxia).

Identify bradycardia (HR under 60/min) and assess adequacy for clinical condition



Persistent bradyarrhythmia causing instability? (hypotension, AMS, shock, chest pain, acute HF)





The Tachycardia Algorithm

Adult Tachyarrhythmia With a Pulse

Unstable → shock • stable → look at the QRS

NUMBERS TO REMEMBER

≥ 150/min
typical tachyarrhythmia

6 → 12 mg
adenosine, rapid push +
flush

≥ 0.12 s
wide QRS

150 mg
amiodarone over 10 min

1 SUPPORT

Airway • oxygen if hypoxemic • IV access

Monitor rhythm, BP and oximetry • 12-lead ECG if available

2 STABLE?

Persistent tachyarrhythmia causing compromise?

Hypotension • altered mental status • shock • ischemic chest pain • acute heart failure

YES — UNSTABLESynchronized cardioversion • sedate if feasible •
regular narrow complex → consider adenosine**NO — STABLE**

Go to QRS width ▼

3 QRS

Is the QRS wide (≥ 0.12 s)?

WIDEAdenosine **only if regular and monomorphic** • antiarrhythmic infusion •
expert consultation**NARROW**Vagal manoeuvres (if regular) • adenosine
(if regular) • β-blocker or CCB • consider
expert

4 REFRACTORY

Not responding? Consider

Underlying cause • higher energy for next cardioversion • add antiarrhythmic • expert
consultation**CARDIOVERSION ENERGY**Use the device's
recommended level; if
unknown, use the **maximum**
setting.**PROCAINAMIDE (STABLE WIDE-QRS)**20–50 mg/min until arrhythmia
suppressed, hypotension, QRS widens >
50% or 17 mg/kg given • maintenance 1–4
mg/min • avoid if prolonged QT or CHF**AMIODARONE (STABLE WIDE-
QRS)**150 mg over 10 min, repeat if
VT recurs • then 1 mg/min for
first 6 h**DON'T MISS IN THE EXAM**

- Unstable with a pulse → **synchronized** cardioversion (not unsynchronized defibrillation).
- Adenosine in wide QRS only if **regular and monomorphic**.

Figure — Adult Tachyarrhythmia With a Pulse: revision card (adapted from the 2025 AHA Guidelines)

Electrical Cardioversion

Tachycardia with serious signs and symptoms caused by the tachycardia

SYNCHRONIZED ENERGIES

200 J
atrial fibrillation

200 J
atrial flutter

100 J
narrow-complex
tachycardia

100 J
monomorphic VT

EXCEPTION

Polymorphic VT → **unsynchronized**, high-energy shock (defibrillation)

1
RATE

Ventricular rate > 150/min → prepare for immediate cardioversion

A brief trial of medication for the specific arrhythmia may be given • ≤ 150/min usually does not need immediate cardioversion

2
READY

Have at the bedside

MONITOR
SpO₂ monitor

SUCTION
Suction device

ACCESS
IV line

AIRWAY
Intubation
equipment

3
SEDATE

Sedate whenever feasible

eg, sedative (diazepam) ± analgesic (fentanyl); many experts recommend anesthesia if readily available

4
SHOCK

Synchronized cardioversion at the energy above

AFTER EACH SHOCK

Resynchronize — the device may revert to unsynchronized

SYNC DELAYED + CRITICAL

Go straight to **unsynchronized** shocks

DON'T MISS IN THE EXAM

- AF and flutter **200 J**; narrow-complex and monomorphic VT **100 J**.
- Polymorphic VT is **never** synchronized.

Figure — Electrical Cardioversion: revision card (adapted from the 2025 AHA Guidelines)

significant tachyarrhythmias in ACLS are usually well above 150 beats per minute. As with bradycardia, the pivotal first decision is whether the patient is stable or unstable; the second is

whether the QRS complex is narrow (under 0.12 seconds) or wide (0.12 seconds or greater), which narrows the differential and dictates safe therapy.

A common examination and clinical pitfall is mistaking sinus tachycardia for a primary arrhythmia requiring cardioversion or antiarrhythmic therapy. Sinus tachycardia is almost always a compensatory response to an underlying process such as fever, pain, hypovolemia, anxiety, hypoxia, or sepsis, and the correct treatment is identification and management of that underlying cause, not cardioversion or adenosine — attempting to slow a compensatory sinus tachycardia can precipitate hemodynamic collapse in a patient who depends on the elevated rate to maintain cardiac output. A regular rhythm with clearly identifiable P waves preceding each QRS, and a rate that varies somewhat with activity, positioning, or fever, points toward sinus tachycardia rather than a primary arrhythmia such as SVT.

Vagal maneuvers — including the modified Valsalva maneuver (forceful exhalation against resistance followed by passive leg raise and supine repositioning) and carotid sinus massage in appropriate patients without carotid bruits or known carotid disease — should always be attempted first for stable, regular, narrow-complex tachycardia before pharmacologic therapy, since they are safe, rapid, and successful in terminating a meaningful proportion of AV-nodal re-entrant tachycardias. When vagal maneuvers fail, adenosine is highly effective because it transiently blocks conduction through the AV node, interrupting the re-entrant circuit responsible for most paroxysmal SVT. Patients should be warned before administration that they may experience a brief but intense sensation of chest pressure, flushing, or impending doom, and continuous ECG monitoring should be running during administration, since transient asystole or bradycardia commonly follows the dose before sinus rhythm resumes.

Category	Definition	First-line management
Unstable, any QRS width	Hypotension, acutely altered mental status, signs of shock, ischemic chest pain, or acute heart failure attributable to the tachycardia	Immediate synchronized cardioversion (unless sinus tachycardia — treat the cause instead); consider brief sedation if time allows but do not delay cardioversion for an unstable patient.
Stable, narrow, regular	QRS under 0.12 sec, regular rhythm (e.g., SVT/AVNRT)	Vagal maneuvers first; if unsuccessful, adenosine 6 mg rapid IV push, then 12 mg if needed.
Stable, narrow, irregular	QRS under 0.12 sec, irregular rhythm (e.g., atrial fibrillation, atrial flutter with variable block, MAT)	Rate control (beta-blocker or calcium-channel blocker); consider expert consultation for rhythm control/anticoagulation.
Stable, wide, regular	QRS 0.12 sec or greater, regular rhythm (e.g., monomorphic VT, SVT with aberrancy)	Consider adenosine only if regular/monomorphic and diagnosis uncertain; treat as VT with antiarrhythmics (amiodarone or procainamide) if diagnosis unclear or confirmed VT; expert consultation advised.

Category	Definition	First-line management
Stable, wide, irregular	QRS 0.12 sec or greater, irregular rhythm (e.g., polymorphic VT/torsades, AFib with aberrancy or WPW)	Avoid AV-nodal blocking agents (adenosine, beta-blockers, calcium-channel blockers) if pre-excited AFib/WPW suspected; treat torsades with magnesium sulfate; expert consultation strongly advised.

Synchronized Cardioversion Energies (2025 Update)

The 2025 guidelines also renamed “supraventricular tachycardia” to “narrow-complex tachycardia” in the algorithm and updated the recommended initial synchronized cardioversion energies as follows. If the device-specific recommended energy is unknown, use the maximum available energy setting.

Rhythm	Initial Energy
Narrow-complex tachycardia (formerly “supraventricular tachycardia”)	100 J
Monomorphic ventricular tachycardia	100 J
Atrial fibrillation	200 J
Atrial flutter	200 J
Polymorphic VT	Treated as defibrillation — unsynchronized, high-energy shock

Distinguishing ventricular tachycardia from supraventricular tachycardia with aberrant conduction (SVT with a bundle branch block or rate-related aberrancy) in a stable, wide-complex, regular tachycardia is a classic diagnostic challenge, since both can look similar on a single-lead monitor and the wrong treatment can be dangerous. Several features favor VT over aberrantly conducted SVT: a history of structural heart disease or prior myocardial infarction, AV dissociation (P waves marching through independently of the QRS complexes), fusion or capture beats, a very wide QRS (generally over 0.16 seconds), and marked left-axis deviation. Because misdiagnosing VT as SVT and administering an AV-nodal blocking agent can occasionally precipitate hemodynamic deterioration, the prevailing teaching for a stable, wide, regular tachycardia of uncertain origin is to treat it as VT unless there is strong, specific evidence otherwise, and to involve expert/cardiology consultation whenever the diagnosis remains unclear and the patient's stability allows time for that consultation.

For stable wide-complex tachycardia believed to be ventricular in origin, procainamide (20-50 mg/min infusion until arrhythmia suppressed, hypotension develops, QRS widens by more than 50%, or a maximum dose of 17 mg/kg is reached) or amiodarone (150 mg IV over 10 minutes, may repeat) are first-line antiarrhythmics; procainamide and amiodarone should generally not be given together due to additive risk of QT prolongation and hypotension. The 2025 AHA update removed sotalol from the tachycardia algorithm altogether, leaving procainamide and amiodarone as the two first-line antiarrhythmic infusions for stable wide-complex tachycardia. Any unstable patient, regardless of QRS width or regularity, other than true sinus tachycardia, proceeds directly to synchronized cardioversion.

Amrita School of Medicine

Adult Post-Cardiac Arrest Care

ROSC is not the finish line — stabilise first, then manage

NUMBERS TO REMEMBER

90–98%
SpO₂ target

60–105
PaO₂ mm Hg

35–45
PCO₂ mm Hg

≥ 65
MAP mm Hg

32–37.5 °C
temperature control

Phase 1 • Initial stabilisation

all can run together

Airway

Place / exchange advanced airway • confirm with capnography

Breathing

100% FiO₂ until SpO₂ reliable, then titrate • ventilate to PCO₂ target

Circulation

Vasopressors and/or fluids for MAP ≥ 65

Diagnose

12-lead ECG • consider CT and/or ultrasound / echo

Phase 2 • Continued management

Treat the cause

Arrest etiologies and complications • consider emergency angiography and/or mechanical circulatory support

Neuro check

Assess off sedation and neuromuscular blockade, if able: **follows commands?**

**?
NEURO**

Follows commands?

NO OR UNSURE

Ongoing critical care • deliberate temperature control • EEG • angiography when appropriate • timed multimodal prognostication

YES

Ongoing critical care • coronary angiography when appropriate

EMERGENCY CARDIAC INTERVENTION IF

Persistent ST elevation • cardiogenic shock • recurrent / refractory ventricular arrhythmias • severe myocardial ischemia

ONGOING CRITICAL CARE

Glucose 70–180 mg/dL (avoid hypo- and hyperglycemia) • keep PaO₂, PCO₂, MAP targets • consider antibiotics

DON'T MISS IN THE EXAM

- Prognosticate ≥ 72 h after ROSC or normothermia — multimodal, never on one test.
- Not following commands → start **temperature control** as soon as possible and get an **EEG**.
- PCO₂ target applies unless there is severe acidemia.

ROSC, return of spontaneous circulation • MAP, mean arterial pressure

Redrawn from the 2025 AHA Guidelines for CPR & ECC

Figure — Adult Post-Cardiac Arrest Care: revision card (adapted from the 2025 AHA Guidelines)

cardiac-arrest care is a distinct phase with its own evidence-based targets, aimed at optimizing

oxygenation, hemodynamics, and neurological recovery while minimizing secondary brain injury from hypoxia, hypotension, hyperoxia, or fever.

The pathophysiology driving post-arrest management is often described as post-cardiac-arrest syndrome, a constellation comprising anoxic brain injury, myocardial dysfunction (post-arrest myocardial stunning), the systemic ischemia-reperfusion response (which can produce a sepsis-like state with vasoplegia, capillary leak, and coagulopathy), and the persistent precipitating pathology that caused the arrest in the first place. Anoxic brain injury is the dominant determinant of long-term outcome and the leading cause of death in patients who achieve ROSC but do not survive to discharge, which is precisely why temperature control, blood pressure support, and ventilation targets in this phase are all oriented primarily around limiting secondary neurological injury on top of the initial ischemic insult.

Under the 2025 AHA update, targeted temperature management should be initiated as soon as feasible after ROSC in any patient who remains comatose (does not follow commands), with a target of 32°C to 37.5°C maintained for at least 36 hours in patients not responding, avoiding cold IV saline infusion to induce cooling. This is followed by controlled, gradual rewarming (typically no faster than 0.25 to 0.5 degrees Celsius per hour) and continued active fever prevention thereafter. Shivering, which increases metabolic demand and can be counterproductive during cooling, is managed with sedation, analgesia, and, when necessary, neuromuscular blockade. All patients should also undergo evaluation for the cause of arrest, including a 12-lead ECG, echocardiography, and consideration of emergent coronary angiography, since a substantial proportion of adult out-of-hospital arrests are precipitated by acute coronary occlusion even without overt ST elevation on the post-ROSC ECG.

Parameter	Target	Rationale / Notes
Targeted temperature management	Select and maintain a constant temperature between 32°C and 37.5°C for at least 36 hours in patients who remain comatose or are not responding; avoid cold IV saline infusion	Reduces cerebral metabolic demand and secondary neuronal injury; avoid fever (over 37.7°C) for at least 72 hours after arrest.
Mean arterial pressure (MAP)	MAP $\geq$ 65 mmHg (avoid hypotension)	Maintains cerebral and coronary perfusion; use IV fluids and vasopressors as needed.
Oxygenation	Titrate FiO ₂ to the lowest level achieving SpO ₂ 92-98%	Avoid both hypoxia and hyperoxia, which are each associated with worse outcomes.
Ventilation (PaCO ₂)	Target normocapnia, PaCO ₂ approximately 35-45 mmHg	Avoid hyperventilation, which reduces cerebral blood flow, and hypoventilation, which worsens acidosis.
Glucose control	Maintain moderate glycemic control (commonly 140-180 mg/dL); avoid hypoglycemia	Both hyperglycemia and hypoglycemia worsen neurological outcome.

Parameter	Target	Rationale / Notes
12-lead ECG / cardiac evaluation	Obtain immediately after ROSC	Identify STEMI or suspected acute coronary occlusion requiring emergent catheterization.
Neuroprognostication	Delay formal prognostication at least 72 hours after return to normothermia (often 4-5 days post-arrest)	Early sedative/paralytic effects and post-arrest encephalopathy can mimic poor prognosis; use multimodal assessment (exam, EEG, imaging, biomarkers).
Seizure surveillance	Continuous or frequent EEG monitoring in comatose patients	Subclinical seizures are common after anoxic injury and may worsen outcome if untreated; treat clinical and electrographic seizures per standard antiepileptic protocols.
Coronary evaluation/reperfusion	Emergent coronary angiography if STEMI or high suspicion of acute coronary occlusion	A substantial proportion of sudden cardiac arrests are due to acute coronary occlusion even without ST elevation; early cardiology involvement improves outcomes.
Fluid and vasopressor selection	Balanced crystalloid for volume; norepinephrine as first-line vasopressor if needed	Avoid large-volume unbalanced saline resuscitation; titrate vasopressors to MAP and clinical perfusion markers (lactate clearance, urine output).

Post-arrest hemodynamic instability is common and multifactorial, arising from a combination of post-arrest myocardial stunning (transient global cardiac dysfunction that typically improves over 24 to 48 hours even without a structural cause), the systemic inflammatory ischemia-reperfusion response described above, and any persistent underlying cause such as ongoing myocardial ischemia or sepsis. Management typically requires a combination of judicious intravenous fluids, vasopressor support (norepinephrine is generally favored as a first-line agent for post-ROSC shock), and, in cases of severe myocardial stunning with low cardiac output despite adequate preload and afterload support, consideration of an inotrope or, in refractory cases, mechanical circulatory support such as an intra-aortic balloon pump or extracorporeal membrane oxygenation at centers with that capability.

Additional priorities include continuous hemodynamic and rhythm monitoring, seizure surveillance and treatment (subclinical seizures are common and often require EEG to detect), and early consultation for emergent coronary angiography when acute coronary occlusion is suspected, even in the absence of ST elevation, if the clinical picture is strongly suggestive. Family communication, goals-of-care discussion, and coordinated multidisciplinary critical care management round out the post-arrest bundle.

Airway Management in ACLS

Adult Foreign-Body Airway Obstruction

Choking: judge severity, then back blows and thrusts

THE WHOLE CARD IN THREE BOXES

5 + 5 back blows + abdominal thrusts	Repeat until expelled or unresponsive	Unresponsive → CPR, compressions first
--	---	--

1 SAFE	Verify scene safety
------------------	---------------------

2 LOOK	Signs of severe obstruction? Weak or absent cough • unable to speak • cyanosis • altered mental status • apnea ABSENT Encourage coughing • keep watching for severe signs PRESENT Activate emergency response ▼
------------------	--

3 ACT	Is the adult responsive? YES Repeated cycles of 5 back blows → 5 abdominal thrusts* • repeat until expelled or the adult becomes unresponsive • if expelled, monitor until advanced care arrives NO CPR until advanced care arrives (adult BLS, Card A) • start with compressions • look in the mouth for a visible object before each breath attempt
-----------------	--

ADULT VS CHILD VS INFANT

	Adult	Child	Infant
Severe sign	unable to speak	unable to speak	unable to cry
Back blows	5	5	5
Then	5 abdominal (chest if late pregnancy)	5 abdominal thrusts	5 chest thrusts
If unresponsive	CPR • adult BLS	CPR • pediatric BLS	CPR • pediatric BLS

DON'T MISS IN THE EXAM

- Mild obstruction (good cough) → **do not interfere**; encourage coughing.
- Late pregnancy, or you cannot encircle the abdomen → use **5 chest thrusts** instead.
- Unresponsive → compressions first; no blind finger sweeps.

* Late pregnancy or cannot encircle abdomen → 5 chest thrusts

Redrawn from the 2025 AHA Guidelines for CPR & ECC

Figure — Adult Foreign-Body Airway Obstruction: revision card (adapted from the 2025 AHA Guidelines)

techniques, chosen based on provider skill, patient anatomy, and clinical trajectory. The overriding

principle is that airway management must never come at the cost of chest compression quality or continuity.

Current evidence suggests that, for most out-of-hospital and many in-hospital cardiac arrests, outcomes with bag-mask ventilation or a supraglottic airway are comparable to those achieved with endotracheal intubation, particularly when intubation is performed by a less experienced provider or requires prolonged interruption of compressions. This has led to a more nuanced, less intubation-first approach in current guidelines: providers are encouraged to use whichever airway strategy they can perform proficiently with minimal disruption to compressions, escalating to advanced airway placement based on team expertise, resuscitation duration, and the patient's clinical trajectory, rather than intubating reflexively and immediately in every arrest.

Selecting the correct basic airway adjunct is a prerequisite to effective bag-mask ventilation and is frequently tested independently of the more advanced airway decision. An oropharyngeal airway is used only in an unconscious patient without a gag reflex, sized by measuring from the corner of the mouth to the angle of the jaw, and inserted to displace the tongue away from the posterior pharyngeal wall. A nasopharyngeal airway is better tolerated in a semi-conscious patient with an intact gag reflex, sized by measuring from the nostril to the earlobe, but should be avoided or used with caution in suspected basilar skull fracture or significant midface trauma given a small but serious risk of intracranial placement. Correct mask sizing and the two-handed 'C-E' or thenar-eminence grip technique for maintaining a seal are essential skills, since an inadequate seal is the most common cause of ineffective bag-mask ventilation even when the rest of the technique is correct.

- Bag-mask ventilation with a properly sized mask and adjunct (oropharyngeal or nasopharyngeal airway) is often sufficient during the initial minutes of resuscitation and requires two-person technique for optimal seal.
- Supraglottic airways (laryngeal mask airway, laryngeal tube, i-gel, King LT) offer a faster, technically simpler alternative to endotracheal intubation with comparable outcomes in cardiac arrest and are frequently used as a first advanced airway.
- Endotracheal intubation provides the most definitive airway control and allows continuous capnography, but should be performed with minimal interruption to compressions (ideally under 10 seconds for tube passage), by the most experienced available provider.
- Once an advanced airway (ET tube or supraglottic device) is placed, compressions become continuous at 100-120/min while ventilations are delivered asynchronously at 1 breath every 6 seconds (10/min).
- Waveform capnography should be used continuously after advanced airway placement both to confirm correct tracheal placement and to monitor CPR quality and detect ROSC.

Capnography (PETCO ₂) finding	Interpretation
Persistent PETCO ₂ under 10 mmHg during CPR	Suggests inadequate compression quality or very low cardiac output; reassess technique, consider causes of poor perfusion.

Capnography (PETCO ₂) finding	Interpretation
PETCO ₂ sustained 10-20 mmHg during CPR	Consistent with reasonably effective CPR; general target range during resuscitation.
Sudden, sustained rise in PETCO ₂ (e.g., to 35-40+ mmHg)	Suggests return of spontaneous circulation (ROSC); check pulse.
Absent or near-zero PETCO ₂ immediately after intubation	Suggests esophageal intubation; reassess tube placement immediately.

Special Resuscitation Situations

Cardiac Arrest in Pregnancy

Two patients, one clock — deliver by 5 minutes if no ROSC

NUMBERS TO REMEMBER

LUD when fundus $\geq$ umbilicus	5 min delivery goal if no ROSC	Above IV above the diaphragm	A → H causes of arrest
--	--	--	----------------------------------

1
START

Start BLS / ALS
 High-quality CPR • continuous **left lateral uterine displacement** if fundal height $\geq$ umbilicus
 • AED / defibrillator when indicated

2
TEAM

Activate the cardiac-arrest-in-pregnancy team • address the cause
 Team may include leader, anesthesiologist, obstetrician, neonatologist, nurses, pharmacists

3
PARALLEL

Run both tracks together

OPTIMISE RESUSCITATION
 Early airway (most experienced person) • IV above diaphragm • on IV magnesium → stop it, give calcium
 • detach fetal monitors • massive transfusion if amniotic fluid embolism suspected

PREPARE DELIVERY
 Resuscitative delivery when fundal height $\geq$ umbilicus

4
5 MIN

No ROSC → deliver by 5 minutes

MOTHER
 Continue ALS

NEWBORN
 Resuscitate using the neonatal algorithm (Card T)

CAUSES OF ARREST: A TO H

A Anesthetic complications	B Bleeding
C Cardiovascular	D Drugs
E Embolic (amniotic fluid or PE)	F Fever
G General (H's and T's)	H Hypertension (eg, preeclampsia)

DON'T MISS IN THE EXAM

- LUD relieves **aortocaval compression** so compressions work.
- Resuscitative delivery helps the **mother** first, and the baby when feasible.

Figure — Cardiac Arrest in Pregnancy: revision card (adapted from the 2025 AHA Guidelines)

Durable LVAD — Unresponsive Patient

Adults and children • perfusion decides, not the pulse

ADEQUATE PERFUSION IF ANY PRESENT (PLUS NORMAL SKIN COLOUR, TEMPERATURE, CAP REFILL)

MAP > 50
mm Hg (doppler / art line)**PETCO₂ > 20**
mm Hg**No pulse**
may be normal with LVAD**1**
ASSESS**Unresponsive with a durable LVAD**

Assist ventilation if needed • assess perfusion

2
PERFUSED?**Adequate perfusion?****YES**

Do not start chest compressions • assess and treat non-LVAD causes • monitor perfusion (recheck ▲)

NO

Start chest compressions • second rescuer checks LVAD function • treat non-LVAD causes • continue BLS / ALS

3
MOVE**Transport • contact the VAD centre**

Keep monitoring perfusion

NON-LVAD CAUSES

Dysrhythmia • hemorrhage / hypovolemia • hypoglycemia • hypoxia • overdose • right ventricular failure • sepsis • stroke

RESTART THE LVAD

Alarms? • LVAD hum? • driveline connected? • power connected? • controller needs replacing?

DON'T MISS IN THE EXAM

- A **missing pulse** does not mean arrest in LVAD patients — judge perfusion.
- Poor perfusion → compressions are **indicated** despite the device.

Figure — Durable LVAD, Adult and Pediatric: revision card (adapted from the 2025 AHA Guidelines)

ALS Termination of Resuscitation

Out-of-hospital rule: stop only when every criterion is met

TICK EVERY BOX (4 CRITERIA, ALL BEFORE TRANSPORT)

☐ Arrest not witnessed

☐ No bystander CPR

☐ No ROSC before transport

☐ No shock delivered before transport

ALL BOXES TICKED

Consider **termination** of resuscitation

ANY BOX EMPTY

Continue resuscitation and consider transport

ALS VS BLS RULE SIDE BY SIDE

	ALS rule — 4 criteria	BLS / universal rule — 3 criteria
Witnessed?	Arrest not witnessed	Arrest not witnessed by EMS
Bystander CPR?	No bystander CPR	— not a criterion
ROSC before transport?	No ROSC	No ROSC
Shock before transport?	No shock delivered	No AED shock delivered

DON'T MISS IN THE EXAM

- ALS rule = 4 criteria; BLS rule = 3 (no bystander-CPR criterion).
- "Consider" termination — the rule supports a decision, it does not make it.

Figure — ALS Termination of Resuscitation: revision card (adapted from the 2025 AHA Guidelines)

BLS / Universal Termination of Resuscitation

Out-of-hospital rule: stop only when every criterion is met

TICK EVERY BOX (3 CRITERIA, ALL BEFORE TRANSPORT)

☐ Arrest not witnessed by EMS personnel☐ No ROSC before transport☐ No AED shock delivered before transport**ALL BOXES TICKED**Consider **termination** of resuscitation**ANY BOX EMPTY****Continue** resuscitation and consider transport

ALS VS BLS RULE SIDE BY SIDE

	ALS rule — 4 criteria	BLS / universal rule — 3 criteria
Witnessed?	Arrest not witnessed	Arrest not witnessed by EMS
Bystander CPR?	No bystander CPR	— not a criterion
ROSC before transport?	No ROSC	No ROSC
Shock before transport?	No shock delivered	No AED shock delivered

DON'T MISS IN THE EXAM

- BLS rule = 3 criteria; ALS rule adds **no bystander CPR**.
- "Witnessed" here means witnessed by **EMS**, not by a bystander.

Figure — BLS/Universal Termination of Resuscitation: revision card (adapted from the 2025 AHA Guidelines)

situations promptly changes management and can be the difference between a failed resuscitation and a successful one.

Special resuscitation situations share a common instructional purpose: they train the clinician to recognize when strict adherence to the standard adult Cardiac Arrest Algorithm alone will fail to save the patient, and when a specific, timely modification of that algorithm is required instead. In each of the scenarios below, the underlying cardiac arrest physiology is still addressed with standard high-quality CPR, defibrillation when indicated, and epinephrine — but an additional, situation-specific intervention is layered on top, and in several cases (pregnancy, tension pneumothorax, anaphylaxis, opioid overdose), the specific intervention is more important to the patient's survival than any single dose of a standard ACLS drug.

Cardiac arrest during pregnancy deserves particular emphasis because two patients are potentially affected and because a unique anatomic consideration — compression of the inferior vena cava and aorta by the gravid uterus once it rises above the pelvic brim, typically beyond approximately 20 weeks gestation — can itself prevent effective resuscitation if not addressed. Continuous manual left uterine displacement, performed by pushing the uterus leftward and cephalad throughout the resuscitation, relieves this aortocaval compression and restores venous return, and should be started immediately upon recognizing arrest in a visibly or reportedly pregnant patient, without interrupting compressions. If ROSC is not achieved within about four to five minutes, the team should proceed with perimortem cesarean delivery at the bedside, since evacuating the uterus relieves aortocaval compression far more effectively than displacement alone and gives both the mother improved chances of successful resuscitation and the fetus a chance of survival; this decision should not be delayed awaiting transport to an operating room.

Situation	Key modification
Pregnancy (cardiac arrest)	Perform manual left uterine displacement to relieve aortocaval compression; standard compression location/depth; if no ROSC by 4-5 minutes, prepare for and perform perimortem cesarean delivery to improve both maternal and fetal outcomes.
Opioid-associated emergency	Give naloxone (0.4-2 mg IV/IM/IN) if opioid overdose suspected with respiratory depression; if pulseless, follow standard cardiac arrest algorithm — naloxone does not replace CPR and ventilation.
Severe hyperkalemia	Give IV calcium chloride/gluconate to stabilize the myocardium, insulin with glucose to shift potassium intracellularly, sodium bicarbonate if acidotic, and consider albuterol and dialysis; may require prolonged resuscitation.
Local anesthetic systemic toxicity (LAST)	Give intravenous lipid emulsion therapy in addition to standard ACLS; reduce individual epinephrine doses if used; prolonged resuscitation may be required and can be successful.
Severe accidental hypothermia	Core temperature under 30°C: withhold or space out medications and limit shocks to one until rewarmed; focus on active rewarming; resuscitation may need to be prolonged, as patients can survive extended arrest.
Pulmonary embolism (suspected massive PE causing arrest)	Consider empiric fibrinolytic therapy during ongoing CPR if massive PE strongly suspected as the cause of arrest; consider surgical or catheter-based embolectomy where available.

Situation	Key modification
Drowning	Prioritize rescue breaths early (ventilation-first approach) given the primary hypoxic mechanism; standard CPR sequence otherwise once compressions begin.
Anaphylaxis	Give intramuscular epinephrine (0.3-0.5 mg of 1:1000 concentration) into the anterolateral thigh immediately, repeated every 5-15 minutes as needed; aggressive IV fluid resuscitation for distributive shock; if arrest occurs, standard ACLS with consideration of higher-dose/continuous epinephrine.
Severe asthma / bronchospasm causing arrest	Suspect breath-stacking/dynamic hyperinflation as a cause of PEA; disconnect the bag-mask or ventilator briefly to allow full exhalation and relieve auto-PEEP if arrest occurs during or after intubation; continue aggressive bronchodilator therapy and consider permissive hypercapnia.
Trauma-related cardiac arrest	Prioritize treatment of reversible traumatic causes (hemorrhage control, tension pneumothorax decompression, pericardiocentesis for tamponade) over standard drug algorithm; consider resuscitative thoracotomy in select penetrating trauma with recent signs of life.

Pediatric and Neonatal Resuscitation — Key Differences

Pediatric Cardiac Arrest — 2 Lanes

Start CPR • bag-mask + O₂ • attach monitor/defib → check rhythm

Shockable

VF / pVT

⚡ Shock ASAP

CPR 2 min
IV / IO

⚡ Shock

CPR 2 min
Epinephrine
Airway + capnography

⚡ Shock

CPR 2 min
Amiodarone / lidocaine
Treat H's & T's

Keep cycling shock → CPR. **Not shockable at a check** → no ROSC: non-shockable lane • ROSC: post-cardiac arrest care.

Non-shockable

Asystole / PEA

💉 Epinephrine ASAP

CPR 2 min • IV / IO
Epi every 3–5 min • airway + capnography

CPR 2 min

Treat H's & T's

Shockable at any check → shock lane (shock + CPR with epinephrine).

DRUG & SHOCK NUMBERS (IV / IO)

2 → 4 J/kg
1st → 2nd shock

≥ 4, max 10
J/kg or adult dose

0.01 mg/kg
epinephrine (max 1 mg)

5 mg/kg
amiodarone (max 300 mg)

1 mg/kg
lidocaine

HIGH-QUALITY CPR

≥ 1/3 AP
depth of chest

15 : 2
2 rescuers, pre-puberty

30 : 2
1 rescuer, or after puberty

1 / 2–3 s
with advanced airway

100–120/min • full recoil • minimise pauses • swap compressor every 2 min • monitor ETCO₂ (and invasive diastolic BP if available)

REVERSIBLE CAUSES — 6 H'S & 5 T'S

Hypovolemia • **Hypoxia** • **H⁺** (acidosis) • **Hypoglycemia** • **Tension pneumothorax** • **Tamponade** • **Toxins** • **Hypo/hyperkalemia** • **Hypothermia** • **Thrombosis** (pulmonary, coronary)

DON'T MISS IN THE EXAM

- Kids have **6 H's**: add **hypoglycemia**.
- Amiodarone may be repeated up to **3 doses** (max 150 mg for later doses).
- Epinephrine 0.01 mg/kg = **0.1 mL/kg** of the 0.1 mg/mL concentration.

Figure — Pediatric Cardiac Arrest: revision card (adapted from the 2025 AHA & AAP Guidelines)

Pediatric Bradycardia With a Pulse

Compromise + HR < 60 despite support → CPR

NUMBERS TO REMEMBER

< 60/min
start CPR if
compromised

0.01 mg/kg
epinephrine (max 1
mg)

0.02 mg/kg
atropine, may repeat
once

0.1–0.5 mg
atropine min – max
single dose

2 min
pulse checks

1 SIGNS

Cardiopulmonary compromise?

Acutely altered mental status • signs of shock • hypotension

NO

Treat causes: support ABCs, consider O₂
and 12-lead ECG • observe

YES

Support ▼

2 SUPPORT

Airway + oxygen • assist breathing (PPV) if needed

Cardiorespiratory monitor • monitor pulse

3 CPR

Still compromised? → start CPR if HR < 60

GIVE

IV / IO access •
epinephrine

ATROPINE FOR

Increased vagal tone or
primary AV block

THEN

Treat underlying causes •
consider transthoracic /
transvenous pacing

4 PULSE?

Check pulse every 2 min

PULSE PRESENT

Back to step 3 check — still compromised?

NO PULSE

Go to pediatric cardiac arrest (Card M)

POSSIBLE CAUSES

Hypothermia • hypoxia • toxins / medications • raised intracranial pressure • increased vagal tone • heart block • physiologic / appropriate

DON'T MISS IN THE EXAM

- In children, **epinephrine** is the first drug — atropine only for vagal tone or primary AV block.
- HR < 60 **with** poor perfusion needs CPR even though a pulse is present.

Figure — Pediatric Bradycardia With a Pulse: revision card (adapted from the 2025 AHA & AAP Guidelines)

Pediatric Tachyarrhythmia With a Pulse

Sinus or SVT? Then compromise × QRS width

DOSES (IV / IO, RAPID PUSH + FLUSH)

0.1 mg/kg
adenosine (max 6 mg)

0.2 mg/kg
repeat adenosine (max 12 mg)

0.5–1 J/kg
first cardioversion

2 J/kg
if not effective

1**SUPPORT****Airway • PPV + oxygen as needed • IV/IO**

Cardiorespiratory monitor • 12-lead ECG if available

STEP 2 • SINUS TACHYCARDIA OR SVT?

	Probable sinus tachycardia	Probable SVT
P waves	present / normal	absent / abnormal
RR interval	variable	not variable
Infant rate	usually < 220/min	usually ≥ 220/min
Child rate	usually < 180/min	usually ≥ 180/min
History	—	abrupt rate change
Action	search for and treat the cause	go to the 2 × 2 grid ▼

STEP 3 • PROBABLE SVT OR POSSIBLE VT → THE 2 × 2 GRID

Narrow QRS ≤ 0.09 s

Wide QRS > 0.09 s

Compromise YES	PROBABLE SVT Adenosine or cardioversion IV/IO in place → adenosine; otherwise synchronized cardioversion	POSSIBLE VT Synchronized cardioversion Expert consultation before further drugs
Compromise NO	PROBABLE SVT Vagal manoeuvres → adenosine Try vagal first, then IV/IO adenosine	VT OR SVT WITH ABERRANCY Adenosine only if regular + monomorphic Expert consultation recommended

DON'T MISS IN THE EXAM

- Paediatric wide QRS cut-off is > 0.09 s (adult ≥ 0.12 s).
- Sedate if needed but **do not delay** cardioversion.

SVT, supraventricular tachycardia • VT, ventricular tachycardia

Redrawn from the 2025 AHA & AAP Guidelines

Figure — Pediatric Tachyarrhythmia With a Pulse: revision card (adapted from the 2025 AHA & AAP Guidelines)

Pediatric BLS — 2 or More Rescuers

Infants to puberty • healthcare providers

NUMBERS TO REMEMBER

10 s
max pulse check

1 / 2–3 s
breaths (20–30/min)

HR < 60
+ poor perfusion → CPR

30:2 → 15:2
1 rescuer → 2 rescuers

1
SAFE

Scene safe? → Check responsiveness • shout for help • activate emergency response • send someone for the AED

2
CHECK

Breathing + pulse together, ≤ 10 s

NORMAL + PULSE
Monitor till
advanced care
arrives

ABNORMAL + PULSE
Open airway • 1 breath / 2–3 s • recheck
pulse at 2 min • opioid? → naloxone • HR <
60 with poor perfusion → CPR

NO PULSE
Start CPR ▼

3
CPR

Start CPR

First rescuer 30 : 2 • second rescuer arrives → 15 : 2 • AED as soon as available • opioid? → naloxone

4
AED

Rhythm check

SHOCKABLE
1 shock → CPR 2 min

NOT SHOCKABLE
CPR 2 min

↺ Repeat until PALS providers take over or the infant / child moves

DON'T MISS IN THE EXAM

- Two rescuers → 15 : 2; a lone rescuer uses 30 : 2.
- Breaths every 2–3 s — faster than the adult rate of every 6 s.

Figure — Pediatric BLS, 2 or More Rescuers: revision card (adapted from the 2025 AHA & AAP Guidelines)

Pediatric BLS — Single Rescuer

Infants to puberty • healthcare providers

NUMBERS TO REMEMBER

10 s
max pulse check**1 / 2–3 s**
breaths (20–30/min)**HR < 60**
+ poor perfusion → CPR**30:2 → 15:2**
1 rescuer → 2 rescuers**1**
SAFE

Scene safe? → Check responsiveness • shout for help • activate emergency response

2
CHECK

Breathing + pulse together, ≤ 10 s

NORMAL + PULSE
Monitor till
advanced care
arrives**ABNORMAL + PULSE**
Open airway • 1 breath / 2–3 s • recheck
pulse at 2 min • opioid? → naloxone • HR <
60 with poor perfusion → CPR**NO PULSE**
Start CPR ▼**2b**
ALONE

Witnessed sudden collapse?

YES
Activate EMS (if not done) • get the AED
and use it **immediately****NO**
Start CPR now**3**
CPR

Start CPR

First rescuer 30 : 2 • second rescuer arrives → 15 : 2 • AED as soon as available • opioid? → naloxone

After 2 min, still alone → activate EMS and fetch the AED (if not done)

4
AED

Rhythm check

SHOCKABLE
1 shock → CPR 2 min**NOT SHOCKABLE**
CPR 2 min

↻ Repeat until PALS providers take over or the infant / child moves

DON'T MISS IN THE EXAM

- Unwitnessed collapse → **2 min of CPR first**, then leave to call and get the AED.
- Witnessed sudden collapse → get the AED **first** (likely shockable).

Figure — Pediatric BLS, Single Rescuer: revision card (adapted from the 2025 AHA & AAP Guidelines)

Child Foreign-Body Airway Obstruction

Choking: judge severity, then back blows and thrusts

THE WHOLE CARD IN THREE BOXES

5 + 5 back blows + abdominal thrusts	Repeat until expelled or unresponsive	Unresponsive → CPR, compressions first
--	---	--

1 SAFE	Verify scene safety
------------------	---------------------

2 LOOK	Signs of severe obstruction? Weak or absent cough • unable to speak • cyanosis • altered mental status • apnea ABSENT Encourage coughing • keep watching for severe signs PRESENT Activate emergency response ▼
------------------	--

3 ACT	Is the child responsive? YES Repeated cycles of 5 back blows → 5 abdominal thrusts • repeat until expelled or the child becomes unresponsive • if expelled, monitor until advanced care arrives NO CPR until advanced care arrives (pediatric BLS, Cards P-Q) • start with compressions • look in the mouth for a visible object before each breath attempt
-----------------	--

ADULT VS CHILD VS INFANT

	Adult	Child	Infant
Severe sign	unable to speak	unable to speak	unable to cry
Back blows	5	5	5
Then	5 abdominal (chest if late pregnancy)	5 abdominal thrusts	5 chest thrusts
If unresponsive	CPR • adult BLS	CPR • pediatric BLS	CPR • pediatric BLS

DON'T MISS IN THE EXAM

- Mild obstruction (good cough) → **do not interfere**; encourage coughing.
- Child = abdominal thrusts, as in adults.
- Remove an object only if you can **see** it — no blind finger sweeps.

Figure — Child Foreign-Body Airway Obstruction: revision card (adapted from the 2025 AHA & AAP Guidelines)

Infant Foreign-Body Airway Obstruction

Choking: judge severity, then back blows and thrusts

THE WHOLE CARD IN THREE BOXES

5 + 5 back blows + chest thrusts	Repeat until expelled or unresponsive	Unresponsive → CPR, compressions first
--	---	--

1 SAFE	Verify scene safety
------------------	---------------------

2 LOOK	Signs of severe obstruction? Weak or absent cough • unable to cry • cyanosis • altered mental status • apnea ABSENT Encourage coughing • keep watching for severe signs PRESENT Activate emergency response ▼
------------------	--

3 ACT	Is the infant responsive? YES Repeated cycles of 5 back blows → 5 chest thrusts • repeat until expelled or the infant becomes unresponsive • if expelled, monitor until advanced care arrives NO CPR until advanced care arrives (pediatric BLS, Cards P-Q) • start with compressions • look in the mouth for a visible object before each breath attempt
-----------------	--

ADULT VS CHILD VS INFANT

	Adult	Child	Infant
Severe sign	unable to speak	unable to speak	unable to cry
Back blows	5	5	5
Then	5 abdominal (chest if late pregnancy)	5 abdominal thrusts	5 chest thrusts
If unresponsive	CPR • adult BLS	CPR • pediatric BLS	CPR • pediatric BLS


DON'T MISS IN THE EXAM

- Mild obstruction (good cough) → **do not interfere**; encourage coughing.
- Infants get **chest** thrusts — **never** abdominal thrusts.
- "Unable to cry" replaces "unable to speak".

Figure — Infant Foreign-Body Airway Obstruction: revision card (adapted from the 2025 AHA & AAP Guidelines)

Neonatal Resuscitation

Heart rate drives every step • < 100 → ventilate • < 60 → compress 3 : 1



TARGET PRE-DUCTAL SPO₂ AFTER BIRTH

65–70% at 2 min	70–75% at 3 min	75–80% at 4 min	80–85% at 5 min	85–95% at 10 min
---------------------------	---------------------------	---------------------------	---------------------------	----------------------------

DON'T MISS IN THE EXAM

- Steps 2–3 happen in the **first minute** — ventilation is the single most important action.
- Compressions only when HR stays < 60 despite effective ventilation — and raise O₂ to 100%.

CPAP, continuous positive airway pressure • UVC, umbilical venous catheter

Redrawn from the 2025 AHA & AAP Guidelines

Figure — Neonatal Resuscitation: revision card (adapted from the 2025 AHA & AAP Guidelines)

tested on how resuscitation principles change across the age spectrum, since pediatric and neonatal arrest differ substantially from adult arrest in both cause and management. The single most

important conceptual difference is etiology: adult cardiac arrest is most often a primary cardiac event (an arrhythmia arising from ischemic or structural heart disease), whereas pediatric and neonatal arrest is overwhelmingly a secondary event resulting from progressive respiratory failure or shock, meaning that asphyxial, hypoxic mechanisms — and therefore ventilation — take on even greater importance in these age groups than in adult arrest.

This etiologic difference explains why pediatric BLS retains a compression-to-ventilation ratio of 30:2 for a single rescuer but shifts to 15:2 for two-rescuer pediatric CPR (reflecting the greater emphasis on ventilation), and why, for an unwitnessed collapse in an infant or child, roughly two minutes of CPR are recommended before leaving the patient to retrieve a phone or AED, since the underlying cause is more often correctable with oxygenation and ventilation than with immediate defibrillation. In contrast, for a witnessed, sudden collapse in a child or adolescent (which raises suspicion for a primary arrhythmic event similar to adult arrest), activating emergency response and retrieving an AED immediately, as in adult BLS, is appropriate.

Parameter	Adult	Child (1 year to puberty)	Infant (under 1 year, excluding newly born)
Compression depth	At least 2 in (5 cm), not over 2.4 in (6 cm)	About 2 in (5 cm), or at least one-third the anteroposterior chest diameter	About 1.5 in (4 cm), or at least one-third the anteroposterior chest diameter
Compression technique	Two hands, heel of hand on lower sternum	One or two hands, heel of hand on lower sternum	Two-finger technique (single rescuer) or two-thumb encircling-hands technique (two rescuers)
Compression rate	100-120/min	100-120/min	100-120/min
Compression-ventilation ratio (no advanced airway)	30:2 regardless of rescuer number	30:2 single rescuer; 15:2 two-rescuer	30:2 single rescuer; 15:2 two-rescuer
Primary arrest etiology	Usually primary cardiac (arrhythmic)	Usually secondary to respiratory failure/shock	Usually secondary to respiratory failure/shock
Epinephrine dose	1 mg IV/IO fixed dose q3-5min	0.01 mg/kg (0.1 mL/kg of 1:10,000) IV/IO q3-5min, max single dose 1 mg	0.01 mg/kg (0.1 mL/kg of 1:10,000) IV/IO q3-5min
Defibrillation energy	120-200 J biphasic initial	2 J/kg initial, then 4 J/kg, then up to 10 J/kg or adult max	2 J/kg initial, then 4 J/kg, then up to 10 J/kg or adult max
Most common reversible causes	H's and T's (as detailed earlier in this chapter)	Hypoxia, hypovolemia, foreign body airway obstruction, sepsis	Hypoxia, hypovolemia, congenital heart disease, sepsis

Neonatal resuscitation (the newly born infant in the delivery room) follows an entirely separate algorithm distinct from pediatric ACLS, reflecting the unique transitional physiology of birth. The neonatal algorithm begins with warming, drying, positioning the airway, and stimulating the infant; if heart rate remains below 100 beats per minute despite these steps and effective positive-pressure ventilation, chest compressions are started using a compression-to-ventilation ratio of 3:1 (markedly

different from pediatric or adult ratios), coordinated so that compressions and breaths are not delivered simultaneously. Epinephrine dosing in the newly born is weight-based, and the overwhelming majority of newly born infants who require resuscitation respond to effective ventilation alone, without needing compressions or medications — underscoring, once again, that airway and breathing take precedence over circulatory interventions in this population.

Pediatric/Neonatal Pearls

- 1. Pediatric and neonatal arrest is usually a respiratory/hypoxic event, not a primary arrhythmia — ventilation is paramount.**
- 2. Two-rescuer pediatric/infant CPR ratio is 15:2, unlike the 30:2 used in adults regardless of rescuer number.**
- 3. Weight-based epinephrine dosing: 0.01 mg/kg IV/IO (0.1 mL/kg of 1:10,000 concentration) every 3-5 minutes.**
- 4. Pediatric defibrillation is weight-based: 2 J/kg initial, escalating to 4 J/kg, then up to 10 J/kg or adult maximum.**
- 5. Neonatal resuscitation uses a distinct 3:1 compression-ventilation ratio and prioritizes effective positive-pressure ventilation above all else.**

Team Dynamics and Communication

Resuscitation outcomes depend not only on individual clinical knowledge but on how effectively a multidisciplinary team functions under pressure. The AHA formally teaches team dynamics as a core ACLS competency, recognizing that breakdowns in communication and role clarity are common, preventable contributors to poor resuscitation performance.

The concept of cognitive load is central to understanding why team dynamics matter so much during resuscitation. A single provider attempting to simultaneously perform chest compressions, track elapsed time, remember when the last epinephrine dose was given, watch the monitor, and consider the H's and T's will inevitably perform each of these tasks worse than a team in which these responsibilities are explicitly divided among multiple people, each focused on a narrower set of tasks. Effective team structure is, in this sense, a direct patient-safety intervention: it reduces the cognitive burden on any single provider, creates redundancy so that a missed detail by one team member can be caught by another, and allows the team leader to dedicate full attention to the higher-order clinical reasoning that determines the overall trajectory of the resuscitation.

Simulation research consistently demonstrates that teams with strong communication and clearly defined leadership outperform teams with equal or even superior individual clinical knowledge but poor coordination. An effective team leader does not necessarily perform hands-on tasks; rather, the leader's primary responsibility is to maintain overview of the entire resuscitation — tracking elapsed time, rhythm, interventions given, and reversible causes considered — while assigning tasks clearly and monitoring the performance of the whole team. This global, low-task-saturation vantage point allows the leader to catch errors, reassign resources, and make higher-level decisions such as when to consider terminating resuscitation, that a provider absorbed in a single hands-on task would likely miss.

Team Roles and Responsibilities

Role	Core responsibilities
Team Leader	Directs the resuscitation without performing hands-on tasks; tracks time, rhythm, interventions given, and reversible causes; assigns tasks clearly and maintains the team's shared mental model.
Compressor	Delivers high-quality chest compressions; rotates with a backup compressor every 2 minutes (or sooner if fatigued) to prevent decline in compression quality.
Airway Manager	Opens and maintains the airway, provides bag-mask or advanced airway ventilation, confirms and monitors advanced airway placement with waveform capnography.
IV/IO & Medication Nurse	Establishes vascular access, prepares and administers medications on the leader's order, and states the drug, dose, and time given aloud as each is pushed.
Monitor/Defibrillator Operator	Attaches and interprets the monitor, charges and delivers shocks on the leader's command, and calls out the rhythm at each rhythm check.
Recorder/Timer	Documents the timeline in real time — every rhythm check, shock, drug, and airway intervention with the exact time — and prompts the leader when the next epinephrine dose or rhythm check is due.

- Establish clear roles at the outset: team leader, compressor, airway manager, medication/IV nurse, monitor/defibrillator operator, and recorder/timer; rotate roles as needed (e.g., compressor every 2 minutes).
- Use closed-loop communication: the team leader gives a clear, direct order to a specific person by name or role, that person verbally confirms receipt and states the action taken, and the leader acknowledges completion.

Worked example: Leader: “Priya, give epinephrine 1 milligram IV now.” Priya (drawing and pushing the drug): “Giving epinephrine 1 milligram IV now.” Priya, after pushing: “Epinephrine 1 milligram IV given.” Leader: “Epinephrine given, thank you — next dose due in 3 to 5 minutes.” This three-part loop — order, confirmation, completion — eliminates the two most common medication errors in resuscitation: a drug ordered but never actually given, and a drug given twice because two people each assumed the other had already given it.

- Give clear, unambiguous messages using standard terminology and appropriate volume/tone; avoid vague or ambiguous instructions.
- Know your role and limitations; ask for assistance or clarification early rather than attempting a task beyond your competence during a critical event.
- Practice constructive intervention: team members should feel empowered to speak up if they observe an error or unsafe action, and the team leader should encourage and respond non-defensively to this input (a key patient-safety principle known as psychological safety).
- Share a mental model: the team leader periodically summarizes the situation, actions taken, and next planned steps aloud so all members maintain situational awareness.
- Respect and support all team members; mutual respect improves team performance and reduces errors under stress.

- Debrief after every resuscitation attempt to identify successes and opportunities for improvement.

Chest Compression Fraction (CCF)

Chest Compression Fraction is the single most widely used quantitative metric of CPR quality, because interruptions in compressions — even brief ones for a pulse check, rhythm analysis, or airway attempt — cause coronary perfusion pressure to collapse and take a further 15 to 20 compressions to rebuild once compressions resume. A high CCF is therefore a direct proxy for how well the team is minimising these interruptions.

Element	Detail
Definition	CCF = (total time chest compressions are being delivered ÷ total resuscitation time) × 100%.
Target	AHA guidelines recommend a CCF of at least 60%, with most high-performing teams achieving 80% or higher.
Worked example	A 20-minute (1200-second) resuscitation in which compressions were paused for a total of 240 seconds (rhythm checks, defibrillation, airway placement) gives 960 seconds of compressions. CCF = $960 \div 1200 \times 100\% = 80\%$.
How to improve it	Charge the defibrillator during ongoing compressions rather than after stopping; limit the pre- and post-shock pause; pre-plan airway and IV/IO attempts to overlap with compressions; keep rhythm checks under 10 seconds.

Recorders and code-review teams calculate CCF retrospectively from defibrillator data logs as a standard component of post-resuscitation debriefing (see below), and many defibrillators now display a running CCF value in real time during the resuscitation itself to give the team immediate feedback.

Documentation and Debriefing After a Resuscitation Event

Accurate, contemporaneous documentation during a resuscitation is both a legal requirement and a clinical necessity, since the recorded timeline directly informs decisions made later in the same event (such as when the next epinephrine dose is due) as well as post-event review and quality improvement. In most hospital code teams, a designated recorder is responsible for this task so that no other team member is distracted from clinical duties by documentation, and the recorder should be positioned to see the clock, the monitor, and hear all verbal orders clearly.

- Record the exact time of arrest recognition, CPR initiation, and every rhythm check, with the rhythm identified at each check.
- Document every shock delivered, including energy level and rhythm immediately preceding the shock.
- Document every medication given, including drug, dose, route, and exact time, to ensure appropriate dosing intervals (e.g., epinephrine every 3-5 minutes) are maintained.
- Record airway interventions performed, including device used, time of placement, and confirmation method (e.g., waveform capnography reading).

- Note the time of ROSC, or, if resuscitation is terminated, the time and rationale for terminating efforts.
- Document team composition and roles, and any complications encountered during the resuscitation (e.g., difficult IV access, airway difficulty).
- Ensure the code documentation ultimately becomes part of the permanent medical record, since it directly informs post-arrest management and any subsequent review.

Following the resuscitation, a structured debrief benefits both patient care and team performance. Clinically, a brief debrief immediately after the event allows the team to confirm that all necessary post-ROSC actions have been initiated (12-lead ECG, temperature management orders, hemodynamic targets, family notification) before team members disperse. Separately, a longer, more reflective debrief — ideally conducted within 24 to 48 hours, in a blame-free, structured format — allows the team to review what went well, identify specific opportunities for improvement (such as delays in defibrillation, communication breakdowns, or equipment issues), and translate those lessons into systems-level changes, such as updated code cart stocking, revised protocols, or additional simulation training. Institutions with structured post-event debriefing programs have been shown to have measurably better CPR quality and outcomes over time, reinforcing that debriefing is not merely an administrative afterthought but an active component of the resuscitation system itself, closing the loop back to the beginning of the Chain of Survival for the next patient.

Common Pitfalls — Do Not Miss

1. Interrupting chest compressions for more than 10 seconds for pulse/rhythm checks, IV access, or airway attempts.
2. Shocking a non-shockable rhythm (asystole or organized PEA) — defibrillation has no benefit and delays effective therapy.
3. Giving atropine during pulseless arrest (PEA/asystole) — it is indicated only for symptomatic bradycardia with a pulse.
4. Failing to systematically consider and treat the H's and T's, especially in PEA and refractory arrest.
5. Over-ventilating the patient (too fast or too large a volume), which raises intrathoracic pressure and reduces venous return and coronary perfusion.
6. Delaying epinephrine administration in non-shockable rhythms — give it as soon as IV/IO access is available.
7. Failing to confirm and continuously monitor advanced airway placement with waveform capnography.
8. Not rotating compressors every 2 minutes, leading to fatigue and degraded compression quality without the team noticing.
9. Using synchronized cardioversion for polymorphic VT or a truly pulseless patient instead of unsynchronized defibrillation.
10. Poor closed-loop communication, leading to missed, duplicated, or delayed orders and medications during the code.
11. Treating sinus tachycardia as a primary arrhythmia with cardioversion or adenosine instead of addressing its underlying cause.
12. Using adult fixed drug doses or adult energy levels in a pediatric patient instead of correct weight-based dosing.

Quick Reference — Key ACLS Numbers

1. Compression rate: 100-120/min; depth at least 2 in (5 cm), not over 2.4 in (6 cm).
2. Compression-ventilation ratio: 30:2 without advanced airway; continuous compressions with 1 breath every 6 sec (10/min) with an advanced airway.
3. Defibrillation energy: biphasic 120-200 J (or per device); monophasic 360 J.
4. Epinephrine: 1 mg IV/IO every 3-5 minutes during arrest.
5. Amiodarone: 300 mg first dose, 150 mg second dose IV/IO for refractory VF/pVT.
6. Atropine: 1 mg IV every 3-5 minutes, maximum 3 mg, for symptomatic bradycardia only.
7. Adenosine: 6 mg rapid IV push, then 12 mg if needed, for stable narrow regular SVT.
8. Post-arrest targets (2025): temperature 32-37.5°C for ≥ 36 h (avoid cold IV saline), MAP ≥ 65 mmHg, SpO₂ 90-98%, PaCO₂ 35-45 mmHg.
9. Pediatric epinephrine: 0.01 mg/kg IV/IO q3-5min; pediatric defibrillation: 2 J/kg initial, then 4 J/kg, up to 10 J/kg or adult max.
10. Perimortem cesarean delivery: consider by 4-5 minutes without ROSC in a pregnant patient with a gravid uterus at/above the umbilicus.

HYPOTHERMIC CARDIAC ARREST

Cardiac arrest in a severely hypothermic patient is managed differently from normothermic arrest because the cold myocardium is both more prone to ventricular fibrillation and more resistant to defibrillation and standard drug therapy, and because deep hypothermia is markedly neuroprotective — patients have been resuscitated successfully after prolonged downtimes that would be uniformly fatal at normal body temperature. The guiding principle is often summarised as “no one is dead until warm and dead”: resuscitative efforts should not be terminated in a hypothermic patient on the basis of downtime or apparent lack of vital signs alone.

Severity	Core Temp	Typical Findings
Mild	32-35°C	Shivering, tachycardia, tachypnoea, confusion
Moderate	28-32°C	Shivering stops, bradycardia, dysrhythmia risk rises, reduced consciousness
Severe	<28°C	Coma, markedly reduced or absent vital signs, high risk of VF, pupils may be fixed and dilated

CPR and defibrillation. Start high-quality CPR and follow the standard adult cardiac arrest algorithm. Below approximately 30°C, the myocardium may not respond to defibrillation or to cardiac medications, so if an initial shock for a shockable rhythm is unsuccessful, further defibrillation attempts may be held while rewarming continues, then resumed once the core temperature rises above 30°C.

Medications. Drug metabolism is markedly slowed in hypothermia, risking toxic accumulation if standard dosing intervals are used. Many protocols withhold epinephrine and other resuscitation drugs below 30°C, then double the interval between doses (rather than the standard 3-5 minutes) between 30°C and 35°C, resuming normal intervals once normothermic.

Rewarming. Rewarming strategy is guided by severity: passive external rewarming (warm blankets, warm environment) for mild hypothermia; active external rewarming (forced-air warming blankets) plus active internal rewarming (warmed IV fluids, warm humidified oxygen) for moderate hypothermia; and active internal core rewarming — extracorporeal life support (ECMO/cardiopulmonary bypass) where available, or warmed peritoneal/pleural/bladder lavage where it is not — for a patient in arrest with severe hypothermia, since ECMO can rewarm at 1-2°C every 3-5 minutes while simultaneously providing circulatory support.

Handling and monitoring. Handle the patient gently and minimise movement, since a hypothermic, irritable myocardium can be provoked into VF by rough handling, including intubation or aggressive limb movement. Continue resuscitation and rewarming until the core temperature reaches at least 32°C, or ideally normothermia, before considering termination of efforts, and remember that other reversible causes (particularly the H's and T's, especially hypovolaemia and hypoglycaemia from prolonged cold exposure) should still be sought in parallel.

Common Pitfalls — Hypothermic Arrest

1. Declaring death based on downtime or apparent absence of vital signs without a confirmed low core temperature and adequate rewarming attempt.
2. Giving repeated standard-interval epinephrine doses below 30°C, risking toxic drug accumulation once the patient rewarms.
3. Handling or intubating the patient roughly, precipitating VF in an irritable, cold myocardium.

Amrita School of Medicine

2025 AHA GUIDELINE UPDATES — SUMMARY

The American Heart Association published a substantive update to the Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care in 2025. The single biggest structural change is the unification of the Chain of Survival described earlier in this chapter; the remaining changes are summarised below by domain for quick reference and exam revision.

Basic Life Support (BLS) — Key Changes

BLS 2025

Unified Chain of Survival: the OHCA/IHCA split is retired in favour of one six-link chain (Recognition & EMS activation, High-quality CPR, Defibrillation, Advanced Resuscitation, Post-Cardiac Arrest Care, Recovery & Survivorship).

Optimised rescuer position: position the patient's torso at roughly the level of the rescuer's knees to improve compression delivery.

Instrumented feedback devices are now strongly recommended during CPR training (professional and lay) to objectively measure performance.

Naloxone is explicitly integrated into the BLS algorithm for suspected opioid-associated respiratory or cardiac arrest, where available.

Adult choking sequence clarified: cycles of 5 back blows followed by 5 abdominal thrusts until the object is expelled or the person becomes unresponsive.

Head-and-neck trauma: if the airway remains obstructed despite jaw-thrust and adjuncts, trained rescuers may proceed to head-tilt/chin-lift.

Obesity: adults with obesity in cardiac arrest should receive CPR using the same methods as non-obese patients.

Routine use of mechanical CPR devices is not recommended for adult cardiac arrest.

ACLS — Key Changes

ACLS 2025

Physiology-guided CPR: continuous arterial blood pressure and ETCO₂ monitoring are recommended to guide CPR quality toward specific haemodynamic targets.

Supraglottic airway is recommended over endotracheal tube for OHCA in settings where tracheal-intubation success rates are low.

A specialised Maternal Cardiac Arrest Team should be alerted and used when available for resuscitation of a pregnant patient; fetal monitoring should not be used during arrest.

IV calcium for suspected hyperkalaemia-related arrest has uncertain effectiveness; evidence remains unclear.

Head-up CPR is discouraged outside rigorous clinical trials; routine Double Sequential Defibrillation is not recommended for refractory VF.

Vasopressin shows no advantage over epinephrine.

Anti-arrhythmics other than amiodarone/lidocaine (β -blockers, bretylium, procainamide, sotalol) have uncertain benefit in arrest.

Synchronized cardioversion energies updated: narrow-complex tachycardia 100 J, monomorphic VT 100 J, atrial fibrillation 200 J, atrial flutter 200 J, polymorphic VT treated as defibrillation (unsynchronized). Sotalol removed from the tachycardia algorithm; "supraventricular tachycardia" renamed "narrow-complex tachycardia."

Post-cardiac arrest temperature control: target 32-37.5°C, maintained at least 36 hours in non-responding patients; avoid cold IV saline infusion; maintain MAP ≥ 65 mmHg and SpO₂ 90-98%.

Tenecteplase added as an approved thrombolytic for acute stroke.

ACS management: LBBB removed as a definitive STEMI criterion; clopidogrel removed as a primary agent; fentanyl added alongside morphine for pain control; enoxaparin or fondaparinux as anticoagulants; ACE inhibitors added.

Ventilation: fixed tidal-volume targets (600-800 mL) removed — new instruction is to squeeze the bag one-third to one-half, enough to see visible chest rise. Medication delivery via the endotracheal tube has been removed.

Paediatric Advanced Life Support (PALS) — Key Changes

PALS 2025

Early epinephrine for non-shockable rhythms (asystole/PEA) in infants and children is reaffirmed and linked to improved outcomes.

Infant chest compressions: the 2-finger technique is no longer taught; use 2 thumb-encircling hands or the heel-of-1-hand technique instead.

Choking management: child (≥ 1 yr) — alternate 5 back blows with 5 abdominal thrusts; infant (<1 yr) — alternate 5 back blows with 5 chest thrusts using the heel of one hand (no finger-based compressions).

CPR quality monitoring by invasive diastolic blood pressure: target ≥ 25 mmHg in infants, ≥ 30 mmHg in children.

Post-cardiac arrest care: avoiding hyperthermia (core temperature $>37.5^\circ\text{C}$) is emphasised as improving neurological outcome.

Source: American Heart Association, 2025 Guidelines for CPR and Emergency Cardiovascular Care.

Important Questions — Advanced Cardiac Life Support

Frequently asked long-answer, short-note and viva questions for the MD/MS examination

1

LONG ANSWER

Describe the adult cardiac arrest algorithm for shockable (VF/pVT) and non-shockable (asystole/PEA) rhythms, including the timing and doses of drugs.

Key points: CPR first, rhythm check every 2 min • shock energies • epinephrine 1 mg every 3–5 min (ASAP in non-shockable, after 2nd shock in VF/pVT) • amiodarone 300/150 mg or lidocaine • H's and T's

2

SHORT NOTE

What are the components of high-quality CPR, and how is CPR quality monitored during resuscitation?

Key points: Depth $\geq$ 5 cm, rate 100–120/min, full recoil, minimal pauses, avoid over-ventilation, rotate compressors • waveform capnography / ETCO_2 • arterial diastolic pressure where available

3

LONG ANSWER

Outline the management of adult bradycardia and tachycardia with a pulse. When is electrical therapy indicated?

Key points: Assess for cardiopulmonary compromise • atropine $\rightarrow$ pacing / dopamine / epinephrine • unstable tachycardia $\rightarrow$ synchronized cardioversion (energies) • stable: narrow vs wide QRS, vagal manoeuvres, adenosine

4

SHORT NOTE

Discuss post-cardiac arrest care and the physiological targets after ROSC.

Key points: Airway and capnography • SpO_2 90–98%, PCO_2 35–45 mm Hg • MAP $\geq$ 65 mm Hg • 12-lead ECG and emergency angiography • temperature control • EEG • multimodal prognostication $\geq$ 72 h

5

SHORT NOTE

List the reversible causes of cardiac arrest (H's and T's) and explain how you would identify and treat any two.

Key points: Hypovolemia, hypoxia, H^+ , hypo/hyperkalemia, hypothermia • tension pneumothorax, tamponade, toxins, pulmonary and coronary thrombosis

6

VIVA

How does resuscitation differ in pregnancy, in children and in the newborn?

Key points: Left lateral uterine displacement, delivery by 5 min • pediatric 15:2 and weight-based doses (2 $\rightarrow$ 4 J/kg) • neonatal ventilation first, HR thresholds 100 and 60, compressions 3:1

Tip: answer long questions with a labelled flow chart or table — examiners reward structure.

CHAPTER 2 — GOOD CLINICAL PRACTICE (GCP)

Introduction and Historical Background

Good Clinical Practice, universally abbreviated as GCP, is the international ethical and scientific quality standard that governs the design, conduct, recording, and reporting of clinical trials involving human participants. It exists because clinical research, by its very nature, exposes people to interventions whose benefits and risks are not yet fully known. Every rule that a medical or nursing student encounters in GCP training today traces back to a specific historical failure in which human subjects were harmed, deceived, or exploited in the name of science. Understanding this history is not a formality; it explains why GCP is structured the way it is, and it equips clinicians to recognise the warning signs of unethical research when they see them.

The modern era of research ethics begins with the Nuremberg Code of 1947, drafted in response to the atrocities committed by Nazi physicians who conducted lethal and mutilating experiments on concentration camp prisoners without consent. The Nuremberg Military Tribunal, in judging these physicians, articulated ten principles that must govern human experimentation. The single most influential of these is the very first: that the voluntary, informed consent of the human subject is absolutely essential. The Code also introduced the ideas that research must be scientifically justified, that unnecessary suffering must be avoided, and that subjects must be free to withdraw at any time. Although the Nuremberg Code had no direct legal force in most countries, it became the moral foundation for every subsequent ethical code in research.

The World Medical Association built upon Nuremberg with the Declaration of Helsinki, first adopted in 1964. Unlike the Nuremberg Code, which arose from a criminal trial, the Declaration of Helsinki was written by physicians for physicians and framed research ethics as a matter of professional duty rather than only legal compliance. It introduced the critical distinction between therapeutic and non-therapeutic research, established the primacy of the wellbeing of the individual research subject over the interests of science and society, and formally recommended independent review of research protocols by an ethics committee before a study begins. The Declaration has since been revised many times (notably in 1975, 1983, 1989, 1996, 2000, 2008, and 2013), each revision responding to emerging issues such as placebo use, post-trial access to treatment, and research in vulnerable or resource-limited populations. It remains a living document and a touchstone of medical professional ethics worldwide.

In the United States, the Belmont Report of 1979 was produced by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. It distilled research ethics into three foundational principles, respect for persons, beneficence, and justice, that remain the conceptual backbone of GCP to this day. The Belmont Report was a direct response to the public exposure, in 1972, of the Tuskegee Syphilis Study, in which the United States Public Health Service had, beginning in 1932, enrolled hundreds of poor African American men with syphilis in Alabama and deliberately withheld effective penicillin treatment, even after it became the standard of care in the 1940s, purely to observe the natural progression of untreated disease. Subjects were never told they had syphilis, were never given the option to leave the study, and were misled about the nature of the study for forty years. The Tuskegee study is taught in every GCP curriculum as the

paradigmatic case of what happens when informed consent, independent oversight, and respect for subject welfare are absent; it remains the single most cited justification for mandatory ethics committee review and continuous safety monitoring in clinical research today.

The Belmont Report's recommendations were codified into United States federal regulation through the National Research Act of 1974 and, later, the Federal Policy for the Protection of Human Subjects, commonly called the Common Rule, first adopted in 1991 and substantially revised in 2018. The Common Rule established the requirement for prospective IRB review at any institution receiving federal research funding, mandated documented informed consent, and created special protections for vulnerable populations such as children, prisoners, and pregnant women. Similar regulatory frameworks developed in parallel elsewhere: the United Kingdom's Research Governance Framework, the European Union's Clinical Trials Directive and later Clinical Trials Regulation, and comparable national frameworks in Japan, India, and beyond. What distinguished these regional frameworks was that, while all shared the same ethical DNA traceable to Nuremberg and Helsinki, their specific procedural and documentation requirements diverged enough to create real friction for sponsors trying to run the same trial across multiple countries simultaneously.

As pharmaceutical development became increasingly global through the late twentieth century, regulators recognised that differing national requirements for clinical trials were duplicating effort, delaying access to new medicines, and creating inconsistent protections for research subjects across countries. This led to the founding of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) in 1990, a joint initiative of regulatory authorities and pharmaceutical industry associations from the European Union, Japan, and the United States. One of the ICH's landmark achievements was the E6 Guideline for Good Clinical Practice, first issued in 1996, which harmonised the ethical and scientific quality standards for designing, conducting, recording, and reporting trials in a single internationally accepted document. In 2016, ICH issued the E6(R2) addendum, which strengthened requirements around risk-based quality management, sponsor oversight of outsourced trial activities, electronic data handling, and the essential documents required in a trial, reflecting the growing complexity of modern, often multinational and technology-enabled, clinical trials. E6(R2) is the current global reference standard and the version examined in this chapter, although students should be aware that ICH finalised a further update, E6(R3), beginning in 2023, which further modernises the guideline around a principles-based, technology-agnostic approach to quality by design; E6(R2) nonetheless remains the operative standard referenced by most current regulatory inspections and training programmes at the time of writing.

One practical consequence of ICH harmonisation deserves particular mention for students who will later work across borders: regulatory authorities increasingly rely on Mutual Recognition Agreements and shared inspection reports, so that a GCP inspection conducted by one authority (for example the European Medicines Agency inspecting a site in a non-EU country) can be relied upon by another authority (for example the US FDA) rather than duplicating the same inspection independently. This mutual reliance model, sometimes described as inspection harmonisation, depends entirely on all parties applying a genuinely common standard, which is precisely what ICH-GCP E6 was designed to provide; it is also why a serious compliance finding at a single site in one

country can rapidly become visible to regulators worldwide, rather than remaining a purely local matter.

Year	Milestone	Key Contribution to GCP
1932-1972	Tuskegee Syphilis Study exposed	Cautionary case demonstrating harm from absent consent, oversight, and transparency
1947	Nuremberg Code	Established voluntary informed consent as absolutely essential
1964	Declaration of Helsinki (WMA)	Physician ethical duty; introduced independent ethics review
1974	US National Research Act	Mandated IRB review for federally funded research; created the Belmont Commission
1979	Belmont Report	Three core principles: respect for persons, beneficence, justice
1990	ICH founded	Harmonised international pharmaceutical/trial standards
1991 / 2018	US Common Rule adopted / revised	Codified IRB review, consent, and vulnerable population protections into federal law
1996	ICH-GCP E6 (original)	First unified international GCP guideline
2016	ICH-GCP E6(R2) addendum	Risk-based quality management, sponsor oversight, e-data integrity
2023 onward	ICH-GCP E6(R3)	Principles-based, technology-agnostic modernisation of quality by design

Definition of GCP and Its Purpose

ICH-GCP E6(R2) defines Good Clinical Practice as an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety, and wellbeing of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that the clinical trial data generated are credible. GCP is therefore not a single rule but a comprehensive framework spanning ethics, science, and quality management, and it applies to every phase of clinical drug, device, and biologic development, from first-in-human studies through post-marketing trials.

GCP serves two purposes that are inseparable and mutually reinforcing. The first is subject protection: ensuring that no person who volunteers for research, whether a healthy volunteer or a patient, is exposed to unreasonable risk, is denied full information about what participation entails, or is coerced or unduly influenced into enrolling. The second is data credibility: ensuring that the results produced by a trial are accurate, complete, verifiable, and free from bias or fraud, so that regulatory authorities, clinicians, and patients can trust the conclusions drawn about a medicine's safety and efficacy. A trial that protects subjects but produces unreliable data has failed just as

surely as one that produces reliable data at the cost of subject welfare; GCP compliance requires both simultaneously.

The consequences of failing to meet the GCP standard are severe and extend well beyond a single site or study. When a regulatory authority such as the US Food and Drug Administration, the European Medicines Agency, or a national competent authority inspects a trial and finds significant GCP non-compliance, the possible outcomes range from a formal warning letter, to rejection of the affected data from a marketing application, to disqualification of an investigator from conducting further regulated research, to criminal prosecution in cases involving fraud or wilful harm to subjects. Because pivotal trials often underpin a medicine's approval in multiple countries simultaneously, a serious compliance failure discovered at one site can jeopardise the entire development programme, delaying patient access to a needed therapy by years and imposing enormous financial cost on the sponsor. This is why GCP is treated not as an administrative burden but as the load-bearing infrastructure of trustworthy medicine.

- GCP applies to all stakeholders in a trial: sponsors, investigators, institutions, ethics committees, monitors, and regulatory authorities.
- GCP is legally binding in most jurisdictions once a trial is conducted for regulatory submission purposes, and is enforced through inspections and audits.
- GCP principles apply regardless of trial phase (I to IV), trial type (drug, device, biologic, behavioural), or funding source.
- Non-compliance with GCP can result in data being rejected by regulators, trial suspension, loss of investigator licensure, and civil or criminal liability.
- Regulatory inspection findings are typically graded by severity (e.g., critical, major, minor), and a pattern of major or critical findings can trigger a For-Cause audit of an investigator's entire research portfolio.

The Ethical Foundations of GCP

Beneath the procedural requirements of GCP lie four bioethical principles that give the framework its moral coherence. These principles, most systematically articulated by Beauchamp and Childress and echoed in the Belmont Report, are not abstract philosophy; they translate directly into concrete GCP requirements such as informed consent forms, risk-benefit assessment by ethics committees, and equitable subject selection criteria. Every clause in a study protocol or consent document can ultimately be traced back to one or more of these four foundations.

Principle	Definition	GCP Application Example
Autonomy	The right of an individual to make voluntary, informed decisions about their own body and participation in research	Informed consent process; the right to withdraw from a trial at any time without penalty
Beneficence	The obligation to act in ways that promote the wellbeing and benefit of research subjects	Designing trials with a favourable risk-benefit ratio; providing appropriate medical care for trial-related injury

Principle	Definition	GCP Application Example
Non-maleficence	The duty to avoid causing harm, or to minimise foreseeable harm, to research subjects	Stopping rules and interim safety analyses; exclusion criteria that protect high-risk individuals
Justice	The fair distribution of the benefits and burdens of research across populations, with no group unfairly targeted or excluded	Equitable subject recruitment; prohibiting selection of vulnerable populations solely for administrative convenience

In everyday trial conduct these four principles frequently pull in different directions at once, and much of the practical skill of ethical research lies in navigating that tension rather than pretending it does not exist. Autonomy and beneficence, for example, can conflict when a subject wishes to withdraw from a study that is providing clear clinical benefit to them, or when a subject wants to enrol in a study that the investigator believes carries excessive personal risk; in both situations, GCP resolves the tension firmly in favour of autonomy, because respecting a competent person's own judgement about their body takes precedence over a paternalistic assessment of what is 'good' for them. Non-maleficence and beneficence must likewise be weighed together at the design stage: almost no clinical intervention is entirely free of risk, so ethics committees are not asked to eliminate all risk but to confirm that anticipated benefit, to the subject or to future patients, reasonably justifies the risk that remains after all feasible safeguards have been built into the protocol. Justice was the principle most flagrantly violated in the Tuskegee case: poor, African American men were selected because they were an accessible and disempowered population, not because the research question specifically required them, and modern GCP's emphasis on equitable, scientifically justified inclusion and exclusion criteria exists precisely to prevent that pattern of exploitation from recurring in a different form.

Ethics in Practice

1. Autonomy and beneficence can conflict, for example when a subject wants to withdraw from a study that is providing them clear clinical benefit; autonomy must prevail.
2. Justice was central to the Tuskegee case: poor, African American men were selected because they were an accessible and disempowered population, not because the research question required them specifically.
3. Non-maleficence underlies the requirement for Data Safety Monitoring Boards in higher-risk trials.

The Thirteen Core Principles of ICH-GCP E6

ICH-GCP E6 sets out thirteen core principles that apply to every clinical trial, regardless of phase, therapeutic area, or geography. These principles are frequently tested in GCP certification examinations and should be committed to memory in substance, if not in exact wording. They function as the constitutional text from which every more detailed GCP requirement, on consent, documentation, monitoring, and reporting, is derived.

#	Core Principle
1	Trials should be conducted in accordance with the ethical principles of the Declaration of Helsinki, and consistent with GCP and applicable regulatory requirements
2	Before a trial is initiated, foreseeable risks and inconveniences should be weighed against the anticipated benefit for individual subjects and society; a trial should be initiated and continued only if the anticipated benefits justify the risks
3	The rights, safety, and wellbeing of trial subjects are the most important considerations and should prevail over interests of science and society
4	Available nonclinical and clinical information on an investigational product should be adequate to support the proposed clinical trial
5	Trials should be scientifically sound and described in a clear, detailed protocol
6	A trial should be conducted in compliance with the protocol that has received prior institutional review board/independent ethics committee approval
7	The medical care given to, and medical decisions made on behalf of, subjects should always be the responsibility of a qualified physician or, when appropriate, a qualified dentist
8	Each individual involved in conducting a trial should be qualified by education, training, and experience to perform their respective tasks
9	Freely given informed consent should be obtained from every subject prior to trial participation
10	All trial information should be recorded, handled, and stored in a way that allows accurate reporting, interpretation, and verification
11	The confidentiality of records that could identify subjects should be protected, respecting privacy and confidentiality rules
12	Investigational products should be manufactured, handled, and stored in accordance with applicable good manufacturing practice and used in accordance with the approved protocol
13	Systems with procedures that assure the quality of every aspect of the trial should be implemented (quality management)

It is useful to group these thirteen principles conceptually rather than treat them as an undifferentiated list. Principles 1, 2, 3, and 9 are fundamentally ethical: they concern the moral justification for doing research on human beings at all, and the primacy of subject welfare and consent. Principles 4, 5, 6, and 7 are scientific and clinical: they require that a trial be well designed, adequately supported by prior evidence, properly authorised, and medically supervised. Principles 8, 10, 11, 12, and 13 are operational and quality-focused: they concern the competence of trial personnel, the integrity of data, the protection of privacy, the handling of investigational product, and the overarching quality management system that ties everything together. Seeing the structure this way helps explain why a violation in one area, for instance inadequate investigator training under principle 8, so often cascades into failures elsewhere, such as poor documentation under principle 10 or compromised subject safety under principle 3.

Institutional Review Board / Independent Ethics Committee (IRB/IEC)

An Institutional Review Board (the term generally used in the United States) or Independent Ethics Committee (the term used in many other regions) is an independent body composed of medical, scientific, and non-scientific members whose responsibility is to protect the rights, safety, and wellbeing of human subjects involved in a trial. No clinical trial may begin, and no amendment to an ongoing trial may take effect, without prior review and documented approval or favourable opinion from the IRB/IEC. This independence from the sponsor and investigator is the single most important structural safeguard in the entire GCP system, because it ensures that the people evaluating a study's ethics have no financial or professional stake in seeing it approved.

ICH-GCP requires that an IRB/IEC be composed of a reasonable number of members who collectively have the qualifications and experience to review and evaluate the science, medical aspects, and ethics of a proposed trial. Membership must include at least one member whose primary area of interest is non-scientific (for example, a lawyer, ethicist, or member of the clergy) and at least one member who is independent of the institution or trial site, to guard against institutional conflicts of interest. Committees must also have both male and female members where local context requires, and members who are affiliated with a study under review must recuse themselves from voting on that study.


Not every protocol submitted to an IRB/IEC requires review by the full convened committee. Most committees operate an expedited review pathway, conducted by the chair or a small designated subcommittee, for research involving no more than minimal risk and falling within specific predefined categories, such as minor amendments to previously approved research, or continuing review of a study where all subjects have completed active intervention and only long-term follow-up remains. Expedited review still carries the full authority of the committee but allows low-risk decisions to be made without the delay of waiting for the next scheduled full-board meeting. In large multinational trials, sponsors increasingly rely on a single central IRB/IEC to review the protocol on behalf of many participating sites, rather than requiring separate local review at every institution; this model, sometimes called a central or commercial IRB, improves consistency of review and shortens trial start-up timelines, while local institutions typically retain a residual local context review to confirm that site-specific factors, such as local standard of care or institutional resources, have been adequately considered.

- Review responsibilities include evaluating the scientific soundness of the protocol, the qualifications of the investigator, the adequacy of facilities, the informed consent document and process, subject recruitment materials, and the provisions for compensation or care in the event of trial-related injury.
- Continuing review must occur at intervals appropriate to the degree of risk, but at least once every twelve months, to confirm the trial remains safe and ethically sound and to review any new safety information.
- Quorum, the minimum number and composition of members required to be present for a valid decision, must be defined in the committee's written operating procedures and met at every meeting where a vote is taken; typically this requires both scientific and non-scientific members to be present.

- The IRB/IEC must maintain written records of all meetings, decisions, and the rationale for those decisions, and must communicate its decisions in writing to the investigator or sponsor within a defined timeframe.
- The IRB/IEC has the authority to approve, require modifications to secure approval, disapprove, or terminate/suspend approval of any trial-related activity.

The IRB/IEC Review and Approval Process

The passage of a protocol through ethics committee review follows a broadly consistent sequence across institutions, although local timelines and documentation formats vary. Investigators and coordinators should understand this pathway because delays or omissions at any step can stall a trial's start-up or, worse, place a site out of compliance if activities begin before formal approval is documented.



A site that allows its IRB/IEC approval to lapse, for example by missing the deadline for continuing review, must halt all trial-related activities involving subjects, including screening and enrolment, until approval is reinstated; any subjects already enrolled generally continue to receive medically necessary care and safety monitoring, but no new study procedures should be initiated. This

scenario, an expired approval, is one of the most frequently cited findings in regulatory inspections and is entirely preventable with a well-maintained regulatory tracking calendar at the site level.

The Informed Consent Process

Informed consent is the process by which a subject voluntarily confirms their willingness to participate in a trial, after having been informed of all aspects relevant to that decision. It is a process, not merely a signed document: the signed Informed Consent Form (ICF) is the record that the process occurred, not a substitute for it. Consent must be obtained before any trial-specific procedure is performed, must be given freely without coercion or undue inducement, and must be documented in writing, dated, and signed (or thumb-printed with an impartial witness where the subject cannot read) by both the subject and the person who conducted the consent discussion. Consent is an ongoing obligation: subjects must be informed promptly if new information emerges that may affect their willingness to continue.

Required Element	What It Must Convey to the Subject
Purpose of the research	That the study involves research, its objectives, and the expected duration of participation
Procedures	What will be done to the subject, including any invasive or experimental procedures and randomisation if applicable
Risks and benefits	Reasonably foreseeable risks or discomforts, and any expected benefits to the subject or others
Alternatives	Any appropriate alternative procedures or treatments available, including the option of no treatment
Voluntary participation	That participation is voluntary and refusal involves no penalty or loss of benefits otherwise entitled
Confidentiality	That records identifying the subject will be kept confidential, and who may access them (monitors, auditors, IRB, regulators)
Compensation and costs	Any compensation for participation, and whether treatment for trial-related injury is available and who bears its cost
Contact information	Whom to contact for questions about the trial, subject rights, or in the event of injury
Right to withdraw	That the subject may withdraw at any time without penalty or loss of benefits to which they are otherwise entitled

Consent is rarely a one-time event in a trial of any meaningful duration. Whenever material new information becomes available, such as an updated safety finding, an amended protocol procedure, or a revised risk-benefit assessment, subjects who are already enrolled must be re-consented using a revised, IRB/IEC-approved consent form before continuing in the study. This process, generally called re-consent, must be documented with the same rigour as the original consent: a newly dated and signed form, and, where the change is significant, a fresh explanation and opportunity to ask questions. Sites must also take care to always use the current, approved version of the consent

form; continuing to consent new subjects using an outdated version after an amendment has been approved is a well-recognised and entirely avoidable GCP violation.

Cultural and linguistic context materially affects how informed consent should be delivered. Consent forms must be translated into a language the subject understands and, wherever feasible, the discussion should be conducted in that same language, using a professional interpreter rather than a family member, to avoid inadvertent mistranslation or pressure. In some cultural contexts, decisions that are formally individual are, in practice, made collectively within a family or community; GCP does not prohibit family involvement in the decision-making conversation, but it does require that the final decision and signature be the subject's own free choice, and investigators must be alert to situations where family or community pressure crosses the line into coercion.

Vulnerable Populations in Research — Extended Guidance

Certain populations require special consent procedures and additional protections because their capacity to consent freely or fully is limited, because they are in a position of reduced power relative to the investigator, or because coercion, even unintentional, is more likely. GCP does not prohibit enrolling vulnerable subjects in research; excluding them entirely would itself be a form of injustice, denying them potential access to beneficial investigational treatment. Instead, GCP requires additional, specific safeguards proportionate to the vulnerability involved.

In paediatric research, a parent or legally authorised guardian must provide consent, and the child, where developmentally capable, should provide assent, an affirmative agreement to participate expressed in age-appropriate language; a child's dissent should generally be respected even when a parent has consented, particularly in non-therapeutic research. For subjects who are cognitively impaired or otherwise lack decision-making capacity, consent must be obtained from a legally authorised representative, and the subject's assent should still be sought to the extent they are able to understand and communicate a preference. Emergency research, where the condition under study (for example cardiac arrest or severe traumatic brain injury) precludes prospective informed consent, is permitted under strict regulatory exception frameworks that require community consultation, public disclosure, an independent data monitoring committee, and consent from a legally authorised representative as soon as feasible, with the subject's own consent sought for continued participation once they regain capacity.

Prisoners and other institutionalised or detained individuals occupy a uniquely constrained position: the very fact of incarceration or institutionalisation can make voluntary consent difficult to establish, because participation may be perceived, rightly or wrongly, as a route to improved conditions, earlier parole consideration, or simply a welcome change from routine. GCP and most national regulatory frameworks therefore require that research involving prisoners be limited to specific permitted categories (commonly conditions particularly affecting prisoners as a class, or studies of the incarceration experience itself), that a prisoner representative sit on the reviewing IRB/IEC, and that any possible benefit of participation, such as payment, not be of a magnitude that could impair the subject's ability to weigh the risks realistically against everyday prison life.

Pregnant women and their fetuses require particular consideration because an intervention can affect two lives with potentially different risk-benefit balances, and because pregnant women have

historically been excluded from trials altogether, an approach now recognised as its own form of injustice that leaves clinicians without adequate safety and dosing data for this population. Modern GCP and regulatory guidance favour a more nuanced approach: inclusion should be considered where the research question specifically requires pregnant women (for example, studies of a condition unique to or more severe in pregnancy), where the risk to the fetus is minimal, and where the consent process explicitly addresses the risks to both the pregnant woman and the fetus. Students, employees, and subordinates of the investigator, along with staff members of the research institution itself, present a different form of vulnerability: the power differential between, for example, a professor-investigator and their own student, or a hospital and its junior staff, creates a realistic risk that a person could feel obligated to participate to avoid professional disadvantage, even where no explicit threat is made. GCP addresses this through heightened scrutiny of the consent process in such relationships, sometimes requiring that consent be obtained by a party not in a position of authority over the potential subject, and through IRB/IEC attention to whether recruitment materials or incentives could function as undue influence.

- Economically or educationally disadvantaged persons may be more susceptible to undue influence from payment or from the promise of otherwise-unaffordable medical care; IRBs/IECs specifically assess whether compensation is fair without being coercive for the specific population being recruited.
- Terminally ill patients may over-estimate the likelihood of personal therapeutic benefit from an experimental treatment (the 'therapeutic misconception'), so consent discussions with this population must be especially explicit about the uncertain and often unproven nature of the intervention.
- Adults with fluctuating or borderline decision-making capacity (for example, early dementia) may require a capacity assessment at the time of consent, and re-assessment at subsequent visits, rather than a single one-time judgement.
- Refugee, displaced, or non-citizen populations may fear that declining to participate, or withdrawing, could affect their access to care or their immigration status; investigators must proactively clarify that this is never the case.

Roles and Responsibilities of Key Stakeholders

A clinical trial is a collaborative undertaking involving distinct parties, each with clearly defined GCP obligations. Confusion about who is responsible for what is a common root cause of GCP violations, particularly at sites running multiple concurrent studies. The table below summarises the principal duties of each stakeholder as defined in ICH-GCP E6(R2).

Stakeholder	Key Duties
Sponsor	Designs and funds the trial; selects qualified investigators Ensures adequate safety monitoring and reporting to regulators Oversees quality management, including risk-based monitoring

Stakeholder	Key Duties
Investigator	Conducts the trial per protocol and GCP at the site Protects subject rights, safety, and wellbeing; obtains informed consent Maintains accurate source documents and reports safety events promptly
Sub-Investigator	Performs delegated trial procedures under the Principal Investigator's supervision Must be listed on the delegation of duties log with defined tasks Shares responsibility for GCP compliance for tasks personally performed
Clinical Research Coordinator (CRC)	Manages day-to-day study logistics and subject visits Assists with consent process, data entry, and specimen handling under investigator delegation Maintains regulatory binder and supports monitor/auditor visits
Monitor / Clinical Research Associate (CRA)	Verifies subject rights are protected and data are accurate (source data verification) Confirms protocol and GCP compliance at the site Reports monitoring findings to the sponsor and follows up on corrective actions
Sponsor's Medical Monitor	Provides ongoing medical/scientific oversight of the trial for the sponsor Reviews and adjudicates reported serious adverse events for causality and expectedness Advises investigators on protocol-related clinical questions
Biostatistician	Designs the statistical analysis plan and sample size justification Performs interim and final analyses, including any planned interim safety looks Supports randomisation scheme design and blinding integrity
Pharmacovigilance / Drug Safety Physician	Processes and medically reviews incoming safety reports Determines SUSAR status and expedited regulatory reporting obligations Maintains the aggregate safety database and signal detection activities
Data Safety Monitoring Board (DSMB)	Independently reviews unblinded interim safety and efficacy data Recommends trial continuation, modification, or early termination Operates independently of sponsor and investigator influence
IRB / IEC	Reviews and approves protocol, consent forms, and amendments before implementation Conducts continuing review at appropriate intervals Safeguards subject rights independent of sponsor or investigator interests
Regulatory Authority	Authorises the trial to proceed (e.g., IND/CTA review) and the investigational product's use Inspects sites, sponsors, and IRBs/IECs for GCP compliance Reviews safety reports and can require trial modification, suspension, or termination

Sponsors increasingly delegate operational trial tasks, ranging from monitoring to data management to safety reporting, to Contract Research Organisations (CROs). ICH-GCP E6(R2) is explicit that delegating a task does not delegate the sponsor's ultimate responsibility for the quality and integrity of the trial: the sponsor remains fully accountable for the trial's compliance with GCP regardless of how many functions are outsourced. This is why E6(R2) placed new emphasis on sponsor oversight of CROs, requiring documented vendor qualification, clear contractual definition of delegated tasks,

and ongoing sponsor oversight activities, such as periodic CRO performance audits, throughout the life of the trial rather than a one-time qualification check at contract signature.

GCP Training and Investigator Qualification

ICH-GCP core principle 8 requires that every individual involved in conducting a trial be qualified by education, training, and experience to perform their assigned tasks, and this requirement is operationalised through a combination of formal GCP certification, documented professional credentials, and a site-specific delegation of duties log. Before an investigator or coordinator can be granted access to trial-related activities, the site must be able to demonstrate, on paper, that the person is competent to perform the specific tasks they will undertake.

Formal GCP training, whether delivered as part of a university curriculum, an institutional research office programme, or a recognised external certification (several widely used courses are accredited against the Transcelerate mutual recognition standard used across much of the pharmaceutical industry), typically covers the historical background and ethical foundations described earlier in this chapter, the thirteen core ICH-GCP principles, the informed consent process, IRB/IEC roles and responsibilities, adverse event identification and reporting, source documentation standards, and investigational product accountability. Most sponsors and institutions require GCP certification to be renewed periodically, commonly every two to three years, both because regulatory guidance evolves and because refresher training measurably reduces the rate of documentation and consent errors found at monitoring visits and audits.

The Principal Investigator (PI) bears ultimate responsibility for the conduct of the trial at their site, but in practice delegates many specific tasks to sub-investigators, coordinators, pharmacists, and other qualified staff. This delegation must be documented on a delegation of duties log (sometimes called a delegation log), a living document that lists every individual authorised to perform trial-related tasks, the specific tasks each is authorised to perform, the date delegation began (and ended, if applicable), and evidence that the person is qualified for that task, cross-referenced to their curriculum vitae, professional licence, and GCP training record. A delegation log that is not kept current, for example listing a staff member who left the study team eight months earlier as still authorised, or failing to add a new coordinator before they begin performing consent discussions, is one of the most commonly cited findings in regulatory inspections, precisely because it is so easy to overlook amid the daily pressures of running a trial.

- Investigator CVs must be current, signed, and dated, and should be updated and re-filed whenever there is a material change in qualifications, licensure, or professional role.
- Medical licences and any required specialty certifications must be verified as active and unrestricted for the duration of the investigator's participation in the trial.
- Financial disclosure forms, documenting any financial interest the investigator or their immediate family holds in the sponsor or investigational product, must be completed before the trial begins and updated if circumstances change, to allow sponsors and regulators to assess potential conflicts of interest.

- Site staff performing informed consent, adverse event assessment, or protocol-specified clinical evaluations must have delegation specifically covering those tasks; delegation of purely administrative tasks does not authorise clinical judgement calls.
- Training records (GCP certification, protocol-specific training, and training on any amendment) should be retained in the site regulatory file alongside the delegation log, since monitors and auditors routinely cross-check the two documents against each other.

Because clinical trials frequently involve staff and institutions across many countries, several industry consortia have worked to establish mutually recognised GCP training standards so that a certificate earned through one accredited provider is accepted by sponsors and institutions worldwide, rather than requiring staff to repeat substantially similar training for every new sponsor relationship. This portability matters practically: a nurse or physician moving from an academic medical centre to a community-based research site, or a coordinator supporting several concurrent industry-sponsored trials, should not need duplicate certification purely because different sponsors historically favoured different training vendors. What sponsors and institutions do still require, regardless of where the underlying GCP certificate originated, is protocol-specific training delivered separately for each individual study, since GCP certification establishes general competence but can never substitute for training on the specific procedures, risks, and requirements of the particular trial a staff member is about to support.

Essential Documents and the Trial Master File

Essential documents are those which individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. They are compiled into the Trial Master File (TMF) at the sponsor level and an Investigator Site File at the site level. Regulatory inspectors and auditors reconstruct the entire history of a trial from these documents, so their completeness, accuracy, and timeliness are treated as a direct proxy for GCP compliance. ICH-GCP E6(R2) organises essential documents according to the three stages of a trial: before the trial commences, during the clinical conduct of the trial, and after completion or termination of the trial.

Trial Stage	Essential Document	Purpose
Before trial commences	Protocol and amendments (including signature page)	Defines objectives, design, methodology, and statistical plan; signature page evidences investigator agreement to conduct per protocol
Before trial commences	Investigator's Brochure (IB)	Summarises nonclinical and clinical data on the investigational product
Before trial commences	Informed Consent Form (template)	Documents the information to be provided to subjects
Before trial commences	Investigator CVs and medical licenses	Evidences qualification of study personnel
Before trial commences	IRB/IEC approval letter and committee composition/roster	Documents ethics committee authorisation to begin and confirms independence/quorum
Before trial commences	Financial disclosure and insurance/indemnity documentation	Discloses conflicts of interest; confirms coverage for trial-related injury

Trial Stage	Essential Document	Purpose
During the trial	Signed and dated Informed Consent Forms	Evidence that each subject consented before participation
During the trial	Case Report Forms (CRFs)	Records subject data collected per protocol
During the trial	Monitoring visit reports	Documents monitor findings and follow-up actions
During the trial	Drug/investigational product accountability records	Tracks receipt, dispensing, and return/destruction of study product
During the trial	Randomisation and blinding/code-break records	Documents allocation scheme and any instances where blinding was broken, with justification
During the trial	SAE and safety reports	Documents identification and reporting of safety events
After completion/termination	Final study report	Summarises conduct, results, and any deviations for the full trial
After completion/termination	Certificate of investigational product destruction/return	Confirms disposition of unused study product
After completion/termination	Study closure/IRB closure report	Formally closes out site and ethics committee oversight

Because the Trial Master File is the artefact against which every regulatory inspection is ultimately conducted, sponsors and sites increasingly track TMF completeness in real time using electronic TMF systems with automated completeness and timeliness metrics, rather than waiting until study closure to discover gaps. A commonly cited inspection-readiness benchmark is that a TMF should be able to demonstrate that essential documents were filed contemporaneously, that is, close to the time the underlying event occurred, rather than reconstructed or backfilled shortly before an anticipated audit; a TMF that is complete but was assembled retrospectively immediately before an inspection is itself a signal of poor ongoing quality management, even if every individual document appears satisfactory in isolation.

Trial Master File Principles

1. The TMF must permit reconstruction of the trial's conduct at any point, even years after completion, for audit or inspection.
2. ICH-GCP E6(R2) requires records be retained for the period specified by applicable regulatory requirements, often many years post-approval or discontinuation.
3. Electronic TMF systems must have audit trails, access controls, and validated backup procedures.

Adverse Event Classification and Reporting Timelines

Accurate classification of safety events is fundamental to protecting current and future trial subjects, because it determines how urgently information must be escalated to sponsors, ethics committees, and regulators. GCP defines a hierarchy of terms, moving from any untoward medical occurrence

through to the most urgent category requiring expedited regulatory reporting. Investigators must be trained to correctly distinguish these categories, because misclassification (commonly under-classification) is one of the most frequently cited findings in GCP inspections.

Term	Definition	Reporting Timeline
Adverse Event (AE)	Any untoward medical occurrence in a subject administered a study product, not necessarily caused by it	Recorded in the CRF for every visit; no expedited reporting required unless it becomes serious
Adverse Drug Reaction (ADR)	An AE for which a causal relationship with the investigational product is at least a reasonable possibility	Recorded in CRF; escalated if also serious or unexpected
Serious Adverse Event (SAE)	An AE resulting in death, life-threatening event, hospitalisation or prolongation of hospitalisation, persistent/significant disability, congenital anomaly, or other medically important event	Investigator to sponsor: within 24 hours of awareness
Unexpected Adverse Event	An AE whose nature or severity is not consistent with the applicable Investigator's Brochure or product information	Assessed alongside seriousness to determine SUSAR status
Adverse Event of Special Interest (AESI)	A pre-specified AE of scientific or medical concern (serious or not) that requires ongoing, focused monitoring and rapid communication to the sponsor	Reported per protocol-specific timeline, often faster than routine AEs even if non-serious
SUSAR (Suspected Unexpected Serious Adverse Reaction)	A serious event that is both unexpected (not in the Investigator's Brochure) and suspected to be caused by the investigational product	Fatal/life-threatening: sponsor to regulator/IRB within 7 calendar days, with complete follow-up within 8 additional days; all other SUSARs: within 15 calendar days


Determining whether an event is a suspected adverse reaction requires a structured causality assessment, considering factors such as the temporal relationship between exposure and the event, whether the event resolves on stopping the product (dechallenge) or recurs on restarting it (rechallenge), the presence of a more likely alternative explanation such as underlying disease or concomitant medication, and any known class-effect or mechanistic plausibility. Many sites use a structured causality scale (categories such as unrelated, unlikely, possible, probable, and definite) to standardise this judgement across investigators and reduce inter-rater variability; whatever scale is used, the investigator's causality assessment must be documented with a brief written rationale, not simply a checked box, because this assessment directly drives whether an event proceeds down the expedited SUSAR reporting pathway.

Beyond individual case reports, sponsors are also required to periodically compile and submit aggregate safety information covering all accumulated data on an investigational product across every ongoing trial, commonly known as a Development Safety Update Report (DSUR) and typically submitted annually to regulators and to participating IRBs/IECs. Unlike an individual SAE or SUSAR report, which addresses a single event in a single subject, the DSUR examines the safety profile in aggregate, looking for emerging patterns, changes in the frequency or severity of known risks, and

any new signals that would not be apparent from any one case in isolation. Investigators and IRBs/IECs are expected to review the DSUR for their trial and consider whether the evolving safety profile changes the trial's risk-benefit balance sufficiently to warrant a protocol amendment, an updated consent form, or, in rare cases, early termination of the study.

The Serious Adverse Event Reporting Pathway

The following pathway illustrates how a safety event identified at a trial site moves through assessment and escalation. The investigator's initial causality and expectedness assessment is the critical decision point that determines which of three reporting routes a given event follows; sponsors then bear responsibility for further escalation to regulators, ethics committees, and any independent safety oversight body.



In blinded trials, an unresolved question is often whether reporting a suspected SUSAR requires unblinding the subject's treatment assignment. Regulatory guidance generally favours unblinding individual cases when knowledge of the assigned treatment is necessary to assess the event properly or to satisfy expedited reporting obligations, while taking steps to limit unblinded information to only those personnel who need it (typically the sponsor's safety physician and the regulatory reporting team), so that the study team responsible for ongoing subject assessment and outcome measurement remains blinded wherever possible. Where a DSMB exists, it is typically the only body with routine access to unblinded aggregate safety and efficacy data, allowing it to assess emerging

risk-benefit trends without breaking the blind for the wider study team or biasing ongoing data collection.

Monitoring, Quality Assurance, and Quality Control

Monitoring is the act of overseeing the progress of a clinical trial to ensure it is conducted, recorded, and reported in accordance with the protocol, standard operating procedures, GCP, and applicable regulatory requirements. It is the sponsor's principal mechanism for confirming, in real time, that subject rights are protected and that data being generated at the site are accurate and verifiable. Quality assurance (QA) refers to the planned, systematic actions established to ensure the trial is performed and data generated, documented, and reported in compliance with GCP, while quality control (QC) refers to the operational techniques and activities used to verify that quality requirements have actually been fulfilled, such as checking a percentage of CRF entries against source documents.

Visit Type	Timing	Primary Purpose
Pre-study (site selection) visit	Before site is selected	Assess site's facilities, staff qualifications, and feasibility to conduct the trial
Site initiation visit	Before first subject enrolled	Train site staff on protocol, GCP, and study procedures; confirm site readiness
Routine/interim monitoring visits	Periodically throughout enrolment and follow-up	Source data verification, review of consent documentation, drug accountability, and safety reporting
For-cause monitoring visit	Triggered by a specific concern (e.g., data irregularity, complaint, non-compliance signal)	Focused, in-depth review of the specific issue and its broader impact on the site's data and subjects
Centralised/remote monitoring review	Ongoing, between or in place of some on-site visits	Statistical review of aggregated data across sites to detect trends, outliers, or potential fraud
Close-out visit	After last subject completes/study ends at site	Reconcile all data and drug supplies; confirm essential documents are complete and archived

Source data verification (SDV) is the process of comparing data recorded in the CRF against the original source documents (for example, medical charts, laboratory reports, and imaging records) to confirm accuracy, completeness, and consistency. Traditionally SDV was performed on one hundred percent of data points, but E6(R2) explicitly endorses risk-based monitoring, an approach in which monitoring intensity and methods (on-site, centralised/remote, or a combination) are tailored to the specific risks of a given trial, site, or data point, concentrating monitoring resources on the areas of greatest risk to subject safety and data integrity rather than applying uniform scrutiny everywhere. Risk-based monitoring can include centralised statistical review of data trends across sites to detect outliers, unusual patterns, or potential fraud that on-site visits alone might miss.

The shift toward remote and centralised monitoring accelerated markedly from 2020 onward, when travel restrictions made frequent on-site visits impractical for many ongoing trials, and sponsors and

regulators alike gained confidence that a well-designed combination of remote source document review (using secure electronic health record access or remote video review), centralised statistical monitoring, and targeted on-site visits could maintain equivalent oversight quality to traditional, purely on-site models. This experience has permanently changed monitoring practice: most current risk-based monitoring plans now combine periodic on-site visits, focused on the highest-risk activities such as consent verification and investigational product accountability, with continuous centralised data review that can flag an emerging problem at a specific site far sooner than a visit occurring only once every eight to twelve weeks would.

- Risk-based quality management (as emphasised in E6(R2)) requires sponsors to identify critical data and processes early, assess risks to those items, and implement proportionate mitigation and monitoring strategies.
- Monitors document every visit in a written monitoring report, including findings, follow-up items, and communications with site staff.
- Escalation pathways must exist for significant non-compliance findings so they reach appropriate sponsor management, and, where warranted, the IRB/IEC and regulators.

Students frequently conflate monitoring, auditing, and inspection, but the three activities are distinct in both purpose and authority. Monitoring, as described above, is performed by or on behalf of the sponsor on an ongoing basis throughout the trial, and is primarily supportive: its goal is to identify and correct issues in real time, before they compound. An audit is a systematic, independent examination of trial-related activities and documents, conducted by the sponsor's own quality assurance function (deliberately separate from the clinical operations team running the trial), to assess GCP compliance and to verify that the routine monitoring process is itself functioning effectively; audits are typically periodic and risk-triggered rather than continuous. An inspection is conducted by a government regulatory authority, carries statutory force, and can result in formal regulatory action, up to and including rejection of trial data or disqualification of an investigator; inspections may occur routinely for pivotal trials supporting a marketing application, or may be triggered for cause by a specific complaint or safety signal. A site with a mature quality culture treats sponsor audits as a genuine opportunity to identify and fix problems before an inspection does, rather than as an adversarial exercise to be merely survived.

Investigational Product Management

Core principle 12 of ICH-GCP requires that investigational products be manufactured, handled, and stored in accordance with applicable good manufacturing practice, and used in accordance with the approved protocol. In practice, this translates into a demanding set of site-level responsibilities collectively referred to as drug accountability, covering the entire lifecycle of the investigational product from the moment it arrives at the site to its final destruction or return to the sponsor.


Every shipment of investigational product received at a site must be logged, including the quantity, lot or batch number, expiry date, and condition on arrival, and reconciled against the sponsor's shipping documentation. The product must then be stored under the conditions specified in the protocol and product labelling, most commonly a defined temperature range that is continuously monitored, using calibrated equipment, with a documented, auditable temperature log. A temperature excursion, any deviation outside the specified storage range, must be identified


promptly (ideally through an automated alert system), the affected product quarantined immediately and not dispensed to any subject, and the sponsor notified so that a stability assessment can determine whether the affected product remains usable or must be discarded. Failure to detect or act on a temperature excursion in a timely manner is a recurring and serious inspection finding, because it directly threatens both subject safety, if compromised product is administered, and data integrity, if drug potency has degraded in a way that affects efficacy results.

Dispensing of investigational product to each subject must be individually logged: the date, quantity dispensed, lot number, the subject's own identification, and the identity of the staff member who dispensed it. For oral or self-administered products, sites typically also perform drug accountability at each return visit, counting returned unused product and comparing it against what was dispensed, to calculate a compliance percentage and to identify any pattern suggesting under-dosing, over-dosing, or non-adherence that could affect both subject safety and the reliability of efficacy results. A complete chain of custody, an unbroken documented record of who had control of the investigational product at every point from manufacture through administration or destruction, must be maintained and must be reconstructable from the accountability records alone, without needing to rely on staff recollection.

Randomisation and blinding procedures are also part of investigational product management in blinded trials: unblinded pharmacy staff or an interactive response technology (IRT/IVRS) system typically manage allocation and dispensing precisely so that the site's clinical team remains blinded to treatment assignment, preserving the scientific validity of the comparison. Any instance in which the blind is broken, whether through a genuine medical emergency requiring the treating physician to know the subject's assignment, or through an accidental unblinding event, must be documented with the date, the reason, and who authorised or performed the unblinding, since premature or unjustified unblinding can compromise the interpretability of trial results and, in some cases, require the subject's data to be handled differently in the final analysis.

Temperature control begins well before the product reaches the site: cold-chain shipments, common for biologics and many injectable products, are typically dispatched with a validated shipping container and an embedded electronic data logger that continuously records temperature during transit. On receipt, site staff must download or read this shipment-level temperature record, in addition to confirming that ongoing site storage conditions are satisfactory, since a product can arrive with normal appearance and correct labelling while having nonetheless been compromised in transit by an excursion the receiving staff would have no way of detecting through visual inspection alone. Any transit excursion must be handled with the same rigour as an in-house storage excursion: the affected units quarantined, the sponsor notified, and the product withheld from dispensing pending a documented stability determination.





- Storage areas for investigational product must be secure and access-limited, typically to designated pharmacy or delegated study staff only.
- Expired investigational product must never be dispensed; expiry dates must be checked at each dispensing occasion, not only at receipt.
- Discrepancies in accountability records (e.g., missing units, unexplained overages) must be documented, investigated, and reported to the sponsor and, where significant, to the IRB/IEC.
- Destruction of unused investigational product must follow the sponsor's approved procedure and be documented with a signed certificate of destruction, including quantities and method.

Data Integrity: The ALCOA-C Principles

Because regulatory decisions about the safety and efficacy of medical products rest entirely on the data collected during trials, GCP places heavy emphasis on data integrity. The ALCOA-C mnemonic (an extension of the original ALCOA framework developed by the US FDA) summarises the attributes that all trial data, whether paper or electronic, must possess to be considered trustworthy and inspection-ready.

Principle	One-Line Explanation
Attributable	It must be clear who recorded the data and when, with no anonymous or unattributed entries
Legible	Data must be readable and permanent, not erased, obscured, or written in a way that cannot be clearly interpreted

Principle	One-Line Explanation
Contemporaneous	Data must be recorded at the time the observation or activity occurred, not reconstructed later from memory
Original	The first recording of data (or a certified true copy) must be preserved; original source records should not be discarded
Accurate	Data must correctly reflect what actually happened, free from transcription or measurement errors
Complete	All data, including repeat or corrected results and any excluded data, must be retained with a documented reason for exclusion

As trials have moved from paper case report forms toward electronic data capture (EDC) systems, electronic source records, and eConsent platforms, data integrity expectations have extended to computerised systems validation, a requirement that any software used to create, modify, or store regulated trial data be formally validated to demonstrate it performs as intended, is secure against unauthorised access or alteration, and produces a complete, tamper-evident audit trail of every entry and change (an expectation frequently referenced against frameworks such as the US FDA's 21 CFR Part 11). For students and clinicians who will primarily work at the site level, the practical implication is that logging into an EDC system under a colleague's credentials, sharing passwords for convenience, or making an entry on someone else's behalf without clear attribution each independently breaches the attributable principle, even if the underlying clinical data entered is entirely accurate.

A frequently underappreciated aspect of data integrity is that generating an audit trail is not, by itself, sufficient; the audit trail must also be actively reviewed. GCP-mature organisations build periodic audit trail review into their quality processes, specifically looking for patterns such as data being entered and then altered shortly before a monitoring visit, entries made outside of expected working hours or by a user who was not at the site on the date in question, or a disproportionate volume of late corrections clustered around a specific subject or visit. None of these patterns is, by itself, proof of misconduct, but each is exactly the kind of signal that a well-designed audit trail review is intended to surface for further investigation, and reviewing the trail only reactively, after a problem has already been suspected through some other route, defeats much of its purpose.

Data Integrity in Practice

1. Any correction to a paper source document should follow the single-line-strike-through convention: strike through the original entry so it remains legible, write the correction, then date and initial the change.
2. Electronic systems must generate a secure, time-stamped audit trail that captures every data entry and modification.
3. Backdating entries or altering source documents to match CRF data after the fact is data fabrication and a serious GCP violation.

Trial Registration and Transparency

Modern GCP requires far more than protecting the subjects enrolled in a given trial; it also requires transparency to the broader scientific and patient community. Sponsors are generally obligated to register interventional clinical trials on a public, recognised clinical trial registry (for example, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform, or regional equivalents) before enrolling the first subject, and to post summary results within a defined period after trial completion, regardless of whether the results are favourable. This requirement exists to prevent selective publication of only positive results (publication bias) and to allow patients, clinicians, and researchers to identify ongoing and completed studies relevant to a given condition.

Protocols evolve during a trial as new information emerges, recruitment challenges arise, or safety data prompt design changes. Any protocol amendment that could affect subject safety, the scope of the investigation, or the scientific quality of the trial must receive prior IRB/IEC approval, and often prior regulatory authority notification or approval, before implementation. The only exception is where an amendment is necessary to eliminate an immediate hazard to subjects, in which case it may be implemented immediately with subsequent, prompt notification to the IRB/IEC and regulator.

Registry transparency obligations do not end at initial registration: sponsors must also keep the registry record current throughout the trial, updating recruitment status, key eligibility criteria if amended, and the estimated completion date, and must correct the record promptly if material errors are identified. Many major medical journals now enforce this obligation editorially, refusing to publish results from any trial that was not prospectively registered before enrolment began, a policy adopted specifically to close the loophole of authors registering a trial only after seeing which outcomes turned out favourable, a practice known as selective outcome reporting.

Protocol Deviations vs Protocol Violations — How They Are Classified and Handled

GCP distinguishes between a protocol deviation and a protocol violation, a distinction that is frequently tested and frequently misunderstood in practice. A protocol deviation is any unplanned departure from the approved protocol that does not significantly affect the subject's rights, safety, or wellbeing, or the integrity of the study data (for example, a study visit conducted two days outside its allowed window). A protocol violation is a more serious departure that does compromise subject safety, rights, or data integrity, or that represents a wilful or repeated pattern of non-compliance (for example, enrolling a subject who did not meet eligibility criteria, or failing to obtain informed consent before a procedure). All deviations must be documented and reported to the IRB/IEC per its policy; violations typically trigger a formal corrective and preventive action (CAPA) plan and may require regulatory notification.

Many sponsors and sites further stratify deviations into a graded severity scale, commonly minor, major, and critical, to standardise how quickly each must be reported and how significant the resulting corrective action must be. A minor deviation, such as a laboratory sample collected slightly outside its specified time window with no clinical consequence, is generally logged and trended but does not require individual expedited reporting. A major deviation, such as a missed safety assessment that delays detection of a potential adverse event, requires prompt reporting to the sponsor and IRB/IEC and a documented corrective action to prevent recurrence. A critical deviation, effectively equivalent to a protocol violation, such as administering the wrong dose of investigational

product or enrolling a subject who did not meet a safety-critical exclusion criterion, requires immediate reporting, an urgent clinical safety assessment of the affected subject, and, frequently, a root cause analysis examining whether the same failure could have affected other subjects or sites.

The corrective and preventive action process that follows a significant deviation or violation typically involves several linked steps: first, an immediate correction addressing the specific instance, such as promptly re-obtaining a compliant consent or notifying a subject of a missed assessment; second, a root cause analysis asking why the failure occurred, distinguishing between a one-off human error, a systemic training gap, or a flawed site process; third, a corrective action addressing the immediate cause, such as retraining a specific staff member; and fourth, a preventive action addressing the underlying system, such as revising a site standard operating procedure or adding a checklist step, so that the same category of error is structurally less likely to recur, not merely less likely because one individual has been reminded to be careful. Sponsors and monitors specifically look for evidence of this fourth, systemic step, because corrective action alone without preventive action tends to produce recurring findings of the same type at subsequent visits.

Individual deviations also carry meaning in aggregate, and sponsors increasingly analyse deviation data at the level of an entire trial or even an entire investigator's research portfolio rather than reviewing each occurrence in isolation. A single site reporting an unusually high rate of a specific deviation type compared with other sites running the same protocol, for example a disproportionate number of visit-window deviations, may indicate a local scheduling or staffing problem worth addressing proactively, even though no single instance would independently meet the threshold for a major finding. This trending approach reflects the broader shift in GCP toward risk-based, data-driven oversight: rather than treating every deviation as an isolated administrative event, mature quality systems treat the pattern of deviations across a programme as an early warning signal for where additional training, resources, or process redesign is needed.

Aspect	Protocol Deviation	Protocol Violation
Impact on subject safety/rights	Minimal or no impact	Significant, actual or potential impact
Impact on data integrity	Minimal or no impact	Significant, actual or potential impact
Typical example	Visit conducted outside allowed window	Enrolling an ineligible subject; consent obtained after procedure began
Required action	Document and report per IRB/IEC policy	Document, report urgently, implement CAPA, notify regulator if required
Recurrence pattern	Isolated, non-systemic	May reflect wilful or repeated non-compliance
Severity grading (typical)	Graded minor to major depending on consequence	Generally graded critical; may meet the threshold for regulatory notification
Downstream consequence	Logged and trended for site quality oversight	May prompt for-cause audit, additional monitoring, or investigator disqualification in severe/repeated cases

Worked Case Study: A Documented GCP Violation and Its Consequences

Consider a realistic, composite scenario based on patterns commonly identified in regulatory inspection reports, useful for illustrating how a seemingly small documentation lapse can escalate into a significant compliance event. At a mid-sized academic site conducting a Phase III cardiovascular outcomes trial, a routine monitoring visit identified that the informed consent form for one enrolled subject was dated by the subject one day after the date recorded for the subject's baseline screening procedures, including a blood draw and an electrocardiogram. In other words, the documentation suggested that trial-specific procedures had been performed before consent was obtained, a direct breach of ICH-GCP core principle 9.

The monitor flagged the discrepancy in the monitoring visit report and escalated it to the sponsor's clinical operations and quality teams the same day, in line with the site's escalation pathway for significant findings. The sponsor initiated a for-cause review, which involved re-examining source documents for every subject enrolled by the same coordinator, interviewing the coordinator and the investigator, and reviewing the site's consent-taking process from end to end. The review established that the discrepancy was not an isolated data entry error: the coordinator had, under time pressure to meet a recruitment target set by the site, drawn blood and performed the electrocardiogram for two additional subjects before completing the consent discussion, intending to 'complete the paperwork afterward,' apparently believing this posed no real risk to subjects because the procedures themselves were low-risk and would have been performed anyway once consent was obtained minutes later.

This finding was classified as a critical protocol violation, not a minor documentation deviation, because it represented an actual breach of the fundamental requirement that consent precede any trial procedure, and because the root cause analysis revealed a repeated pattern affecting multiple subjects rather than a single clerical mistake. The consequences unfolded across several levels. At the subject level, the affected subjects were re-consented, with the discrepancy and its implications explained to them, and offered the choice to continue or withdraw from the study; all three elected to continue. At the site level, the sponsor issued a formal corrective action request requiring the coordinator to undergo retraining on consent procedures before resuming any subject-facing duties, and required the site to revise its workflow so that screening procedures could not be initiated in the electronic system until a consent completion checkbox, verified by a second staff member, had been marked. At the sponsor level, the finding was reported to the IRB/IEC as a protocol violation, and, because it affected data integrity for a pivotal trial, was disclosed to the regulatory authority in the site's next periodic compliance update; the affected subjects' data were retained in the safety analysis but flagged and excluded from the per-protocol efficacy population.

The broader lesson drawn from this case, and from similar real inspection findings that follow the same underlying pattern, is that GCP violations rarely originate from malicious intent; they far more often originate from well-intentioned staff facing operational pressure (recruitment targets, understaffing, or a packed visit schedule) who make a shortcut decision without recognising its regulatory significance. This is precisely why root cause analysis and preventive, systemic action, rather than blame directed solely at the individual, are central to an effective GCP quality culture: fixing only the individual's behaviour leaves the underlying pressure that caused the shortcut fully

intact, and therefore leaves the site vulnerable to the same failure recurring with a different staff member.

Common Pitfalls — Do Not Miss

1. Consent obtained after a study procedure has already started, rather than strictly before.
2. Missing or incomplete source documentation that cannot support the data recorded in the CRF.
3. Delegation log not updated to reflect who is currently authorised to perform specific study tasks.
4. Continuing trial activities after IRB/IEC approval has expired.
5. Under-reporting or late reporting of Serious Adverse Events beyond the required timelines.
6. Protocol deviations occurring but not being documented or reported to the IRB/IEC.
7. Inadequate investigational product/drug accountability records, with unexplained discrepancies in dispensed versus returned product.
8. Coercive or overly persuasive language in the consent process or recruitment materials.
9. Using an outdated version of the informed consent form after an amendment has been approved.
10. Failing to obtain an impartial witness signature when consenting an illiterate subject.
11. Undetected or unaddressed temperature excursions in investigational product storage.

Quick Reference — GCP Essentials

1. GCP protects subject rights, safety, and wellbeing while ensuring credible trial data (ICH-GCP E6(R2)).
2. Four ethical foundations: Autonomy, Beneficence, Non-maleficence, Justice.
3. Thirteen ICH-GCP core principles govern every trial, with subject rights/safety/wellbeing prevailing over science and society.
4. Informed consent must be voluntary, fully informed, documented, and obtained before any trial procedure.
5. SAE reporting: investigator to sponsor within 24 hours; fatal/life-threatening SUSARs to regulator/IRB within 7 days (+8-day follow-up); other SUSARs within 15 days.
6. ALCOA-C: Attributable, Legible, Contemporaneous, Original, Accurate, Complete.
7. IRB/IEC continuing review must occur at least annually; approval must never be allowed to lapse.
8. Protocol deviations (minor, no significant impact) differ from protocol violations (significant impact on safety, rights, or data integrity).
9. Delegation logs, CVs, and GCP training records must stay current and mutually consistent at all times.

Important Questions — Good Clinical Practice

Frequently asked long-answer, short-note and viva questions for the MD/MS examination

1

LONG ANSWER

Trace the evolution of ethical guidelines in clinical research from the Nuremberg Code to ICH-GCP. What lessons did the Tuskegee study teach?

Key points: Nuremberg Code • Declaration of Helsinki • Belmont Report (respect for persons, beneficence, justice) • ICH-GCP E6 • Tuskegee: deception, withheld treatment, no right to withdraw

2

LONG ANSWER

Describe the informed consent process in a clinical trial, including its essential elements and special situations.

Key points: Voluntariness, comprehension, disclosure • written, dated, signed • impartial witness for participants who cannot read • LAR for vulnerable participants • re-consent after amendments • Indian audio-visual consent requirements

3

SHORT NOTE

Discuss the roles and responsibilities of the investigator, the sponsor and the ethics committee.

Key points: Investigator: protocol, consent, safety, records • sponsor: monitoring, IP, reporting • IRB/IEC: approval, continuing review at least annually, oversight

4

SHORT NOTE

Differentiate AE, SAE and SUSAR. State the reporting timelines.

Key points: Definitions and seriousness criteria • investigator → sponsor within 24 h • fatal / life-threatening SUSARs within 7 days (+8-day follow-up) • other SUSARs within 15 days

5

SHORT NOTE

Explain ALCOA-C and the importance of source documentation in GCP.

Key points: Attributable, Legible, Contemporaneous, Original, Accurate, Complete • source data verification • CRF must match source

6

VIVA

What is the difference between a protocol deviation and a protocol violation? Give examples.

Key points: Deviation: minor, no significant impact • violation: affects safety, rights or data integrity • documentation and reporting to IRB/IEC

Tip: answer long questions with a labelled flow chart or table — examiners reward structure.

CHAPTER 3 — GOOD CLINICAL LABORATORY PRACTICE (GCLP)

Based on ICMR GCLP Guidelines, 2021 (Indian Council of Medical Research)

Amrita School of Medicine

Table of Contents

Q1 Principles/objectives of GCLP; role of Lab Director & QA department

Q2 Standard Operating Procedure — definition and components

Q3 QC vs QA; quality assurance practices

Q4 Internal Quality Control (IQC) and EQA/Proficiency Testing

Q5 Non-conformance — definition and management

Q6 Importance of staff competency assessment

Q7 Principles of biosafety in a clinical laboratory

Q8 Pre-analytical phase — errors and minimisation

Q9 Specimen rejection criteria and sample transport

Q10 Essential elements of a Quality Management System

Q11 Specimen management workflow: collection to storage

Q12 Document control and record retention

Q13 Equipment qualification, calibration and maintenance

Q14 Biosafety and biosecurity for human specimens

Q15 Laboratory audits and GCLP compliance

Q16 Method verification and validation

Q17 Corrective and Preventive Action (CAPA)

Case 1 Unlabelled serum sample with matching request form

Case 2 IQC sample outside acceptable limits

Case 3 Refrigerator temperature excursion overnight

Case 4 ELISA performed without competency assessment

Case 5 Outdated, unsigned SOPs found on audit

Part I — Long-Answer Questions

Q1. Principles, objectives of ICMR GCLP; role of Lab Director and QA department

Background and Objectives

The Indian Council of Medical Research first issued Guidelines for Good Clinical Laboratory Practices (GCLP) in 2008 and revised them in 2021 to keep pace with advances in laboratory medicine and clinical research. GCLP is defined as the set of principles that ensures the uniformity, consistency, reliability, reproducibility, quality and integrity of data generated by laboratories that examine human biological samples, whether for patient care or for clinical research.

- **Reliability of data:** ensuring that every reported result reflects the true analyte concentration/finding in the specimen.
- **Traceability:** every step from sample collection to report generation is documented and can be reconstructed retrospectively.
- **Uniformity and standardisation:** harmonising practices across laboratories of different sizes and locations across the country.
- **Protection of the specimen donor/patient:** safeguarding safety, confidentiality and informed consent, particularly in research settings.
- **Regulatory and ethical compliance:** aligning with national/international requirements (ICMR, NABL/ISO 15189, GCP) so that data generated is acceptable to regulators, ethics committees and journals.
- **Continual improvement:** building a culture in which errors are analysed and systems progressively strengthened, rather than a static, one-time compliance exercise.

GCLP is applicable to all laboratories examining human biological samples in the course of routine healthcare delivery as well as clinical/biomedical research, and its scope extends across laboratory disciplines — biochemistry, microbiology, haematology, immunology, molecular diagnostics and histopathology — wherever human specimens are analysed to generate data used for patient management or research conclusions.

Role and Responsibilities of the Laboratory Director

- Overall accountability for the technical and scientific operation of the laboratory, including staffing, competence and training.
- Ensuring an effective Quality Management System (QMS) is designed, implemented, resourced and reviewed periodically.
- Approving SOPs, authorising deviations, and ensuring documents are current, version-controlled and accessible.
- Ensuring biosafety, biosecurity and ethical requirements (informed consent, sample confidentiality) are met.
- Reviewing non-conformances, audit findings and corrective/preventive actions, and reporting to institutional/ethics leadership.

- Final authority for releasing/authorising reports and for decisions on repeat testing or result withholding.
- Ensuring adequate infrastructure, budget and staffing are made available for the laboratory to meet its quality objectives, and representing the laboratory before accreditation bodies, sponsors and institutional ethics committees.
- Chairing or actively participating in periodic management review meetings, where QA performance, resource needs, audit outcomes and customer/clinician feedback are reviewed and used to set improvement objectives for the coming period.

Role and Responsibilities of the Quality Assurance Department

- Developing, maintaining and periodically reviewing the QMS, SOPs, and quality manual independent of routine bench work.
- Planning and monitoring Internal Quality Control (IQC) and External Quality Assessment (EQA/PT) participation and performance.
- Conducting internal audits, tracking non-conformances, and driving Corrective and Preventive Action (CAPA) to closure.
- Overseeing document control, record retention, equipment calibration schedules and staff competency assessment records.
- Acting as the independent link between bench-level operations and laboratory/institutional management on quality matters.
- Coordinating staff training programmes, maintaining training records, and ensuring newly introduced tests undergo method validation before clinical/research release.

Key Point

- GCLP deliberately separates the QA function from routine bench supervision so that quality oversight remains objective and is never compromised by production pressure to release results quickly.
- The Laboratory Director retains ultimate accountability, but day-to-day quality system maintenance is delegated to a functionally independent QA department/officer.

Q2. Standard Operating Procedure (SOP): definition and essential components

A Standard Operating Procedure (SOP) is a controlled, written document that describes, in a clear, stepwise and unambiguous manner, how a specific laboratory activity is to be performed so that the activity is carried out consistently, correctly and reproducibly by every trained member of staff, irrespective of who performs it or when.

Essential Components of an SOP

- **Title and identification:** unique document number, title, version number, effective date and department.
- **Purpose/objective:** why the procedure exists and what it is intended to achieve.
- **Scope:** the tests, specimens, instruments or personnel to which the SOP applies.
- **Responsibility:** designation of staff authorised to perform/supervise the procedure.

- **Principle:** brief scientific basis of the test/method, where applicable.
- **Materials, reagents and equipment:** with storage conditions, preparation and stability where relevant.
- **Procedure:** sequential, numbered steps written in unambiguous language.
- **Quality control:** IQC material, frequency, acceptable limits, and action on failure.
- **Calculation and reporting:** formula, units, reference intervals and reporting format.
- **Safety precautions:** biosafety/chemical hazards and precautions specific to the procedure.
- **Limitations and interferences:** known factors affecting accuracy of the result.
- **References:** manufacturer inserts, published literature or guideline documents used.
- **Approval and review:** author, reviewer and approver signatures with dates; scheduled review date.

Key Point

- An SOP is a 'living document' — every revision must be version-controlled, the obsolete copy withdrawn from use, and the change history retained as per document control requirements.

Categories of Laboratory SOPs

- Technical/test SOPs — for individual assays or procedures (e.g., glucose estimation, ELISA).
- Equipment SOPs — operation, calibration and maintenance of a specific instrument.
- Administrative/quality SOPs — document control, sample management, IQC/EQA, incident reporting, biosafety.

Each SOP should be written at a level of detail sufficient for a newly trained but competent staff member to perform the procedure correctly without needing to consult additional sources, while avoiding unnecessary complexity that discourages compliance.

Q3. QC vs QA; quality assurance practices with examples

Aspect	Quality Control (QC)	Quality Assurance (QA)
Definition	Operational techniques used to monitor and verify that a test/process meets defined quality requirements	The overall planned and systematic set of activities that provide confidence that quality requirements will be fulfilled
Focus	Detection of errors in a specific analytical run	Prevention of errors across the entire testing pathway
Scope	Analytical phase only (e.g., control sera, calibration checks)	Pre-analytical, analytical and post-analytical phases together
Tools	IQC materials, Levey-Jennings charts, Westgard rules	SOPs, training, audits, EQA, document control, CAPA
Timing	Performed with/around each analytical run	Continuous, ongoing programme
Responsibility	Bench technologist	Laboratory management/QA department, with participation of all staff

Quality Assurance Practices — Examples

- **Pre-analytical:** standardised requisition forms, positive patient identification, specimen labelling and rejection criteria.
- **Analytical:** IQC with Westgard multi-rule review, EQA/PT participation, equipment calibration and maintenance schedules, documented method validation.
- **Post-analytical:** critical value/panic value reporting protocol, report verification/authorisation, turnaround time monitoring.
- **Systemic:** staff competency assessment, document control, internal and external audits, CAPA tracking, biosafety programme.

Relationship Between QC and QA

QC is properly understood as one operational component that feeds into the larger QA framework: QC data (Levey-Jennings trends, rejection rates) are themselves reviewed as part of the QA programme, and a QA system that lacks robust QC at the bench level cannot deliver reliable data, however well its policies are written. In examination answers, students should therefore present QC as the 'micro-level, analytical-run check' and QA as the 'macro-level, whole-system assurance', linked through continuous monitoring and management review.

Q4. Internal Quality Control (IQC) and External Quality Assessment (EQA)/Proficiency Testing

Internal Quality Control (IQC)

IQC is a set of procedures undertaken within the laboratory, on a day-to-day basis, to monitor the precision and accuracy of test results before they are released, allowing the laboratory to detect analytical errors in real time.

- Uses control materials of known concentration (normal and abnormal levels) run alongside patient samples.
- Mean, standard deviation (SD) and coefficient of variation (CV) are established; results plotted on Levey-Jennings charts.
- Westgard multi-rules (e.g., 1-2s warning, 1-3s, 2-2s, R-4s, 4-1s, 10x rejection rules) applied to accept or reject a run.
- Purpose: detects within-run and between-run imprecision and systematic bias before patient results are released.

External Quality Assessment (EQA) / Proficiency Testing (PT)

EQA/PT is an inter-laboratory comparison programme in which unknown samples are sent by an external, accredited agency to participating laboratories; the laboratory's results are compared against a target value (peer group or reference method) and scored.

- Assesses accuracy and comparability of results across laboratories, independent of the laboratory's own controls.
- Conducted periodically (typically quarterly/as per scheme) by an approved external provider, e.g., CMC Vellore EQAS, AIIMS schemes, national/international programmes.
- Unsatisfactory performance must trigger root-cause analysis and CAPA, with documented review by the Laboratory Director.

Key Distinction

- IQC answers 'Is today's run reliable?' — an internal, continuous check.
- EQA/PT answers 'How does my laboratory compare with others?' — an external, periodic check of overall competence.

Steps to Initiate IQC in a New Laboratory

1. Select an appropriate control material covering clinically relevant (normal and abnormal) concentrations.
2. Run the control on 20 consecutive days to establish a provisional mean and standard deviation.
3. Set tolerance limits (commonly mean $\pm$ 2SD as the warning limit and $\pm$ 3SD as the rejection limit) and construct the Levey-Jennings chart.
4. Run controls with every patient batch thereafter, plot results, and apply Westgard rules to accept or reject the run before releasing patient results.
5. Review cumulative QC data monthly to detect long-term drift and recalculate limits periodically or after any major change (new reagent lot, calibration, service).

Q5. Non-conformance: definition and management

A non-conformance is any deviation from an established requirement — an SOP, a specification, a regulatory requirement or the laboratory's own QMS — that occurs at any stage of the testing process, from sample receipt to report dispatch.

Examples

- Sample received without labelling or with a labelling mismatch; IQC out of range; equipment breakdown mid-run; report issued with a transcription error; SOP found unsigned or expired during audit.

Management of a Non-conformance

6. Detection and documentation: record what, when, where and who identified it, using a standard non-conformance/incident form.
7. Immediate/containment action: stop the affected process, quarantine the sample/report, and prevent an erroneous result from being released.
8. Impact assessment: determine whether any patient report already issued is affected and needs recall/correction.
9. Root-cause analysis: use tools such as the '5-Why' method or fishbone (Ishikawa) analysis to find the underlying cause.
10. Corrective action: eliminate the identified cause so the same non-conformance does not recur.
11. Preventive action: identify and address similar potential failure points elsewhere in the system.
12. Verification of effectiveness: monitor over a defined period to confirm the action has worked.

13. Closure and trend review: close the record, and review non-conformance trends periodically at the QA/management review meeting.

Key Point

- A non-conformance should be treated as a system learning opportunity rather than an occasion for individual blame — a 'no-blame' culture encourages prompt, honest reporting, which is essential for the system to detect problems early.

Q6. Importance of staff competency assessment

Staff competency assessment is the documented process of verifying, at defined intervals, that laboratory personnel possess the knowledge, skill and judgement required to perform their assigned duties accurately and safely.

Why It Matters

- **Direct link to result quality:** the majority of laboratory errors are process/human-related; verified competence reduces error rates.
- **Regulatory/accreditation requirement:** mandatory under NABL/ISO 15189 and GCLP for personnel performing patient/research testing.
- **New technology and test introduction:** competency must be documented before a staff member is permitted to test independently on a new method or instrument.
- **Patient safety:** prevents release of unreliable results from under-trained staff, especially for critical/high-risk tests.

Components of a Competency Assessment Programme

- Direct observation of routine test performance; review of worksheets/QC records; blind sample or split-sample testing.
- Assessment of problem-solving/troubleshooting ability and instrument maintenance skills; periodic (commonly six-monthly in the first year, then annual) reassessment; refresher training when performance gaps are noted.

When Competency Must Be (Re-)Assessed

- Before independent testing begins on any new method, instrument or test.
- At defined periodic intervals thereafter, for as long as the individual continues to perform that test.
- Whenever a policy/procedure is revised, following any staff performance concern, and after any extended absence from bench duties.

Competency records form part of the permanent personnel quality file and are a standard item reviewed during accreditation and GCLP audits.

Q7. Principles of biosafety in a clinical laboratory

Core Principles

- **Risk assessment:** identifying hazards associated with each specimen/procedure and assigning an appropriate biosafety level (BSL 1–4).

- **Standard precautions:** treating every specimen as potentially infectious, regardless of the patient's known status.
- **Primary containment:** personal protective equipment (gloves, gown, eye protection), biosafety cabinets for aerosol-generating procedures.
- **Secondary containment:** laboratory design features — restricted access, negative pressure where required, handwashing stations, controlled ventilation.
- **Safe work practices:** no mouth pipetting, no eating/drinking/applying cosmetics in the work area, safe sharps handling, spill management protocols.
- **Waste management:** segregation and disposal as per Bio-Medical Waste Management Rules — colour-coded bags/containers, autoclaving of infectious waste.
- **Immunisation and post-exposure protocols:** hepatitis B vaccination for staff, documented needle-stick/exposure reporting and post-exposure prophylaxis pathway.
- **Training and biosafety manual:** mandatory induction and periodic refresher training; a written, accessible biosafety manual.

Biosecurity Element

Alongside biosafety (protecting people from agents), GCLP also requires biosecurity — protecting valuable biological materials and data from loss, theft, misuse or unauthorised access, including secure sample storage, inventory control and restricted access to repositories.

Biosafety Levels — Overview

Level	Typical Setting
BSL-1	Agents not known to cause disease in healthy adults — basic teaching/research laboratories
BSL-2	Most routine clinical/diagnostic laboratories handling human blood, body fluids and tissue
BSL-3	Laboratories working with agents that can cause serious/lethal disease via the respiratory route
BSL-4	Laboratories working with dangerous/exotic agents posing high risk of life-threatening disease, no available treatment/vaccine

Q8. Pre-analytical phase in clinical biochemistry: definition, errors and minimisation strategies

Definition

The pre-analytical phase encompasses all processes that occur before a specimen is actually analysed — test ordering, patient preparation, specimen collection, labelling, handling, transport, receipt and processing (e.g., centrifugation, aliquoting) up to the point the sample is loaded onto the analyser. It is widely recognised as the phase responsible for the largest proportion (estimated 60–70%) of total laboratory errors.

Common Pre-analytical Errors and Their Impact

Error	Impact on Result
Patient misidentification / mislabelled sample	Wrong-patient report — serious clinical/medico-legal consequence

Error	Impact on Result
Incorrect fasting status / timing (e.g., non-fasting glucose, lipid profile)	Falsely elevated glucose/triglycerides
Prolonged/incorrect tourniquet application	Haemoconcentration, falsely elevated protein-bound analytes, falsely elevated potassium
Haemolysis during collection	Falsely elevated potassium, LDH, AST; interferes with many photometric assays
Wrong anticoagulant/container or incorrect fill volume	Sample clotting, dilutional errors, unsuitable for the requested test
Delayed or inappropriate transport/storage temperature	Analyte degradation (e.g., glucose falls, ammonia rises)
Inadequate/incorrect centrifugation	Cellular contamination affecting electrolytes/enzymes

Strategies to Minimise Pre-analytical Errors

- Standardised, barcoded requisition and specimen labelling; two-identifier patient verification.
- Written phlebotomy SOPs, trained and certified phlebotomists, correct order-of-draw.
- Clear patient preparation instructions (fasting, drug withdrawal where relevant) communicated in advance.
- Defined specimen rejection criteria applied consistently at accessioning.
- Validated transport conditions (temperature-controlled carriers, defined time limits) and prompt processing after receipt.
- Periodic audit of pre-analytical error rates as a laboratory quality indicator, with feedback to referring wards/clinicians.

Impact on Patient Care and Research

Because pre-analytical errors occur before any analytical QC can detect them, an erroneous result caused by a pre-analytical problem may appear entirely plausible and pass through the analytical phase undetected, only to mislead clinical decision-making or, in a research study, to introduce unrecognised bias/noise into the trial dataset. This is precisely why GCLP places such heavy emphasis on standardising and auditing the pre-analytical phase rather than relying on analytical QC alone.

Key Point

- Pre-analytical quality indicators (e.g., sample rejection rate, haemolysis rate, mislabelling rate) should be tracked as key performance indicators and reviewed at management review meetings, since they are the single largest contributor to the total testing error rate.

Q9. Specimen rejection criteria and sample transport requirements

Significance of Specimen Rejection Criteria

Predefined, written rejection criteria allow the laboratory to identify, at the point of receipt, specimens that cannot yield a reliable result, preventing an inaccurate report from ever reaching a clinician or research record. Rejection protects patient safety, protects data integrity

in clinical trials, and provides an auditable, objective (rather than subjective) basis for refusing a sample.

Common Grounds for Rejection

- Unlabelled or mismatched specimen and requisition; wrong/expired container or anticoagulant.
- Grossly haemolysed, lipaemic or clotted sample unsuitable for the requested test.
- Insufficient quantity (quantity not sufficient, QNS); grossly contaminated specimen; prolonged transport time or transport outside validated temperature range.

Every rejection must be documented (Specimen Rejection Record), the referring clinician/investigator informed promptly, and a repeat sample requested.

Essential Requirements for Sample Transport

- **Leak-proof primary and secondary packaging:** triple packaging system for biological substances as per transport regulations.
- **Temperature control:** validated cold-chain (ice packs/insulated boxes) or ambient transport, as specified per analyte, with monitoring.
- **Time limits:** defined maximum transport/receipt time to preserve analyte stability.
- **Biohazard labelling and documentation:** requisition accompanying the sample, chain-of-custody record for research/legal samples.
- **Trained transport personnel:** aware of spill management and biosafety precautions during transit.

Additional Considerations for Research/Multi-centre Specimens

- Compliance with national and international dangerous goods transport regulations (e.g., IATA classification of biological substances) when specimens travel by air or across state/national borders.
- A signed shipping manifest/chain-of-custody form accompanying every consignment, with receipt confirmation returned to the sending site.
- Defined contingency procedures for delayed, lost or damaged-in-transit shipments, including notification of the sponsor/coordinating centre.

Q10. Essential elements of a Quality Management System (QMS) in a clinical laboratory

A Quality Management System is the coordinated set of policies, processes, procedures and resources through which a laboratory directs and controls quality. GCLP and ISO 15189 describe the QMS in terms of the following essential elements, often summarised as the 'Quality System Essentials':

- **Organisation and personnel:** defined organogram, job descriptions, qualifications, training and competency records.
- **Facilities and safety:** adequate space, environmental control, and a biosafety/chemical safety programme.

- **Equipment:** selection, installation qualification, calibration, maintenance and service contracts.
- **Purchasing and inventory:** vendor qualification, reagent/consumable receipt checks, stock rotation, lot-to-lot verification.
- **Process control (pre-analytical, analytical, post-analytical):** SOPs governing every stage of the testing pathway.
- **Documents and records:** document control system and defined retention schedule.
- **Information management:** laboratory information system controls, data security and confidentiality.
- **Non-conformance management and CAPA:** as detailed under Q5/Q17.
- **Internal and external assessment:** internal audits, EQA/PT participation, management review.
- **Continual improvement:** quality indicators, customer/clinician feedback, and process improvement projects.
- **Customer service and ethics:** confidentiality, informed consent (for research), and complaint handling.

The Quality Cycle

These elements function as a continuous cycle rather than a one-time checklist: quality policy and objectives are set by management → implemented through SOPs, trained staff and qualified equipment → monitored through IQC, EQA, audits and indicators → deviations managed through non-conformance/CAPA → outcomes fed back into management review → objectives and resources revised accordingly for the next cycle. A QMS is therefore judged not by the existence of documents alone, but by evidence that this cycle is genuinely operating.

Q11. Complete workflow of specimen management from collection to storage under GCLP

Sequential Workflow

14. Test requisition: clinician/investigator completes a standardised request form with complete patient/participant identifiers and clinical details.
15. Patient/participant preparation and identification: two-identifier verification, informed consent documented for research specimens.
16. Collection: correct container, anticoagulant, order-of-draw and technique as per SOP; site and time of collection recorded.
17. Labelling: specimen labelled at the bedside/collection site immediately after draw, before leaving the patient.
18. Transport: validated packaging and temperature-controlled transport within defined time limits (see Q9).
19. Accessioning/receipt: specimen logged against the requisition; rejection criteria applied; unique accession number assigned.
20. Processing: centrifugation, aliquoting, and preparation appropriate to the requested analysis.

21. Analysis: testing performed as per validated SOP with concurrent IQC.
22. Result verification and reporting: technical and clinical review, authorisation, and dispatch of the report.
23. Storage/retention or disposal: residual specimen stored under defined temperature/duration for possible repeat testing, or for a research biorepository, and finally disposed of as biomedical waste when the retention period expires.

Key Point

- Every hand-off in this chain must be traceable — GCLP requires that the identity, condition and location of a specimen can be reconstructed at any point from collection to final disposal/storage.

Storage Considerations

- Storage temperature and duration are defined per analyte/specimen type (e.g., refrigerated 2–8°C for short-term retesting, –20°C or –80°C for research/biobank specimens requiring long-term stability).
- Storage equipment (refrigerators, freezers, LN2 vapour tanks) is included in the equipment calibration/maintenance and continuous temperature-monitoring programme (see Q13 and Case 3).
- A specimen inventory/tracking log (manual or electronic) records the exact location of every stored specimen, supporting both efficient retrieval and biosecurity.

Q12. Purpose of document control; importance of laboratory record retention

Purpose of Document Control

Document control is the system by which a laboratory ensures that only the current, approved version of every SOP, policy, form, manual or reference document is in use, and that obsolete versions cannot be mistakenly followed.

- Ensures staff always follow the correct, up-to-date procedure — reducing errors caused by outdated instructions.
- Provides a documented, auditable trail of every review, revision and approval (who, when, why).
- Is a core requirement of accreditation (NABL/ISO 15189) and GCLP inspection.
- Elements: unique document identifiers, version/revision numbers, controlled distribution list, master list of current documents, defined review cycle, and formal withdrawal/archival of superseded copies (typically stamped 'Obsolete').

Importance of Record Retention

- Enables retrospective investigation of a query, complaint or adverse event, and supports medico-legal defence.
- Required for regulatory/ethics compliance in clinical trials, where source data must remain retrievable for defined periods after study completion.

- Supports re-analysis, audit trails and trend analysis (e.g., QC trends, equipment performance over time).
- Retention periods are defined by test type, institutional policy and applicable regulation (e.g., patient reports, worksheets, QC records, equipment logs and consent forms each carry a specified minimum retention period), after which records are archived or destroyed as per a documented policy.

Illustrative Retention Periods (indicative — institutional/regulatory policy governs the exact duration)

Record Type	Typical Minimum Retention
Patient/participant test reports	Several years, per institutional and applicable clinical/legal requirement
Worksheets, IQC and EQA records	Sufficient to allow trend analysis across accreditation cycles
Equipment calibration/maintenance logs	Life of the equipment plus a defined additional period
Clinical trial source data and consent forms	As specified in the study protocol/regulatory requirement, often well beyond study completion

Q13. Equipment qualification, calibration, preventive maintenance and documentation under GCLP

Equipment Qualification

- **Design/selection qualification:** verifying the instrument meets the laboratory's intended use before purchase.
- **Installation Qualification (IQ):** confirming correct installation as per manufacturer specification.
- **Operational Qualification (OQ):** verifying the equipment operates as intended across its working range.
- **Performance Qualification (PQ):** confirming consistent performance under routine working conditions before it is released for patient/research testing.

Calibration

Calibration establishes the relationship between an instrument's readings and a traceable reference standard, performed at manufacturer-recommended intervals, after major maintenance/repair, or when QC indicates drift. Calibration records (date, standard used, result, performed-by) must be retained and reviewed.

Preventive Maintenance (PM)

A scheduled programme of inspection, cleaning, adjustment and part replacement, performed before failure occurs, to keep equipment functioning within specification — documented on a maintenance log/checklist as per manufacturer recommendations and local usage.

Documentation

- Individual equipment log/history file: identification, location, installation date, IQ/OQ/PQ records, service history, calibration records, PM schedule and completion records, breakdown/repair reports, and decommissioning record.

- Equipment taken out of service pending repair must be clearly labelled and excluded from use until requalified.

Consequence of Inadequate Equipment Control

An instrument that drifts out of calibration, or that misses a scheduled preventive maintenance service, may continue to produce plausible-looking numeric results while silently introducing systematic bias into every test performed — a failure mode that IQC is specifically designed to catch, which is why calibration verification and IQC review are always considered together rather than as separate, unrelated activities.

Frequency Considerations

Calibration and preventive maintenance frequencies are set primarily by manufacturer recommendation, but are adjusted upward for high-throughput instruments, after any transport/relocation, following any part replacement, and whenever IQC trends suggest early drift — the schedule itself should be a living document, reviewed annually as part of the QMS rather than fixed permanently at installation.

Q14. Biosafety and biosecurity practices in laboratories handling human specimens

(Cross-refer Q7 for core biosafety principles.) This answer emphasises the combined biosafety-plus-biosecurity framework specifically for laboratories handling human specimens under GCLP.

Biosafety Practices

- Risk-based biosafety level assignment, use of biosafety cabinets for aerosol-generating steps, standard precautions applied to every specimen.
- Spill management SOP, sharps injury protocol with post-exposure prophylaxis pathway, and segregated biomedical waste disposal.
- Staff immunisation (e.g., hepatitis B) and periodic biosafety training/drills.

Biosecurity Practices

- **Access control:** restricted, logged entry to sample storage/repository areas.
- **Inventory control:** accession-numbered, tracked sample storage with defined chain of custody, particularly for research biobanks.
- **Data security:** confidentiality of patient/participant identity and results, secure electronic records and controlled data-sharing agreements.
- **Material transfer control:** documented material transfer agreements before samples leave the institution, particularly for multi-centre research.
- **Loss/theft reporting:** a defined incident-reporting pathway if samples or data are lost, misused or accessed without authorisation.

Why Both Are Needed Together

Biosafety and biosecurity address two distinct but complementary risks: biosafety protects laboratory personnel, the community and the environment from the specimen; biosecurity protects the specimen and the data derived from it (and, by extension, the patient/participant's rights and the research's integrity) from being lost, stolen or misused. A laboratory can be

biosafety-compliant yet biosecurity-deficient (e.g., safe handling practices but an unlocked, unlogged sample freezer) — GCLP requires both to be addressed as part of a single, integrated programme.

Q15. Laboratory audits and their importance in maintaining GCLP compliance

Types of Audit

- **Internal audit:** conducted by the laboratory's own QA team/trained internal auditors against its own SOPs and GCLP requirements, on a planned schedule covering all departments over a defined cycle.
- **External/regulatory audit:** conducted by an accreditation body (e.g., NABL), sponsor, or ethics committee (for clinical trial-linked laboratories).
- **Vertical audit:** traces a single specimen/test end-to-end through the entire pathway.
- **Horizontal audit:** examines one specific process (e.g., document control) across the whole laboratory.

Importance

- Provides objective, systematic evidence of compliance (or gaps) with SOPs, GCLP principles and accreditation standards.
- Identifies non-conformances proactively, before they cause patient/participant harm or data integrity loss.
- Drives continual improvement through CAPA arising from audit findings.
- Builds confidence of clinicians, sponsors, regulators and ethics committees in the reliability of laboratory data.

Audit Process (brief)

24. Planning and checklist preparation → opening meeting → objective evidence review (documents, records, observation, staff interview) → closing meeting with findings → written audit report → CAPA for each finding → follow-up/verification audit.

Grading of Audit Findings

- **Critical/major non-conformance:** a finding likely to directly affect the reliability of reported results or patient/participant safety (e.g., unvalidated test in routine use) — requires urgent CAPA.
- **Minor non-conformance:** an isolated procedural lapse unlikely to affect result reliability (e.g., a single missing initials on a log) — requires CAPA within the routine timeframe.
- **Observation/opportunity for improvement:** not a breach of a defined requirement, but a suggestion for enhancing the system.

Q16. Method verification and validation: discussion and parameters

Definitions

- **Method verification:** confirming that a previously validated (e.g., FDA/CE-marked, manufacturer-validated) method performs as claimed when set up in the laboratory's own hands, before clinical/research use.
- **Method validation:** a more extensive process establishing, with objective evidence, that a new, modified or laboratory-developed method is fit for its intended purpose.

Validation/Verification Parameters

Parameter	What It Assesses
Accuracy/trueness	Closeness of results to a reference/true value (e.g., using reference material or comparison method)
Precision (repeatability & reproducibility)	Agreement between repeated measurements, within-run and between-run/between-day
Analytical sensitivity (limit of detection/quantitation)	Lowest analyte concentration reliably detected/measured
Analytical specificity	Freedom from interference by other substances/cross-reactants
Linearity / reportable range	Range over which results are proportional to analyte concentration
Reference interval verification	Confirming manufacturer/published reference ranges suit the local population
Carry-over	Absence of contamination between consecutive samples
Method comparison	Agreement with an established/reference method (e.g., Bland-Altman, regression)

Results are documented in a validation/verification report, reviewed and approved by the Laboratory Director/QA before the method is released for reporting patient or research results, and the record retained as part of the permanent quality record.

When Validation/Verification Is Required

- Introduction of a new test or a new analytical platform; a significant modification to an existing validated method; a change of major reagent lot or calibrator likely to affect performance; transfer of a method between laboratories/sites in a multi-centre study.
- Verification (rather than full validation) is generally sufficient for an unmodified, already-validated commercial/FDA-approved method being newly set up on the laboratory's own equipment; full validation is required for laboratory-developed or significantly modified methods.

Q17. Corrective and Preventive Action (CAPA) with laboratory examples

Definitions

- **Corrective action:** action taken to eliminate the cause of a detected non-conformance, to prevent its recurrence.
- **Preventive action:** action taken to eliminate the cause of a potential (not-yet-occurred) non-conformance, to prevent its occurrence.

CAPA Process

25. Problem identification and documentation (from non-conformance, audit, complaint, EQA failure, or trend analysis).
26. Immediate/containment action to limit harm.
27. Root-cause analysis (5-Why, fishbone diagram).
28. Action plan: define corrective action (fixes this instance), and preventive action (stops similar issues elsewhere).
29. Implementation with assigned responsibility and target timeline.
30. Effectiveness verification after a defined monitoring period.
31. Closure, with the record retained and trends reviewed at management review.

Illustrative Examples

- **Example 1 — repeated IQC failure:** corrective action = recalibrate/replace reagent lot causing the shift; preventive action = tighten lot-verification SOP for all new reagent lots before use.
- **Example 2 — mislabelled samples from a particular ward:** corrective action = retrain the ward's phlebotomy staff; preventive action = introduce barcode labelling at the bedside across all wards.
- **Example 3 — refrigerator temperature excursion:** corrective action = assess/discard affected samples, service refrigerator; preventive action = install continuous temperature-monitoring alarm system (see Case 3).

Part II — Case-Based Questions

Case 1. Unlabelled serum sample with an accompanying, correctly filled request form (clinical trial)

What should the laboratory do?

- The sample must be treated as a non-conforming specimen at the point of accessioning. It should not be labelled retrospectively by laboratory staff based on the request form, as this breaks the chain of positive identification and introduces the risk of a wrong-patient result.
- The receiving technologist should document the discrepancy on a Specimen Rejection/Non-conformance Record and immediately notify the referring clinician/investigator and the study coordinator (for a clinical trial sample).

Should the sample be processed?

- No — the sample should be rejected and a fresh, correctly labelled specimen requested, unless the specimen is irreplaceable (e.g., a unique timed trial visit sample) — in which case the laboratory may, per its SOP, accept it only after the requesting investigator personally re-confirms and re-labels the sample in the presence of a witness, with full documentation of the exception and sponsor/ethics notification as applicable.
- Any decision to process such a sample must be an explicit, documented exception approved by the Laboratory Director, never routine practice.

Applicable GCLP Principles

- Positive specimen identification and traceability; specimen rejection criteria; non-conformance management; data integrity and reliability, which are especially critical in a clinical trial where sample identity errors can compromise trial data and patient safety.

Examination Perspective

This case tests the candidate's understanding that GCLP prioritises identity certainty over convenience: a matching request form is not, by itself, sufficient proof of the sample's identity, because the mismatch could equally have arisen from a mix-up between two patients' samples and forms rather than a simple labelling omission. The safe default is always rejection and re-collection, with same-sample exceptions reserved for genuinely irreplaceable specimens and only under a documented, witnessed protocol.

Case 2. IQC sample shows values outside acceptable limits

Immediate Actions

32. Stop reporting of patient results from the affected run immediately.
33. Verify the QC material (expiry, reconstitution, storage) and repeat the QC to rule out a handling error.
34. Apply Westgard multi-rules to characterise the failure (random vs systematic error) and check instrument/reagent/calibration status.
35. Troubleshoot and correct the identified cause (e.g., recalibrate, change reagent lot, service instrument).

36. Re-run QC; only proceed once QC is within acceptable limits.

Should Patient Reports Be Released?

- No. Patient results from the failed run must be withheld/held in a 'not verified' status. Once the root cause is corrected and QC passes, affected patient samples should be re-tested before results are released.
- If any affected report had already been dispatched before the QC failure was noticed, it must be recalled/amended per the laboratory's critical-error notification SOP, and the ordering clinician informed without delay.

CAPA Process

Document the non-conformance → root-cause analysis (reagent, calibration, instrument, operator) → corrective action addressing this run's cause → preventive action (e.g., enhanced lot verification, tighter QC review frequency) → verify effectiveness over subsequent runs → close the record and review at the next QA meeting (see Q17 for the general CAPA framework).

Examination Perspective

The key teaching point is sequencing: troubleshooting and correction must occur, and QC must pass, before any patient result generated in the failed run is released — reporting first and investigating later is never acceptable under GCLP, however clinically urgent the report may seem.

Case 3. Refrigerator storing research samples recorded 12°C overnight instead of 2–8°C

What Should Be Documented?

- Date/time the excursion was detected, actual recorded temperature and duration of excursion (if the logger/chart allows reconstruction of the overnight profile), the samples stored in the unit and their intended use.
- Immediate actions taken (e.g., transfer to a working refrigerator), staff notified, and a formal non-conformance/deviation report raised.

How Should Sample Integrity Be Assessed?

- Review analyte/sample-specific stability data for the duration and degree of the temperature excursion (some analytes/specimen types tolerate brief excursions; others, e.g., labile enzymes or research biomarkers, may not).
- Where stability data are inconclusive, samples should be considered compromised and this documented; the Laboratory Director/Principal Investigator should decide, sample by sample, on suitability for continued use, in consultation with the study protocol/sponsor for trial samples.

Corrective and Preventive Actions

- **Corrective:** service/repair or replace the faulty refrigerator; re-collect or discard compromised samples as assessed above; inform the Principal Investigator/ethics committee if trial data integrity is affected.
- **Preventive:** install a continuous temperature-monitoring and alarm system with after-hours alert; institute a documented daily (including weekend/holiday) temperature-log

check; include the incident in the preventive maintenance schedule for all cold-chain equipment.

Examination Perspective

This scenario illustrates that equipment control (Q13) and specimen storage integrity (Q11) are two sides of the same requirement — a well-run specimen storage system depends entirely on the equipment maintaining its qualified operating range, monitored continuously rather than checked only once a day, since overnight/unattended excursions are otherwise detected too late to prevent compromise.

Case 4. Technician performs a new ELISA assay without documented competency assessment

Is This Compliant with GCLP?

- No. GCLP requires that competency be formally assessed and documented before any staff member performs a new test independently. Testing performed without this documentation is a non-conformance, regardless of the technologist's actual skill level.

Documentation Required Before Independent Testing

- Completed, method-specific training record for the new ELISA (principle, procedure, QC, troubleshooting).
- Method validation/verification record for the assay itself (see Q16).
- A formal competency assessment — direct observation, review of results against a known/split sample, and documented sign-off by a qualified supervisor — before the technologist is authorised to test and report independently.

Risks That May Arise

- Increased risk of pre-analytical/analytical error (e.g., incorrect pipetting, washing, incubation timing) leading to inaccurate results.
- Undetected assay failure due to unfamiliarity with troubleshooting, and potential release of unreliable patient or research data.
- Non-compliance findings at accreditation/regulatory audit, and possible invalidation of research data generated by an uncertified operator.

Examination Perspective

The scenario should be recognised as a training/documentation gap rather than necessarily a skill gap — the technician may in fact perform the assay correctly, but GCLP requires objective, documented proof of competence before independent testing, not an assumption of competence based on general experience or qualification.

Case 5. Audit finds several SOPs outdated and unsigned

Deficiencies Identified

- Failure of document control — SOPs past their scheduled review date remain in use (outdated content risk).

- Absence of documented authorisation — unsigned SOPs indicate the procedure was never formally approved, so it lacks the authority of an approved document.
- Likely absence of, or non-adherence to, a periodic document review schedule and master document list.

Document Control Process Under GCLP

- Every SOP is drafted, reviewed and approved by designated, competent personnel before issue, with each version bearing a unique number, version/revision number and effective date.
- A master list of controlled documents tracks the current version of every SOP; superseded versions are withdrawn from work areas and archived, clearly marked obsolete.
- Documents are reviewed at a defined frequency (e.g., every one to two years, or sooner if a process/regulation changes) and re-approved even if content is unchanged.

Suggested Corrective Actions

37. Immediately review and formally sign/approve all currently-in-use SOPs found unsigned; withdraw and archive genuinely outdated versions.
38. Reconcile the master document list against what is physically present at each workstation.
39. Assign clear ownership (QA department) for tracking review due-dates, with an automated reminder system where possible.
40. Retrain staff on the document control SOP and verify, at the next internal audit, that the corrective action has been effective.

Examination Perspective

Outdated, unsigned SOPs are a classic GCLP audit finding because document control is easy to neglect once initial approval is complete; examiners expect the candidate to link the specific deficiency (missing signature / lapsed review date) to the specific document-control requirement it breaches, rather than describing document control only in general terms.

Appendix A — Glossary of Key GCLP Terms

Term	Meaning
Accuracy	Closeness of a measured value to the true value
Precision	Closeness of agreement between repeated measurements
Calibration	Establishing the relationship between instrument readings and traceable reference values
CAPA	Corrective and Preventive Action — systematic response to non-conformances and potential failures
EQA/PT	External Quality Assessment / Proficiency Testing — inter-laboratory comparison programme
IQC	Internal Quality Control — day-to-day, within-laboratory monitoring of test performance
Non-conformance	Any deviation from a defined requirement, SOP or specification
QMS	Quality Management System — the coordinated policies, processes and resources by which quality is directed and controlled
Reference interval	The range of values expected in a defined healthy/reference population
SOP	Standard Operating Procedure — a controlled, written, step-by-step description of a procedure
Traceability	The ability to reconstruct the history, handling and location of a specimen or measurement result
Turnaround time (TAT)	Time interval from specimen receipt to result reporting
Validation	Objective demonstration that a method/process consistently meets its intended requirements
Verification	Confirming that an already-validated method performs as claimed in the local laboratory

Appendix B — Key Annexures Referenced in ICMR GCLP Guidelines

The ICMR Guidelines for Good Clinical Laboratory Practices include a series of illustrative annexures/formats that laboratories may adapt to their own documentation system. Candidates should be familiar with their purpose:

- Equipment Log Book — individual equipment history, service and calibration record.
- Requisition Form — standardised test request capturing patient/participant and clinical details.
- Accession List — laboratory-wide log of specimens received against a unique accession number.
- Worksheet / Requisition-cum-Worksheet — bench record of test performance, reagents and results.
- Reporting Format — standardised layout for issuing verified, authorised results.
- Specimen Rejection Record — documentation of rejected specimens and the reason for rejection.
- Steps to Initiate IQC in Laboratories — practical guide to establishing IQC limits (see Q4).
- Calculation of Mean, Standard Deviation and Tolerance Range — statistical basis for IQC limit-setting.
- Corrective Actions — format for recording and tracking CAPA (see Q5, Q17).
- Basics of EQA — outline of external quality assessment participation (see Q4).

Appendix C — Quick-Revision Summary

High-Yield Points for Examination

- GCLP = uniformity + reliability + traceability + protection of the sample donor + regulatory/ethical compliance.
- QC = analytical-run level check; QA = whole-system, all-phase assurance; both are continuous, not one-time activities.
- ~60–70% of total testing errors are pre-analytical — most preventable through standardisation and staff training.
- Every non-conformance follows the same generic cycle: detect → contain → root-cause → correct → prevent → verify → close.
- Document control and record retention exist to guarantee that the current procedure is followed and that the entire testing history remains reconstructable.
- Competency must be documented BEFORE independent testing, not assumed from general qualification or experience.
- Biosafety protects people from specimens; biosecurity protects specimens/data from people — GCLP requires both.

This document is intended as a structured revision aid for MD postgraduate examination preparation and should be read alongside the full ICMR Guidelines for Good Clinical Laboratory Practices (2021) and the institution's own laboratory quality manual.

Appendix D — Examination Preparation Tips

For Long-Answer Questions

- Begin with a precise definition, then structure the answer under clear subheadings — examiners reward organisation as much as content.
- Use a comparison table wherever a question asks to 'differentiate' or 'compare' (e.g., QC vs QA, IQC vs EQA) — this is the fastest way to demonstrate clarity of understanding.
- Close descriptive answers with a short 'key point' or summary line that captures the single most examinable fact.

For Case-Based Questions

- Answer the three sub-questions in the order asked; do not merge them into a single narrative paragraph.
- Anchor every action recommended in the case to a named GCLP principle (traceability, non-conformance management, competency assessment, document control, etc.) rather than describing actions in isolation.
- Where the scenario involves a decision to release or withhold a result, state the decision explicitly and justify it — examiners specifically look for a clear, defensible decision, not just a list of considerations.
- Always close a case answer by naming the CAPA (or equivalent systemic) response, since GCLP case questions are designed to test system-level, not just situational, thinking.

Common Cross-Links Between Questions

Several themes recur across both the long-answer and case sections of this document, and examiners often frame questions that require linking them: non-conformance management and CAPA (Q5, Q17) underpin every case scenario; document control (Q12) explains why SOPs must be current and signed (Case 5); competency assessment (Q6) explains the requirement breached in Case 4; and equipment/storage control (Q13, Q11) together explain the correct response to Case 3. Recognising these links, rather than treating each question as an isolated topic, is what distinguishes a strong postgraduate-level answer.

Appendix E — Model Answer Framework

Where examination time is limited, the following generic skeleton can be adapted to almost any GCLP long-answer question, ensuring completeness without wasted time:

41. Definition — state the term/concept being asked about in one or two precise sentences.
42. Context/rationale — briefly explain why this element matters within the overall GCLP framework (patient safety, data reliability, regulatory compliance).
43. Core content — the main body of the answer, organised under clear subheadings, using bullet points, numbered sequences or a comparison table as appropriate to the question type.
44. Worked example or illustrative scenario — a brief, concrete example strengthens an otherwise descriptive answer and demonstrates applied understanding.
45. Key point/summary — a one- or two-line closing statement capturing the single most important, examinable takeaway.

Applying the Framework — Worked Example

For a question such as 'Discuss the importance of turnaround time (TAT) monitoring in a clinical laboratory', the skeleton above would be applied as follows: define TAT as the interval from specimen receipt to result reporting; explain its rationale as a direct determinant of clinical decision-making speed, particularly for critical/emergency tests; describe core content — factors affecting TAT across the pre-analytical, analytical and post-analytical phases, and methods of monitoring (mean/median TAT, percentage within target, outlier review); give a worked example such as a potassium result delayed beyond the critical-value reporting window in an emergency department; and close with the key point that TAT is itself a quality indicator that must be tracked, benchmarked and reviewed at management review, in the same way as IQC/EQA performance.

Final Reminder

- GCLP examination answers are strongest when they consistently connect a specific laboratory action back to the underlying principle it serves — reliability, traceability, safety, or continual improvement — rather than listing procedural steps in isolation.
- Revise this document alongside the original ICMR GCLP 2021 guidelines and your department's own SOPs and quality manual for full examination preparedness.

Important Questions — Good Clinical Laboratory Practice

Frequently asked long-answer, short-note and viva questions for the MD/MS examination

1

LONG ANSWER

Explain the principles of Good Clinical Laboratory Practice as per the ICMR GCLP guidelines, 2021, and the organisation of a GCLP-compliant laboratory.

Key points: Organisation and personnel • roles of laboratory director and independent QA • facilities • SOPs • equipment • sample handling • records and reporting

2

SHORT NOTE

Define a standard operating procedure (SOP). List its essential components.

Key points: Title and ID, version and effective date • purpose, scope • responsibilities • procedure • references • review, approval and document control

3

SHORT NOTE

Compare internal quality control with external quality assessment (proficiency testing).

Key points: IQC: daily run-by-run monitoring with control materials • EQA: inter-laboratory comparison, periodic, external agency • both feed CAPA

4

SHORT NOTE

Describe the pre-analytical requirements for sample collection, labelling, transport and storage.

Key points: Patient identification and labelling • correct container and volume • temperature and time limits • chain of custody • rejection criteria

5

SHORT NOTE

Discuss equipment qualification and calibration in a clinical laboratory.

Key points: Installation, operational and performance qualification • calibration schedules and traceability • maintenance logs • out-of-calibration actions

6

VIVA

What is the difference between method validation and method verification? How is a non-conformance handled?

Key points: Validation for new or modified methods; verification for established methods • non-conformance record → root cause → CAPA → effectiveness check

Tip: answer long questions with a labelled flow chart or table — examiners reward structure.

CHAPTER 4 — BASICS OF CLINICAL RESEARCH

Introduction to Clinical Research and the Evidence Hierarchy

Clinical research is the systematic investigation of health-related questions in human beings, spanning the discovery of new therapies, the evaluation of diagnostic tests, and the study of disease causation and prognosis. It differs fundamentally from basic laboratory science because it must balance the pursuit of generalisable knowledge against the safety, autonomy, and welfare of individual research participants. Every clinician, whether a bedside nurse, a resident, or a consultant, will at some point need to read, appraise, or contribute to clinical research, making a working understanding of its methods and vocabulary an essential clinical skill rather than an optional academic pursuit.

The modern practice of medicine rests on the philosophy of evidence-based medicine (EBM), which holds that clinical decisions should integrate the best available research evidence with clinical expertise and individual patient values and preferences. Clinical research is the engine that generates the first of these three pillars. Without a structured framework for weighing the quality of that evidence, however, clinicians risk giving equal credence to a single anecdotal case report and to a large, well-conducted meta-analysis, a mistake that can have serious consequences for patient care and public health policy.

Not all evidence carries equal weight. The evidence hierarchy, sometimes drawn as a pyramid, ranks study designs according to their ability to minimise bias and establish causal relationships. Evidence lower in the pyramid is easier and cheaper to generate but more vulnerable to confounding and bias, while evidence higher in the pyramid requires more resources but yields more trustworthy conclusions. Understanding this hierarchy allows the clinician to judge how much confidence to place in a given piece of literature before applying it to patient care.

Level (lowest to highest)	Evidence Type	Key Strength	Key Limitation
1	Expert opinion / editorials	Fast, easy to produce, captures clinical experience	Highly subjective, prone to bias, no systematic data
2	Case report / case series	Identifies novel or rare phenomena, hypothesis-generating	No comparison group, cannot establish causation
3	Cross-sectional study	Quick snapshot of prevalence and associations	Cannot determine time sequence (cause vs effect)
4	Case-control study	Efficient for rare diseases, relatively inexpensive	Prone to recall and selection bias; cannot compute incidence directly
5	Cohort study (prospective/retrospective)	Can establish temporal sequence, calculates incidence and relative risk	Time-consuming, expensive if prospective; confounding still possible
6	Randomized controlled trial (RCT)	Randomization minimizes confounding, strongest for causal inference	Expensive, time-limited, may lack external validity (strict eligibility)

Level (lowest to highest)	Evidence Type	Key Strength	Key Limitation
7	Systematic review / meta-analysis	Synthesizes all available evidence, increases statistical power	Only as good as included studies; publication bias may distort pooled estimate

At the very top of the pyramid sit systematic reviews and meta-analyses of multiple well-conducted RCTs, which represent the strongest form of evidence because they aggregate data across many independent trials and populations. However, the hierarchy is a general guide and not an absolute rule: a poorly conducted RCT with major protocol violations may in practice provide weaker evidence than a meticulously conducted cohort study. Critical appraisal of study quality, not merely study type, must always accompany the use of this hierarchy.

Formal grading systems such as GRADE (Grading of Recommendations, Assessment, Development and Evaluations) build on this hierarchy by allowing the initial quality rating assigned to a body of evidence to be upgraded or downgraded based on factors such as risk of bias, inconsistency between studies, indirectness of the evidence to the clinical question, imprecision of the estimate, and the presence of a dose-response relationship. Clinical practice guidelines increasingly report their recommendations alongside a GRADE quality rating (high, moderate, low, or very low), giving clinicians a transparent sense of how much the underlying evidence base can be trusted.

It is also useful to remember that the 'best' study design is not fixed across all clinical questions; it depends on the type of question being asked. For questions of therapy or prevention, the RCT sits at the top of the hierarchy. For questions of prognosis, well-designed prospective cohort studies are often the strongest available evidence. For questions about the accuracy of a diagnostic test, cross-sectional studies comparing the test against a reference standard are most appropriate. For questions about harm or aetiology, cohort or case-control studies are frequently the only ethical option, since deliberately exposing participants to a suspected harmful agent would violate the basic ethical principle of non-maleficence. Recognising which type of clinical question is being asked is therefore the first step in correctly applying the evidence hierarchy.

Types of Study Designs

Clinical study designs can be broadly divided into descriptive designs, which characterise patterns of disease without a comparison group, and analytic designs, which compare groups to test a hypothesis. The choice of design depends on the research question, the frequency of the outcome or exposure, available resources, and ethical considerations. The table below summarises the designs most frequently encountered in undergraduate and postgraduate examinations, including several hybrid designs that combine features of the classic observational and experimental templates.

Design	Definition	Typical Use	Key Strength	Key Limitation
Case report / series	Detailed description of one or a small group of patients with an unusual presentation or outcome	Documenting novel disease presentations, rare adverse drug reactions	Simple, inexpensive, can prompt further research	No control group; cannot generalise or infer causation
Cross-sectional study	Measures exposure and outcome simultaneously in a defined population at one point in time	Estimating disease prevalence, health surveys	Quick, low-cost, good for planning health services	Cannot establish temporal (cause-effect) relationship; susceptible to prevalence-incidence bias
Case-control study	Compares individuals with a disease (cases) to those without (controls), looking backward for exposure differences	Studying rare diseases or outcomes with long latency (e.g., cancer)	Efficient, relatively quick, suited to rare outcomes	Recall bias, selection bias; cannot calculate incidence or relative risk directly (uses odds ratio)
Nested case-control study	Cases and matched controls are sampled from within an already-assembled cohort, using biological samples or data collected at baseline	Studying costly biomarkers (e.g., stored blood samples) within a large existing cohort without analysing every member	Retains temporal sequence of a cohort while being far cheaper, since only cases and a sample of controls need full exposure assessment	Still limited by the quality and completeness of the original cohort's baseline data
Cohort study (prospective)	Follows exposed and unexposed groups forward in time to observe development of outcome	Studying multiple outcomes of a single exposure, calculating incidence	Establishes temporal sequence; can calculate relative risk and incidence	Expensive, time-consuming, loss to follow-up threatens validity
Cohort study (retrospective)	Uses existing records to reconstruct exposure and outcome status that have already occurred	Occupational or environmental exposure studies using historical records	Faster and cheaper than prospective cohort	Depends on quality/completeness of existing records; more prone to bias
Randomized controlled trial (RCT, parallel-group)	Participants are randomly allocated to intervention or control (comparator) group and followed prospectively	Testing efficacy and safety of a new drug, device, or intervention	Randomization balances known and unknown confounders; strongest causal evidence	Costly, time-limited, strict eligibility criteria may reduce generalisability (external validity)

Design	Definition	Typical Use	Key Strength	Key Limitation
Randomized crossover trial	Each participant receives both the intervention and the comparator in a randomized sequence, separated by a washout period	Studying chronic, stable conditions with reversible outcomes (e.g., symptom control in asthma or migraine)	Each participant serves as their own control, greatly reducing between-person variability and the sample size required	Unsuitable for curative treatments or conditions that change over time; carryover effects can bias results if the washout period is too short
Ecological study	Compares exposure and outcome at the level of populations or groups (e.g., countries, districts) rather than individuals	Generating hypotheses about associations across regions, such as dietary salt intake and average population blood pressure	Inexpensive, uses routinely available aggregate data, useful for broad hypothesis generation	Vulnerable to the ecological fallacy: an association seen at group level may not hold true for individuals within that group

In practice, the decision of which design to use is rarely arbitrary; it reflects a trade-off between scientific rigour and feasibility. A researcher investigating a disease with an incubation period of several decades, such as many occupational cancers, cannot realistically mount a randomized trial and must instead rely on observational methods. Conversely, when evaluating a genuinely novel therapeutic agent for which no long-term outcome data yet exist, only a prospectively randomized and controlled design can provide convincing evidence of both efficacy and safety within a feasible time frame.

- Descriptive designs (case reports, case series, cross-sectional surveys) generate hypotheses; analytic designs (case-control, cohort, RCT) test them.
- As a rough rule of thumb: rare exposures favour a cohort design, rare outcomes favour a case-control design.
- The RCT remains the gold standard for demonstrating efficacy because randomization is the only design feature that controls for unmeasured (unknown) confounders on average.
- Examination tip: when a question describes 'looking back from disease to exposure,' think case-control; when it describes 'following forward from exposure to disease,' think cohort.
- The ecological fallacy is a distinct and commonly tested error: concluding that an association observed between groups (for example, countries with higher average fat intake having higher average heart disease rates) necessarily applies to individuals within those groups, when individual-level data may show a different or even opposite pattern.

Observational versus Experimental Studies

All clinical study designs can be classified into two broad families: observational studies, in which the investigator merely observes and records what naturally occurs without intervening, and experimental studies, in which the investigator actively assigns an intervention and controls the conditions under which it is delivered. This distinction is the single most important branch point in

study design because it determines both the strength of causal inference that can be drawn and the ethical framework that governs the research.

In an observational study the exposure of interest, whether a lifestyle factor, an occupational hazard, a pre-existing illness, or a treatment chosen by the patient's own physician, occurs entirely outside the researcher's control. The investigator's task is limited to identifying, measuring, and statistically accounting for the many other factors that may differ between exposed and unexposed individuals. Because this comparability can never be fully guaranteed, causal claims from observational data must be made cautiously, typically supported by a structured framework such as the Bradford Hill criteria, which considers factors including strength of association, consistency across studies, temporality, a biological gradient (dose-response relationship), and biological plausibility.

Experimental studies, by contrast, place the investigator in direct control of who receives which intervention. This active manipulation, particularly when combined with random allocation, is what allows experimental designs to isolate the causal effect of the intervention from the influence of both known and unknown confounding variables. This power comes at a price: experimental studies are subject to strict ethical oversight, require substantially more infrastructure (regulatory approval, monitoring, informed consent processes), and can only be conducted when genuine clinical equipoise exists.

- Clinical equipoise refers to a state of genuine collective uncertainty within the expert medical community about whether a treatment is beneficial, which is the ethical precondition for randomizing patients to receive it or not.
- It is unethical to experimentally assign participants to a known harmful exposure (for example, deliberately assigning individuals to begin smoking) purely to study its effects; such questions can only be addressed through observational designs.
- Community or cluster trials, a form of experimental study, randomize entire groups (villages, schools, clinics) rather than individuals, often used for public health interventions such as vaccination campaigns or health education programmes.
- Natural experiments, a special observational scenario, arise when an external event (such as a policy change, a natural disaster, or a change in insurance coverage) effectively creates exposed and unexposed groups without deliberate researcher assignment, offering some of the causal strength of an experiment without ethical concerns.
- Pragmatic trials sit at a middle ground: they retain the random allocation of a classic experimental design but relax many of the strict eligibility criteria and controlled conditions of a traditional explanatory RCT, aiming to reflect how an intervention performs under everyday, real-world clinical conditions rather than under ideal, tightly monitored ones.
- The choice between observational and experimental designs should always be justified in the study protocol with explicit reference to feasibility, cost, urgency of the clinical question, and ethical permissibility.
- Investigator role: observational studies leave the investigator as a passive observer of a naturally occurring exposure, whereas experimental studies place the investigator in active control, assigning the intervention.

- Control of confounding: observational studies are limited to statistical adjustment or matching, leaving residual confounding likely, whereas randomization in experimental studies distributes known and unknown confounders evenly between groups.
- Causal inference: observational data can suggest an association and causation may be inferred cautiously using frameworks such as the Bradford Hill criteria, whereas a well-conducted experimental study remains the strongest design for establishing causation directly.
- Ethical considerations: observational designs generally carry lower ethical risk and are suited to situations where randomization would be unethical or impossible, whereas experimental designs require genuine clinical equipoise and can never ethically randomize participants to a known harmful exposure.
- Typical use case: observational designs are best suited to studying rare exposures or long-latency diseases, or questions where randomization would be unethical (e.g., smoking and lung cancer), whereas experimental designs are the standard for testing new drugs, vaccines, devices, or procedures before regulatory approval.

Phases of Clinical Trials

Before a new drug or biologic reaches routine clinical use, it must pass through a structured sequence of human trial phases, each designed to answer a specific question with an appropriately sized and monitored population. This phased approach protects participant safety by exposing progressively larger numbers of people to the investigational product only after preceding phases have established an acceptable safety margin.

Phase	Objective	Typical Population Size	Typical Duration	Primary Focus
Phase 0	Exploratory, first-in-human microdosing to confirm pharmacokinetic behaviour	10-15 participants	Days to a few weeks	Pharmacokinetics/pharmacodynamics at sub-therapeutic doses
Phase I	First substantial human exposure; establish safety and tolerability	20-100 healthy volunteers (or patients for oncology drugs)	Several months	Safety, tolerability, dose-ranging, pharmacokinetics
Phase IIa	Early, smaller pilot studies exploring dosing and initial signals of biological activity	Roughly 50-150 patients with the target condition	Several months to about a year	Dose exploration and pilot evidence of biological/clinical activity


Phase	Objective	Typical Population Size	Typical Duration	Primary Focus
Phase IIb	Larger, better-controlled studies to establish the optimal dose and regimen before pivotal testing	Roughly 150-350 patients	About 1-2 years	Confirming dose-response and preliminary efficacy at the selected dose
Phase III	Confirmatory evidence of efficacy and safety versus standard of care	300 to several thousand patients, multicentre	1-4 years	Confirmatory efficacy and comparative safety (basis for regulatory approval)
Phase IIIb	Additional trials conducted after the pivotal submission but before formal marketing approval	Variable, often several hundred to a few thousand	Overlaps with regulatory review period	Supporting secondary indications, gathering supplementary data, or preparing for launch
Phase IV	Post-marketing surveillance after regulatory approval	Thousands to millions (real-world population)	Ongoing, for the life of the product	Long-term safety, rare adverse events, comparative effectiveness

The overall drug development pathway, from initial preclinical discovery through Phase IV surveillance, typically spans ten to fifteen years and costs hundreds of millions to over a billion dollars per approved medicine when failed candidates are accounted for. Attrition is steep at every stage: only a small minority of compounds entering Phase I trials ultimately reach regulatory approval, most commonly because of safety signals or lack of demonstrable efficacy identified during Phase II or Phase III testing. This is why Phase II is sometimes informally called the 'valley of death' in drug development, as it is where the largest proportion of candidate drugs fail.

- Phase III trials are usually the pivotal trials submitted to regulators and are frequently randomized, double-blind, and placebo- or active-controlled, often requiring two independent confirmatory trials for approval.
- Phase IV studies detect rare adverse events (occurring in, for example, 1 in 10,000 patients) that are statistically undetectable in the smaller pre-approval trial populations, since a trial would need tens of thousands of participants to reliably observe such rare events.
- Adaptive trial designs, increasingly used across Phases II and III, allow pre-specified modifications (such as dropping an ineffective arm or adjusting sample size) based on interim data, improving efficiency without compromising statistical validity.
- Seamless Phase I/II or Phase II/III designs, another modern innovation, allow a trial to transition directly from one phase's objective to the next within a single continuous protocol, shortening overall development time while maintaining rigorous pre-specified decision rules.

The Clinical Trial Lifecycle

The journey of an investigational drug from laboratory bench to pharmacy shelf follows a well-defined regulatory pathway. Preclinical (nonclinical) research using in-vitro and animal models establishes initial safety and biological plausibility before any human is exposed to the compound. Once sufficient preclinical data exist, the sponsor submits an application to the national regulator, commonly termed an Investigational New Drug (IND) application in the United States or a Clinical Trial Application (CTA) in other jurisdictions, seeking permission to begin human testing. The flowchart below traces the full lifecycle from preclinical work through the three principal human trial phases to regulatory approval and ongoing post-marketing surveillance.



Each transition point in this lifecycle involves formal regulatory gatekeeping. Sponsors cannot progress to the next phase without submitting cumulative safety and efficacy data for review, and regulators may impose a clinical hold, pausing or halting a trial, if new safety concerns emerge at any stage. This layered, sequential structure is what allows regulators to balance the urgency of bringing beneficial new therapies to patients against the imperative of not exposing large populations to an inadequately characterised risk.

It is worth emphasising to students that this lifecycle, although presented as a linear sequence, rarely proceeds without setbacks in practice. A safety signal identified during Phase II may send a programme back to earlier dose-finding work; a marginal Phase III result may prompt a regulator to request an additional confirmatory trial before approval; and even an approved product can be withdrawn from the market years later if Phase IV surveillance uncovers an unacceptable risk. The lifecycle is best understood as a continuous cycle of evidence generation and re-evaluation rather than a one-way path that ends at approval.

The Study Protocol

The study protocol is the master document that defines exactly how a clinical study will be conducted. It serves as the single reference point for investigators, ethics committees, regulators, and monitors, and any deviation from it must be justified and documented. A well-written protocol is the foundation of a scientifically valid and ethically sound trial; poorly defined protocols are a leading cause of trial failure, regulatory rejection, and post-hoc data manipulation.

Protocol Element	Purpose / Content
Background and rationale	Summarises existing evidence and justifies why the study question is important and unanswered
Objectives	States the specific scientific questions the study is designed to answer, usually primary and secondary objectives
Primary and secondary endpoints	Defines the precise outcome measures used to judge success (primary) and additional outcomes of interest (secondary)
Study design	Specifies the type of study (e.g., randomized, double-blind, parallel-group, placebo-controlled) and overall structure
Inclusion and exclusion criteria	Defines exactly who is eligible to participate, ensuring a well-defined and reproducible study population
Sample size justification	Provides the statistical calculation (based on expected effect size, power, and significance level) supporting the number of participants enrolled
Statistical analysis plan	Pre-specifies the statistical tests, handling of missing data, and analysis populations (e.g., intention-to-treat vs per-protocol) before unblinding
Safety monitoring plan	Describes how adverse events will be captured, graded, reported, and reviewed, including the role of a data safety monitoring board

Beyond these core elements, a complete protocol also addresses practical operational matters: the schedule of study visits and assessments, the procedures for obtaining and documenting informed consent, the handling and storage of biological samples, participant compensation and insurance arrangements, and the criteria under which a participant may be withdrawn from the study or the

trial itself may be stopped early. Every one of these operational details is reviewed by the ethics committee before approval, because each carries implications for participant welfare.

- Pre-specifying the statistical analysis plan before data lock prevents 'data dredging' or selectively reporting only favourable post-hoc analyses.
- Inclusion and exclusion criteria directly affect external validity: overly strict criteria produce a homogeneous, less generalisable trial population, while overly broad criteria may introduce excessive heterogeneity and dilute a true treatment effect.
- Any protocol amendment during the trial must be reviewed and approved by the ethics committee/institutional review board before implementation, and significant amendments may require re-consenting already-enrolled participants.
- An independent Data Safety Monitoring Board (DSMB), separate from the investigators and sponsor, periodically reviews unblinded safety and efficacy data during a trial and can recommend continuation, modification, or early termination of the study.
- A short, plain-language document called a protocol synopsis is usually prepared alongside the full protocol, summarising the key design features in a few pages for rapid review by ethics committees, regulators, and prospective investigators.

Randomization

Randomization is the process of allocating participants to study arms purely by chance, so that each participant has a known (often equal) probability of receiving any given intervention. It is the defining methodological feature of the RCT and is the only technique that balances both known and unknown confounding variables between groups, on average, making the groups comparable at baseline aside from the intervention under study.

Randomization Method	Description	Primary Purpose
Simple randomization	Allocation determined purely by chance for each participant (e.g., coin toss, computer-generated random number)	Eliminates selection bias in allocation; simplest method but can produce imbalanced group sizes in small trials
Block randomization	Participants randomized in fixed-size blocks (e.g., blocks of 4 or 6) ensuring roughly equal group sizes throughout enrolment	Maintains balanced group sizes over time, useful when interim analyses are planned
Stratified randomization	Randomization performed separately within subgroups (strata) defined by important prognostic factors (e.g., age, disease stage)	Balances known confounders/prognostic factors between groups, particularly important in small trials
Cluster randomization	Whole groups or clusters (e.g., hospitals, villages, clinics) rather than individuals are randomized to intervention or control	Used when individual randomization is impractical or when intervention is delivered at the group level; requires special statistical analysis

Randomization Method	Description	Primary Purpose
Minimization	A dynamic, non-random allocation algorithm that assigns each new participant to whichever group would minimise imbalance across several prognostic factors simultaneously	Achieves excellent baseline balance across multiple factors even in small trials, though it requires computerised tracking and is technically not fully random

Randomization must always be paired with allocation concealment, the practice of hiding the upcoming assignment sequence from the individuals enrolling participants, so that recruiters cannot consciously or unconsciously steer particular patients toward a preferred arm. Allocation concealment is distinct from blinding: concealment applies before and at the point of enrolment, while blinding applies after allocation has occurred. Common techniques to ensure allocation concealment include centralised telephone or web-based randomization systems and the use of sequentially numbered, opaque, sealed envelopes, though the latter is more prone to tampering and is now considered a weaker safeguard than centralised electronic systems.

- A common examination distinction: randomization prevents selection bias at the point of allocation, while blinding prevents performance and detection bias after allocation has taken place.
- Block randomization with a small, fixed block size can inadvertently allow investigators to predict the next assignment near the end of a block, which is why variable block sizes are often preferred.
- In cluster-randomized trials, the unit of randomization (the cluster) differs from the unit of analysis (often the individual), requiring specialised statistical methods that account for within-cluster correlation, such as the intraclass correlation coefficient.
- Minimization is particularly useful in smaller trials with several important prognostic factors to balance, since simple or even stratified randomization can, by chance, produce imbalance when many strata are involved; its main drawback is a degree of predictability that partially compromises allocation concealment.

Blinding (Masking)

Blinding, also called masking, refers to keeping one or more parties involved in a trial unaware of which intervention a participant has been allocated to. Its purpose is to prevent conscious or subconscious bias in the assessment of outcomes, the reporting of symptoms, and the management decisions made during the trial. The degree of blinding achievable depends on the nature of the intervention; some interventions (such as surgery versus medication) are inherently difficult or impossible to fully blind.

Blinding Level	Who Is Blinded	Primary Purpose
Open-label	No one is blinded; both participant and investigator know the assigned treatment	Used when blinding is not feasible (e.g., surgery vs no surgery); highest risk of performance and observer bias

Blinding Level	Who Is Blinded	Primary Purpose
Single-blind	Only the participant is unaware of the treatment assignment	Reduces bias arising from participant expectation, but investigator assessment can still be influenced
Double-blind	Both the participant and the investigator/outcome assessor are unaware of the assignment	Minimises both performance bias (participant behaviour) and observer/ascertainment bias (investigator assessment)
Triple-blind	Participant, investigator, and the data analyst/statistician are all unaware of the assignment	Additionally prevents analytic or reporting bias during statistical analysis and interim data review

- Blinding primarily protects against performance bias (differential care given based on known allocation) and detection/ascertainment bias (differential outcome assessment).
- Placebo-controlled double-blind designs are considered the methodological benchmark for drug trials wherever ethically and practically feasible, since an inert but identical-appearing placebo allows both participant and assessor blinding to be maintained.
- When full blinding is impossible (e.g., comparing surgical to medical management), investigators should still blind the outcome assessor wherever possible; this hybrid approach is termed a PROBE design (Prospective, Randomized, Open-label, Blinded Endpoint) and is common in cardiovascular and surgical research.
- The success of blinding can itself be formally tested at the end of a trial by asking participants and investigators to guess the treatment assignment; a guess rate close to chance suggests blinding was effectively maintained.
- Even in an open-label trial, using a hard, objective outcome measure (such as death or a laboratory value read by an external blinded laboratory) rather than a subjective one (such as a symptom score reported to the treating clinician) can substantially reduce the risk of detection bias.

Bias and Confounding

Bias refers to any systematic (non-random) error in the design, conduct, or analysis of a study that distorts the true relationship between exposure and outcome. Confounding, though related, arises from a third variable that is independently associated with both the exposure and the outcome, distorting the apparent association between them. Recognising the common sources of bias is essential both for designing sound studies and for critically appraising published literature.

Bias / Error Type	Brief Description	Control Measure
Selection bias	Systematic differences between those selected for study and those who are not, or between comparison groups at enrolment	Randomization, clearly defined and consistently applied inclusion/exclusion criteria

Bias / Error Type	Brief Description	Control Measure
Information (measurement) bias	Systematic error in how exposure, outcome, or covariate data are measured or classified	Standardised, validated measurement instruments and blinded outcome assessment
Recall bias	Differential accuracy or completeness of participants' memory of past exposures, often greater in cases than controls	Use of objective records rather than self-report where possible; symmetric questioning of cases and controls
Confounding	A third factor independently associated with both exposure and outcome, distorting the observed association	Randomization (best), restriction, matching, stratification, or statistical adjustment (multivariable regression)
Attrition bias	Systematic differences between groups in the number, reasons, or characteristics of participants who withdraw or are lost to follow-up	Intention-to-treat analysis, minimising loss to follow-up, reporting reasons for withdrawal
Publication bias	Tendency for studies with positive or statistically significant results to be published more often than negative or null studies	Prospective trial registration, publishing negative results, funnel plot analysis in meta-analysis
Detection (surveillance) bias	One group is monitored or investigated more intensively than the other, making an outcome more likely to be identified in that group simply because it is looked for more often	Standardising the frequency and intensity of follow-up and diagnostic testing across all study groups
Immortal time bias	A period of follow-up during which, by design, the outcome of interest cannot occur is misclassified or misallocated, artificially favouring the exposed or treated group	Careful, time-aligned definition of exposure and follow-up start, or use of time-varying exposure analysis methods
Hawthorne effect	Participants alter their behaviour simply because they know they are being observed or studied, independent of any actual intervention effect	Use of a control group that is observed with equal intensity, and where feasible, blinding of participants to the specific behaviour under study

It is important to distinguish bias from confounding at the conceptual level: bias arises from flaws in study design or measurement and generally cannot be corrected after data collection, whereas confounding can often be identified and statistically adjusted for during analysis, provided the confounding variable was measured. This is why careful a priori identification of plausible confounders during protocol design is so important.

- For a variable to be a true confounder, it must be associated with the exposure, be an independent risk factor for the outcome, and must not lie on the causal pathway between exposure and outcome (an intermediate variable should not be adjusted for as a confounder).
- Lead-time bias, common in cancer screening studies, occurs when early detection appears to prolong survival simply because diagnosis happened earlier in the disease course, without any true change in the disease's natural history.

- Berkson's bias, a form of selection bias, can arise in hospital-based case-control studies when the combination of exposure and disease increases the likelihood of hospital admission, distorting the observed association.
- Residual confounding may persist even after statistical adjustment if a confounder was measured imprecisely, or if an important confounder was never measured at all (unmeasured confounding), which remains the fundamental limitation of observational research relative to randomized designs.
- Immortal time bias is a frequently tested and subtle concept: it typically arises when a study defines the exposed group based on a status only achieved some time after the follow-up clock has already started, meaning that person-time before the exposure was actually confirmed is incorrectly credited to the exposed group, during which the outcome could not yet have been recorded against them.

Sample Size and Basic Biostatistics

A sound understanding of a small set of core statistical concepts is indispensable for interpreting clinical research, determining an adequate sample size, and avoiding common misinterpretations of results. These concepts recur throughout the biostatistics portion of most clinical and licensing examinations, and they form the shared language through which researchers communicate the strength and precision of their findings.

- Null hypothesis (H0) and alternative hypothesis (H1): the null hypothesis states there is no true difference or association between groups; the alternative hypothesis states that a difference or association does exist. Statistical testing is designed to assess the evidence against the null hypothesis.
- P-value: the probability of observing results as extreme as, or more extreme than, those obtained, assuming the null hypothesis is true. A conventional significance threshold of p less than 0.05 is used, meaning there is less than a 5 percent probability that the observed result occurred by chance alone if H0 were true. A p-value does not indicate the size or clinical importance of an effect, nor the probability that the null hypothesis is true.
- Confidence interval (CI): a range of values, typically the 95 percent CI, within which the true population parameter is expected to lie with a specified level of confidence upon repeated sampling. A CI that does not cross the null value (e.g., 1 for a risk ratio, 0 for a mean difference) indicates statistical significance and additionally conveys the precision of the estimate; a narrow CI reflects a precise estimate, while a wide CI reflects greater uncertainty, often due to a small sample size.
- Statistical power and Type I/Type II error: Type I error (α) is the probability of incorrectly rejecting a true null hypothesis (a false positive), conventionally set at 0.05. Type II error (β) is the probability of failing to reject a false null hypothesis (a false negative). Statistical power, equal to 1 minus β , is the probability of correctly detecting a true effect when one exists, and is conventionally set at 80 percent or higher.
- Effect size: the magnitude of the difference or association between groups (e.g., mean difference, risk ratio, odds ratio, hazard ratio), independent of sample size. Larger

anticipated effect sizes require smaller sample sizes to detect with adequate power, and vice versa.

- Sample size calculation integrates the expected effect size, the acceptable Type I error rate, the desired power, and the expected variability (standard deviation) in the outcome measure; underestimating any of these parameters at the design stage commonly produces an underpowered study that fails to detect a real treatment effect.
- Minimal clinically important difference (MCID): the smallest change in an outcome measure that a patient or clinician would consider meaningful; sample size calculations should ideally be built around this clinically meaningful difference rather than around whatever effect size is statistically convenient to detect.

Consider a hypothetical trial of a new antihypertensive drug versus placebo, reporting a mean systolic blood pressure reduction of 8 mmHg (95 percent CI, 5 to 11 mmHg; p less than 0.001) in the treatment arm. The narrow confidence interval and small p -value together suggest a precise and statistically robust effect. However, the clinician must still ask whether an 8 mmHg reduction is clinically meaningful for cardiovascular risk reduction in the population being treated, illustrating why statistical output must always be interpreted alongside clinical judgement rather than in isolation.

Trials are also commonly classified by the type of comparison they are designed to demonstrate. A superiority trial aims to show that a new treatment is genuinely better than the comparator, and is the default assumption for most readers unless stated otherwise. A non-inferiority trial instead aims to show that a new treatment is not unacceptably worse than an existing standard, usually because it offers some other advantage such as a more convenient dosing schedule, fewer side effects, or lower cost; this requires pre-specifying a non-inferiority margin, the maximum acceptable difference by which the new treatment could be worse while still being considered an acceptable alternative. An equivalence trial, less common, aims to show that two treatments produce very similar effects in both directions. Recognising which of these three frameworks a trial has adopted is essential to interpreting its conclusions correctly, since the statistical analysis and the appropriate interpretation of a confidence interval differ across all three.

A crucial exam and clinical pitfall is confusing statistical significance with clinical significance. A very large sample size can render even a trivially small, clinically meaningless difference statistically significant (p less than 0.05), while a genuinely important clinical effect in a small, underpowered study may fail to reach statistical significance. The clinician must always ask not only 'was this significant?' but also 'is this difference large enough to matter for my patient?' Reporting the effect size alongside its confidence interval, rather than the p -value alone, is now widely recommended practice to keep this distinction visible to readers.

Endpoints in Clinical Trials

An endpoint is a precisely defined outcome measure used to determine whether an intervention under study has an effect. Endpoints must be specified in the protocol before the trial begins to prevent selective outcome reporting, and they form the basis of the sample size calculation and the statistical analysis plan.

- Primary endpoint: the single most important outcome measure, pre-specified as the main basis for judging efficacy and for the sample size calculation. Example: all-cause mortality at 30 days in a sepsis treatment trial.
- Secondary endpoints: additional outcomes of interest analysed alongside the primary endpoint, often hypothesis-generating rather than confirmatory. Example: length of ICU stay, incidence of organ dysfunction in the same sepsis trial.
- Surrogate endpoints: indirect markers that are believed to predict clinical benefit but are not themselves direct measures of how a patient feels, functions, or survives. Example: LDL cholesterol level as a surrogate for cardiovascular events, or HbA1c as a surrogate for diabetic complications. Surrogate endpoints allow faster, smaller trials but carry the risk that improving the surrogate marker does not always translate into genuine clinical benefit, as famously demonstrated when certain antiarrhythmic drugs that suppressed abnormal heart rhythms (the surrogate) were later shown to increase mortality (the true clinical outcome).
- Composite endpoints: combine multiple individual events into a single outcome measure, increasing statistical power and event rate. Example: 'major adverse cardiac events' (MACE), typically combining cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. A limitation is that the least clinically important component of the composite (e.g., a soft outcome like hospitalisation) often drives most of the observed effect, potentially overstating the clinical impact of the intervention.
- Patient-reported outcomes (PROs): endpoints derived directly from the patient's own report of how they feel or function, such as pain scores, quality-of-life questionnaires, or symptom diaries, captured without interpretation by a clinician. PROs are increasingly required by regulators alongside traditional clinical endpoints, particularly for conditions where symptom relief and functional status, rather than survival alone, are the primary concern of patients.

When appraising a trial that reports a composite endpoint, it is good practice to examine the results for each individual component separately, since a favourable composite result can sometimes mask a neutral or even unfavourable effect on the most clinically important individual component, such as mortality. Regulators and journal reviewers increasingly require that the individual components of any composite endpoint be reported alongside the combined result for exactly this reason.

Worked Example: Designing a Simple Cohort Study

Abstract methodological rules are best consolidated by working through a concrete example from research question to a basic protocol outline. Suppose a hospital-based nurse researcher observes that colleagues who work permanent rotating night shifts appear, anecdotally, to develop hypertension more often than colleagues on fixed day shifts, and wishes to investigate this systematically. The steps below illustrate how this everyday clinical observation can be converted into a feasible, methodologically sound cohort study.

- Step 1, refine the research question: a vague question such as 'do night shifts cause health problems?' must be sharpened into a specific, answerable question, for example, 'among nurses aged 25-55 in a single hospital network, is exposure to rotating night shifts for five or

more years associated with a higher incidence of new-onset hypertension over five years of follow-up, compared with nurses who work fixed day shifts?'


- Step 2, define exposure and outcome precisely: exposure ('rotating night shift work') must be operationally defined (for example, at least three night shifts per month for a minimum duration), and outcome ('new-onset hypertension') must use an objective, reproducible definition, such as two separate clinic blood pressure readings above a defined threshold, or initiation of antihypertensive medication, rather than a vague or self-reported label.
- Step 3, choose the design: because the exposure (long-term rotating night shift work) is relatively common among nurses and multiple downstream outcomes might eventually be of interest (hypertension, but potentially also metabolic syndrome or sleep disorders), a prospective cohort design is appropriate, following exposed (night shift) and unexposed (day shift) nurses forward in time.
- Step 4, define the source population and sampling frame: eligible participants might be all currently employed nurses without pre-existing hypertension across a defined network of hospitals, recruited through occupational health records, with clear exclusion criteria (for example, pre-existing hypertension, pregnancy, or known secondary causes of hypertension at baseline).
- Step 5, identify likely confounders in advance: age, baseline body mass index, family history of hypertension, dietary salt intake, smoking status, and baseline physical activity level are all plausible confounders that must be measured at baseline so they can be statistically adjusted for in the final analysis.
- Step 6, decide on follow-up duration and outcome ascertainment: a follow-up period of five years, with blood pressure measured at standardised annual health checks by assessors unaware of the participant's shift-work status where feasible, balances scientific need against practical feasibility and cost.
- Step 7, perform a sample size calculation: using an estimated baseline hypertension incidence in day-shift nurses, an anticipated relative risk to be detected, a two-sided alpha of 0.05, and 80 percent power, the researcher calculates the minimum number of participants needed in each group, then inflates this figure to account for anticipated loss to follow-up.
- Step 8, pre-specify the statistical analysis plan: the primary analysis might compare cumulative incidence of hypertension between groups using a relative risk with a 95 percent confidence interval, followed by a multivariable regression model adjusting for the confounders identified in Step 5, with a clearly defined plan for handling participants lost to follow-up.
- Step 9, anticipate limitations at the design stage: the researcher should acknowledge in the protocol that residual confounding from unmeasured factors (such as chronic stress or unmeasured dietary patterns) may remain, and that the single-network setting may limit generalisability to nurses working under different scheduling systems elsewhere.

This worked example demonstrates how each concept introduced earlier in this chapter, defining a clear question, selecting an appropriate design, anticipating confounders, calculating an adequate sample size, and pre-specifying the analysis plan, comes together in the design of even a comparatively simple, single-centre observational study. The same disciplined sequence of steps

applies, with appropriate modification, to the design of a randomized trial, a case-control study, or any other analytic design encountered in clinical practice.

Choosing a Study Design

Selecting the correct study design for a given research question is a stepwise decision process that weighs the frequency of the exposure and outcome, the time frame available, ethical constraints, and the resources at hand. The sequence below summarises the practical reasoning a researcher works through when moving from a research question to a final design choice.



Applying this reasoning to concrete examples clarifies the decision process. A trial comparing a new antihypertensive drug against placebo, where genuine clinical equipoise exists and randomization poses no unusual ethical concern, is best suited to a randomized controlled trial. Investigating the association between a rare occupational chemical exposure and a range of possible later health outcomes, where the exposed population can feasibly be tracked forward in time, calls for a prospective cohort study. Studying risk factors for a rare paediatric cancer, where working backward

from a small number of identified cases is far more efficient than following an enormous unselected cohort forward, calls for a case-control study. Estimating the prevalence of hypertension across a city population at a single point in time, without needing to establish causality, is best answered with a cross-sectional survey. Finally, an unusual cluster of a novel drug reaction observed in only three patients is, at this early stage, best documented as a case series to alert the wider medical community and generate hypotheses for future controlled study.

- Feasibility constraints (time, funding, participant availability) often narrow the choice of design even when a more rigorous design would be scientifically preferable.
- Ethical permissibility is a hard constraint, not a soft preference: no degree of scientific rigour justifies randomizing participants to a known harmful exposure.
- The frequency of the outcome of interest is often the single most practical determinant of design choice: rare outcomes favour case-control designs, common outcomes are efficiently studied with cohort or cross-sectional designs.

Beyond Drug Trials — Device, Diagnostic, and Public Health Research

Although much of the vocabulary of clinical research, phases, endpoints, blinding, developed historically around the evaluation of new drugs, the same underlying principles of controlling bias and confounding apply equally to the evaluation of medical devices, diagnostic tests, and public health interventions. Each of these categories, however, presents distinctive methodological challenges that a purely drug-trial mental model does not fully anticipate.

Medical device trials differ from drug trials in several important ways. Many devices, particularly surgical and implantable devices, cannot be convincingly blinded to either the patient or the operator, making the PROBE design (blinded endpoint assessment despite an open-label procedure) especially important. Device performance is also frequently operator-dependent, meaning outcomes can improve over the course of a trial simply as surgeons and technicians climb the learning curve with a new device, a phenomenon that can confound comparisons with an established comparator technique. Regulatory pathways for devices often differ substantially from those for drugs; many jurisdictions classify devices by risk category, with only the highest-risk devices requiring extensive premarket clinical trial data comparable to a drug's Phase III programme, while lower-risk devices may be approved based on demonstrating substantial equivalence to an already-marketed device.

Diagnostic accuracy studies ask a fundamentally different question from therapeutic trials: not 'does this intervention improve outcomes?' but 'how well does this test distinguish between people who have a condition and people who do not?' Such studies compare a new or index test against an accepted reference standard (sometimes called a gold standard) in a population representative of those in whom the test would be used in practice, generating measures such as sensitivity, specificity, and predictive values. A key methodological hazard specific to diagnostic studies is spectrum bias, in which the accuracy of a test measured in a study population of only clearly diseased and clearly healthy individuals overstates its true accuracy in the more diagnostically ambiguous patients typically encountered in everyday practice. The STARD (Standards for Reporting of Diagnostic Accuracy Studies) guideline plays a role for diagnostic research analogous to that of CONSORT for trials.

Public health and community intervention research, meanwhile, often evaluates interventions delivered at the level of entire populations, such as water fluoridation, mass vaccination campaigns, tobacco taxation, or school-based health education programmes, where randomizing individuals is frequently impossible because the intervention cannot be confined to some members of a community while excluding their neighbours. Such research therefore relies heavily on cluster-randomized trials, natural experiments, and time-series or before-after designs that compare outcomes across a defined population before and after an intervention is introduced, tools that must contend with secular trends and other population-level changes occurring independently of the intervention itself.

Research Category	Typical Design Features	Distinctive Methodological Challenge
Drug trials	Randomized, often double-blind, placebo- or active-controlled, phased development (I-IV)	Establishing efficacy and safety across a phased, incremental exposure of increasing numbers of participants
Device trials	Often open-label or PROBE design due to difficulty blinding a procedure; risk-based regulatory pathway	Operator learning curve effects and difficulty achieving full blinding of the intervention itself
Diagnostic accuracy studies	Cross-sectional comparison of an index test against a reference standard in a representative population	Spectrum bias and verification bias (reference standard not applied equally to all participants)
Public health / community interventions	Cluster-randomized trials, natural experiments, before-after or interrupted time-series designs	Intervention cannot be confined to individuals; secular trends can mimic or mask a true intervention effect


- When appraising a device trial, always check whether the outcome assessor was blinded even if the procedure itself could not be, and whether operator experience with the device was accounted for.
- When appraising a diagnostic accuracy study, check whether the reference standard was applied to all participants regardless of index test result (avoiding verification bias) and whether the study population resembles the population in which the test will actually be used.
- When appraising a public health intervention study, check whether a concurrent, comparable control population or time period was used, since a simple before-after comparison without a control cannot distinguish the intervention's effect from unrelated background trends.

Systematic Reviews and Meta-Analysis Basics

A systematic review is a structured, pre-planned synthesis of all available evidence addressing a specific, clearly formulated research question, conducted using explicit, reproducible methods to identify, appraise, and summarise relevant studies. It differs from a traditional narrative review, in which an expert author selects and discusses literature according to their own judgement, in that a systematic review follows a pre-registered protocol with explicit inclusion criteria, a comprehensive

and documented search strategy, and a standardised approach to assessing the quality (risk of bias) of each included study.

When the included studies are sufficiently similar in their populations, interventions, and outcomes, their results may be statistically combined in a meta-analysis, producing a single pooled estimate of effect with a corresponding confidence interval. This pooled estimate typically carries greater statistical power and precision than any single included study, because it effectively increases the total sample size available for analysis. Meta-analyses are commonly displayed using a forest plot, a graphical summary in which each included study is represented by a box (whose size often reflects that study's weight in the pooled analysis) and a horizontal line (representing its confidence interval), with the overall pooled estimate displayed as a diamond at the bottom of the plot.



Two related concepts are essential to interpreting a meta-analysis correctly: heterogeneity and the choice of statistical model. Heterogeneity refers to genuine variability in the true effect size across the included studies, arising from differences in populations, intervention delivery, outcome definitions, or study quality. It is commonly quantified using the I-squared (I^2) statistic, expressed as

a percentage: as a rough guide, values below about 25 percent suggest low heterogeneity, values around 50 percent suggest moderate heterogeneity, and values above about 75 percent suggest substantial heterogeneity between studies. When heterogeneity is low, a fixed-effect model, which assumes all studies are estimating one single true underlying effect, may be appropriate. When heterogeneity is present, a random-effects model, which assumes the true effect varies from study to study and estimates the average of this distribution of effects, is generally preferred and typically produces a wider, more conservative confidence interval around the pooled estimate.

- PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) provides the reporting checklist and flow diagram now expected by most journals publishing systematic reviews.
- A funnel plot, a scatter plot of each study's effect size against a measure of its precision or sample size, is used to visually assess the possibility of publication bias; marked asymmetry in the funnel plot can suggest that smaller studies with unfavourable results were less likely to be published.
- Sensitivity analyses, in which the meta-analysis is repeated after excluding studies of lower quality or unusual design, help assess how robust the pooled conclusion is to methodological choices.
- A meta-analysis can never be more reliable than the studies that feed into it; pooling several small, biased studies simply produces a more precise but still biased overall estimate, a limitation summarised by the phrase 'garbage in, garbage out.'

Regulatory Framework for Clinical Research

Clinical research involving human participants is governed by national and international regulatory bodies that set standards for ethical conduct, data integrity, and participant safety. While specific procedures vary by country, the underlying principles are harmonised internationally through guidelines such as those issued by the International Council for Harmonisation (ICH), particularly ICH-GCP (Good Clinical Practice).

Regulatory Body / Framework	Jurisdiction	Role / Key Guideline
US FDA (Food and Drug Administration)	United States	Reviews IND applications, approves NDAs/BLAs, enforces 21 CFR regulations governing clinical trial conduct
European EMA (European Medicines Agency)	European Union	Coordinates scientific evaluation and centralised marketing authorisation (MAA) across EU member states
Indian CDSCO / New Drugs and Clinical Trials (NDCT) Rules, 2019	India	Central Drugs Standard Control Organisation regulates clinical trial approval, ethics committee registration, and compensation for trial-related injury under the NDCT Rules 2019
ICH (International Council for Harmonisation)	International (harmonises US, EU, Japan, and other member regulators)	Issues globally recognised guidelines, most notably ICH E6 (Good Clinical Practice), harmonising quality, ethical, and scientific standards for trial design and conduct

Regulatory Body / Framework	Jurisdiction	Role / Key Guideline
WHO International Clinical Trials Registry Platform (ICTRP)	Global (World Health Organization)	Links national and regional trial registries into a single searchable platform, promoting transparency and discouraging duplicate or unregistered trials

- Good Clinical Practice (GCP), codified in ICH E6, is the international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve human participants.
- Every trial site must obtain approval from an independent Ethics Committee or Institutional Review Board (IRB) before enrolment begins, and this approval must be renewed or reviewed periodically throughout the trial.
- Informed consent, freely given by a competent participant after full disclosure of risks, benefits, and alternatives, is a non-negotiable regulatory and ethical requirement across all jurisdictions, and must be documented in a manner the participant can understand, in their own language wherever feasible.
- The historical foundations of modern research ethics, including the Nuremberg Code, the Declaration of Helsinki, and the Belmont Report (which articulated the core principles of respect for persons, beneficence, and justice), continue to inform present-day regulatory requirements worldwide.
- In India specifically, the NDCT Rules 2019 introduced defined timelines for regulatory decision-making, mandatory registration of ethics committees with CDSCO, and a structured framework for determining compensation in cases of trial-related injury or death.

Ethics Committee Oversight in Clinical Research

While the previous section outlined the broader national and international regulatory landscape, the Ethics Committee (also called an Institutional Review Board, IRB, or Institutional Ethics Committee, IEC, depending on the jurisdiction) is the body whose review most directly touches every individual trial before a single participant is enrolled. Its core mandate is to independently safeguard the rights, safety, and wellbeing of research participants, weighing the anticipated risks of a study against its potential benefits to participants and to society.

An ethics committee is deliberately composed of a diverse membership, typically including clinicians and scientists from relevant specialties, a biostatistician, a legal expert, an ethicist or person knowledgeable in ethics, and at least one lay member representing the community and patient perspective, who is not affiliated with the research institution. This diversity of membership is intended to ensure that a protocol is scrutinised from scientific, statistical, legal, ethical, and community viewpoints simultaneously, rather than being approved solely on the basis of its scientific merit.

- Initial review: before any participant is enrolled, the ethics committee reviews the full protocol, the informed consent document, investigator qualifications, and the proposed risk-

benefit balance, and may approve the study as submitted, request modifications, or reject it outright.

- Continuing review: for trials of longer duration, the ethics committee conducts periodic reviews (commonly at least annually) of accumulating safety data, protocol amendments, and any reported adverse events, retaining the authority to suspend or terminate a study if participant safety appears compromised.
- Informed consent review: the committee specifically assesses whether the consent document is written in clear, comprehensible language appropriate to the study population, and whether the consent process allows adequate time and opportunity for questions before a participant agrees to enrol.
- Risk-benefit assessment: the committee weighs the anticipated risks of study participation, physical, psychological, social, or economic, against the anticipated direct benefit to participants and the broader value of the knowledge to be gained, and approves a study only when this balance is judged favourable.
- Protection of vulnerable populations: additional safeguards are required when a study involves participants with limited capacity to give free and informed consent, such as children, pregnant women, individuals with cognitive impairment, prisoners, or economically or educationally disadvantaged individuals, to ensure their participation is not the product of undue influence or coercion.
- Conflict of interest management: the committee also reviews and manages financial or professional conflicts of interest among investigators that could, even unintentionally, influence the design, conduct, or reporting of the study.

In day-to-day practice, ethics committee oversight and the broader Good Clinical Practice framework described in the preceding section operate together rather than separately: GCP defines the standard the trial must meet, while the ethics committee is the local, independent body charged with verifying, before and throughout the trial, that this standard is genuinely being upheld for the specific participants enrolled at a given site.

Data Management in Clinical Trials

Robust data management underpins the credibility of a clinical trial's results. Poor data quality, whether from transcription errors, incomplete records, or inconsistent capture, can undermine even a well-designed study. Modern trials rely on structured processes and increasingly on electronic systems to ensure data are accurate, complete, and traceable back to their source, a principle often summarised by the acronym ALCOA: data should be Attributable, Legible, Contemporaneous, Original, and Accurate.

- Case Report Form (CRF): the standardised document, paper or electronic, used to collect all protocol-specified data for each participant at each visit; it is the primary interface between clinical observation and the trial database.
- Electronic Data Capture (EDC): web-based or software systems that allow direct electronic entry of trial data, replacing paper CRFs; EDC systems include built-in validation checks

(range checks, logic checks) that flag inconsistent or implausible entries in real time, substantially reducing downstream data cleaning burden.

- Source data verification (SDV): the process by which trial monitors compare data entered on the CRF/EDC against the original source documents (e.g., hospital charts, laboratory reports) to confirm accuracy and completeness; risk-based monitoring approaches now often target SDV toward the most critical data fields (such as primary endpoints and serious adverse events) rather than verifying every data point at every site.
- Data query resolution: when a discrepancy, missing value, or implausible entry is identified (either automatically by the EDC system or by a monitor/data manager), a query is raised to the site investigator, who must resolve and document the correction, creating an auditable trail of any changes made to the original data.
- Database lock: the point at which no further changes can be made to the trial database, occurring after all queries are resolved and data are verified as complete; database lock must precede unblinding and final statistical analysis to preserve data integrity, and any change required after lock requires a formal, documented and justified database re-opening procedure.

Throughout the trial, a full audit trail is maintained, recording who entered or changed each piece of data, when, and why. This traceability is a core requirement of Good Clinical Practice and allows regulators, during a site inspection or audit, to reconstruct the complete history of any data point. Trial sponsors typically also appoint an independent data monitoring committee to review accumulating safety data at pre-specified intervals, providing an additional layer of oversight distinct from routine data management activities.

Pharmacovigilance Basics

Pharmacovigilance is the science and set of activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other medicine-related problems, extending across a drug's entire lifecycle but becoming especially critical after regulatory approval, when the drug is used in far larger and more heterogeneous populations than were studied in pre-approval trials, including groups such as pregnant women, children, the elderly, and patients with multiple comorbidities who are typically excluded from pre-approval trials.

- Adverse Event (AE) versus Adverse Drug Reaction (ADR): an AE is any untoward medical occurrence in a patient given a medicinal product, regardless of causal relationship, whereas an ADR is a response that is judged to be at least possibly caused by the drug.
- Spontaneous reporting systems: voluntary reporting mechanisms (e.g., the FDA's MedWatch, India's Pharmacovigilance Programme of India/PvPI, and the WHO's global database managed by the Uppsala Monitoring Centre) through which healthcare professionals and patients report suspected adverse drug reactions after a product reaches the market.
- Signal detection: the systematic process of identifying a new, previously unrecognised potential causal association between a drug and an adverse event, typically by statistical disproportionality analysis of large spontaneous reporting databases, comparing the

observed frequency of a drug-event pair against what would be expected if there were no association.

- Causality assessment: once a possible signal is identified, structured tools such as the WHO-UMC causality categories or the Naranjo algorithm are used to systematically assess how likely it is that a specific reported reaction was actually caused by the suspected drug, ranging from 'certain' to 'unlikely'.
- Periodic Safety Update Reports (PSURs), also called Periodic Benefit-Risk Evaluation Reports (PBRERs) in some jurisdictions: standardised, periodic reports that marketing authorisation holders are legally required to submit to regulators, summarising cumulative worldwide safety data and benefit-risk assessment for a marketed product.
- Post-marketing surveillance (Phase IV) complements spontaneous reporting by allowing detection of rare adverse events, long-term safety signals, and effects in special populations not adequately represented in pre-approval trials, sometimes leading to new safety warnings, restrictions on use (a 'black box warning' in the US), or in serious cases, withdrawal of the product from the market.

Reporting an adverse event is not the sole responsibility of the pharmaceutical industry; front-line nurses and clinicians are frequently the first to notice an unexpected reaction in a patient and play an essential role in initiating the spontaneous reporting process. Recognising that under-reporting is a well-documented and persistent limitation of spontaneous reporting systems worldwide, since only a fraction of true adverse reactions are ever formally reported, is an important reason why active surveillance methods, such as structured registries and large linked healthcare databases, are increasingly used to complement traditional spontaneous reporting.

Reporting and Publication Standards

Transparent and complete reporting of clinical research is essential so that readers can judge the validity of a study's methods and the trustworthiness of its conclusions. Over the past three decades, structured reporting guidelines have been developed for the major study types, and adherence to these guidelines is now required by most major medical journals as a condition of publication.

Reporting Guideline	Applies To	Core Purpose
CONSORT (Consolidated Standards of Reporting Trials)	Randomized controlled trials	Ensures complete, transparent reporting of trial methodology, participant flow, and results via a standardised checklist and flow diagram
STROBE (Strengthening the Reporting of Observational Studies in Epidemiology)	Cohort, case-control, and cross-sectional studies	Provides a checklist to ensure clear reporting of design, setting, participants, and potential sources of bias in observational research
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)	Systematic reviews and meta-analyses	Standardises reporting of the search strategy, study selection, data extraction, and synthesis methods, including a study flow diagram

Reporting Guideline	Applies To	Core Purpose
STARD (Standards for Reporting of Diagnostic Accuracy Studies)	Diagnostic accuracy studies	Ensures transparent reporting of test methodology, reference standard comparison, and diagnostic accuracy measures

Prospective trial registration, for example on ClinicalTrials.gov or the WHO International Clinical Trials Registry Platform, requires investigators to publicly document a trial's design, primary and secondary endpoints, and planned sample size before enrolment begins. Registration is now mandated by the International Committee of Medical Journal Editors (ICMJE) as a precondition for publication in member journals, and it serves as a powerful safeguard against selective outcome reporting and publication bias, since reviewers and readers can compare the registered protocol against the final published report.

- Publication bias occurs because studies with positive, statistically significant, or novel findings are more likely to be submitted and accepted for publication than negative or null studies, distorting the overall body of literature.
- Trial registries and mandatory reporting of results (even when negative) help counteract publication bias and allow systematic reviewers to identify unpublished or missing studies through methods such as funnel plot analysis.
- Adherence to CONSORT, STROBE, PRISMA, or STARD checklists, as appropriate to the study type, is now a standard requirement of peer review at most indexed biomedical journals, and reviewers and editors routinely request the completed checklist alongside the manuscript.
- Outcome switching, in which the endpoints reported in the final publication differ from those pre-specified in the trial registry, is a recognised and detectable form of reporting bias that undermines the credibility of a study's conclusions.

Landmark Clinical Trials That Shaped Modern Practice

Studying the abstract principles of clinical research methodology is reinforced by considering how they have played out in real, practice-changing trials. The examples below are widely cited in medical education not because their exact statistics need to be memorised, but because each illustrates how a well-designed study directly altered the standard of care, and each carries a broader methodological lesson relevant to this chapter.

- ISIS-2 (Second International Study of Infarct Survival), a large randomized trial in patients with suspected acute myocardial infarction, evaluated intravenous streptokinase, oral aspirin, both, or neither. It demonstrated that both aspirin and streptokinase independently reduced vascular mortality, with the combination proving more effective than either alone, and established early antiplatelet therapy as a routine, inexpensive, and highly effective component of acute myocardial infarction management worldwide. Methodological lesson: a simple, pragmatic, very large randomized trial with a hard clinical endpoint (mortality) can

generate practice-changing evidence even using an inexpensive, widely available intervention.

- The Diabetes Control and Complications Trial (DCCT), a randomized trial in patients with type 1 diabetes, compared intensive glycaemic control against conventional therapy and found that intensive control substantially reduced the risk of microvascular complications, including diabetic retinopathy, nephropathy, and neuropathy, over the course of follow-up. Methodological lesson: a trial with careful, objective, disease-specific endpoints (rather than a single surrogate marker alone) can definitively change long-term management goals for a chronic disease.
- The Women's Health Initiative (WHI), a large randomized trial investigating combined hormone replacement therapy in postmenopausal women, found a risk-benefit balance materially different from what had previously been suggested by earlier observational studies, prompting a substantial and rapid reappraisal of hormone replacement therapy prescribing practice worldwide. Methodological lesson: findings from observational studies, however consistent, can be contradicted by a well-conducted RCT, underscoring why randomized evidence carries greater weight for questions of causal treatment effect whenever it is ethically and practically obtainable.

Beyond their individual clinical findings, these trials collectively illustrate a recurring theme of this chapter: methodological rigour, an appropriately large and representative sample, randomization where feasible, clearly defined and clinically meaningful endpoints, and transparent reporting, is what allows a single study to durably change how millions of patients are treated. Students are encouraged to view every major guideline recommendation encountered in clinical practice as ultimately resting on a chain of evidence of exactly this kind, and to apply the same critical appraisal skills developed in this chapter when reading about new trials as they continue to reshape medical practice.

Common Pitfalls — Do Not Miss

1. Underpowered studies: enrolling too few participants to reliably detect a true effect, leading to false-negative (Type II error) conclusions.
2. Inadequate blinding: failing to blind participants, investigators, or outcome assessors, introducing performance and detection bias.
3. Presenting post-hoc subgroup analyses as if they were primary, pre-specified findings, inflating the risk of false-positive (chance) results.
4. Loss to follow-up not adequately addressed: high or differential attrition between groups without intention-to-treat analysis can bias results.
5. Confusing statistical significance with clinical significance: a small p-value does not guarantee the effect is large enough to matter to patients.
6. Protocol deviations affecting validity: unauthorised changes to eligibility, dosing, or endpoint assessment that compromise the integrity of the trial.
7. Inadequate allocation concealment: allowing recruiters to predict or influence upcoming randomization assignments.
8. Selective outcome reporting: publishing only favourable endpoints while omitting pre-specified endpoints that showed no effect.
9. Overgeneralising results from a narrow trial population to patients who would have been excluded by the trial's eligibility criteria.
10. Misinterpreting surrogate endpoint improvement as proof of genuine clinical benefit without confirmatory outcome data.
11. Treating a large I-squared value in a meta-analysis as a minor technicality rather than a signal that pooling the studies into one estimate may be scientifically inappropriate.
12. Mistaking a non-inferiority trial's conclusion for evidence of superiority, or applying a superiority-trial mindset when interpreting a non-inferiority margin.

Quick Reference — Clinical Research Glossary

1. RCT (Randomized Controlled Trial) — a study in which participants are randomly allocated to intervention or control groups to test causal efficacy.
2. CRF (Case Report Form) — the standardised document used to record protocol-specified participant data during a trial.
3. IND (Investigational New Drug application) — a regulatory submission required before beginning human trials of a new drug in the US.
4. Endpoint — a pre-specified outcome measure used to judge the effect of an intervention (primary, secondary, surrogate, or composite).
5. Confounder — a third variable independently associated with both exposure and outcome that distorts their apparent association.
6. Power — the probability that a study will correctly detect a true effect of a given size, conventionally set at 80 percent or higher.
7. P-value — the probability of observing results as extreme as those found, assuming the null hypothesis is true.
8. Blinding (masking) — concealing treatment assignment from participants, investigators, or analysts to reduce bias.
9. Pharmacovigilance — the science of detecting, assessing, and preventing adverse effects of medicines, particularly after marketing approval.
10. Heterogeneity (I-squared) — the degree of variability in true effect size across studies included in a meta-analysis.
11. Ethics Committee / IRB — an independent body that reviews and monitors research to protect the rights and safety of participants.

Important Questions — Basics of Clinical Research

Frequently asked long-answer, short-note and viva questions for the MD/MS examination

1

LONG ANSWER

Classify study designs used in clinical research with examples. Describe the hierarchy of evidence.

Key points: Descriptive vs analytical • observational (cross-sectional, case-control, cohort) vs experimental (RCT) • systematic review and meta-analysis at the top

2

SHORT NOTE

Compare cohort and case-control studies in terms of design, measures of association, strengths and limitations.

Key points: Exposure → outcome vs outcome → exposure • RR vs OR • rare outcomes vs rare exposures • recall and selection bias

3

LONG ANSWER

Describe the design of a randomised controlled trial. Explain randomisation, allocation concealment and blinding.

Key points: Eligibility, arms, outcomes • simple, block and stratified randomisation • allocation concealment vs blinding • intention-to-treat analysis

4

SHORT NOTE

What are bias and confounding? Describe how they can be minimised at the design and analysis stages.

Key points: Selection, information and recall bias • confounder definition • restriction, matching, randomisation • stratification and multivariable analysis

5

SHORT NOTE

Describe the phases of clinical trials with their objectives.

Key points: Phase 0 to IV • safety and dose finding → efficacy → confirmation → post-marketing surveillance

6

VIVA

What determines the sample size of a study? What is a meta-analysis?

Key points: Effect size, variability, α , power, dropouts • pooled estimate from systematic review, forest plot, heterogeneity

Tip: answer long questions with a labelled flow chart or table — examiners reward structure.

Educational disclaimer: This book is prepared for academic/teaching purposes and summarises standard, widely accepted clinical and regulatory principles (AHA ACLS framework; ICH-GCP E6(R2); OECD GLP Principles; standard clinical research methodology). Clinical doses, regulatory timelines, and procedural details must be individualised and cross-checked against current institutional protocols, local regulations, and the current full-text source guidelines before use in practice. Not a substitute for current official guidelines or clinical/regulatory judgement.

CHAPTER 5

BIOSTATISTICS

A Revision Guide for MD / DM Students

Comprehensive Reference — Exam Preparation & Thesis/Research Methodology

Contents

Section A: Foundations

- 5.1 Introduction to Biostatistics
- 5.2 Types of Data & Scales of Measurement
- 5.3 Presentation of Data
- 5.4 Measures of Central Tendency
- 5.5 Measures of Dispersion
- 5.6 Normal Distribution & Other Probability Distributions
- 5.7 Sampling

Section B: Inferential Statistics

- 5.8 Standard Error & Confidence Intervals
- 5.9 Hypothesis Testing
- 5.10 Tests of Significance — Parametric Tests
- 5.11 Tests of Significance — Non-Parametric Tests
- 5.12 Correlation & Regression
- 5.13 Multivariate Analysis (Brief)

Section C: Epidemiology-linked Biostatistics

- 5.14 Measures of Disease Frequency & Association
- 5.15 Diagnostic Test Evaluation
- 5.16 Screening & Bias
- 5.17 Survival Analysis

Section D: Research Methodology & Thesis Application

- 5.18 Study Designs
- 5.19 Sample Size Calculation
- 5.20 Randomization & Blinding
- 5.21 Writing the Statistical Methods Section of a Protocol/Thesis
- 5.22 Choosing the Right Statistical Test
- 5.23 Common Statistical Software — Basics
- 5.24 Reading & Critiquing Published Statistics
- 5.25 Common Errors in Medical Statistics

Appendices

- Practice Problems (end of each Section)
- Appendix I: Quick Formula Reference
- Appendix II: Glossary of Key Terms

5 Biostatistics

Section A — Foundations

5.1 Introduction to Biostatistics

Definition

Biostatistics is the application of statistical methods to biological, medical and public health data — covering the collection, organisation, analysis, interpretation and presentation of data.

Detailed Explanation

Statistics as applied to medicine serves three broad purposes: to describe a population or phenomenon (descriptive statistics), to draw valid conclusions about a population from a representative sample (inferential statistics), and to guide clinical/public-health decision-making using quantitative evidence rather than opinion or anecdote.

In an MD/DM programme, biostatistics is used at every stage of a thesis — from calculating an adequate sample size, to choosing the correct test for a given hypothesis, to interpreting the software output and writing conclusions that are statistically defensible in a viva.

Key Points

- Two broad branches: Descriptive statistics (summarising and presenting data) and Inferential statistics (drawing conclusions about a population from a sample).
- Scope in medicine: clinical research, epidemiology, thesis/dissertation work, drug trials, hospital records, vital statistics, quality control in laboratories, health service planning.
- Population = entire group of interest (e.g., all diabetics in Kerala); Sample = subset actually studied.
- Parameter = a numerical value describing the population (usually unknown, denoted by Greek letters — μ , σ); Statistic = the corresponding value calculated from a sample (denoted by Roman letters — $\bar{y}$, s), used to estimate the parameter.
- Variable: any characteristic that varies from one individual to another (e.g., age, blood pressure, disease status); a Constant does not vary.

When to Use

- Descriptive statistics — presenting baseline characteristics of study subjects (Table 1 of a thesis/paper).
- Inferential statistics — testing a hypothesis and generalising sample findings to the source population.

★ Points to Remember

- Biostatistics = descriptive + inferential branches.
- Sample statistics are used to estimate unknown population parameters.
- Every step of an MD/DM thesis — protocol, data collection, analysis, and viva defence — depends on correct biostatistical reasoning.

5.2 Types of Data & Scales of Measurement

Definition

Data in medicine are broadly classified as Qualitative (categorical) or Quantitative (numerical), and are further measured on four hierarchical scales — Nominal, Ordinal, Interval and Ratio.

Detailed Explanation

Correctly identifying the type/scale of a variable is the single most important step in any statistical analysis, because it determines every subsequent choice: which descriptive summary to use (mean vs median vs proportion), which graph to draw, and — most importantly — which inferential test is valid.

A common examiner trap is to treat ordinal data (e.g., pain score 1–5) as if it were interval/ratio data and apply a mean and t-test; strictly, ordinal data should be summarised with median and analysed with non-parametric tests, though in practice Likert-type scores are sometimes treated as continuous when the scale has many points.

Key Points

- Qualitative/Categorical: Nominal (no inherent order — blood group, sex, religion) and Ordinal (ordered categories with unequal/unknown gaps — mild/moderate/severe, cancer stage).
- Quantitative/Numerical: Discrete (whole-number counts — number of children, number of pregnancies) and Continuous (can take any value within a range — height, blood glucose, haemoglobin).
- Nominal scale: categories only, no order, no arithmetic possible (e.g., blood group A/B/AB/O).
- Ordinal scale: categories have a logical order, but intervals between categories are not necessarily equal (e.g., NYHA class I–IV).
- Interval scale: ordered, equal intervals, but no true/absolute zero — ratios are not meaningful (e.g., temperature in °C; 20°C is not 'twice as hot' as 10°C).
- Ratio scale: ordered, equal intervals, AND a true zero point — ratios are meaningful (e.g., weight, height, pulse rate, age; 0 kg truly means absence of weight).

Scale Comparison

Scale	Order?	Equal Intervals?	True Zero?	Example
Nominal	No	No	No	Blood group
Ordinal	Yes	No	No	Pain score (mild/mod/severe)
Interval	Yes	Yes	No	Temperature (°C)
Ratio	Yes	Yes	Yes	Height, weight, Hb

When to Use

- Choice of statistical test depends primarily on the type/scale of the data — always classify each study variable at the protocol-writing stage itself.

Example

In a thesis on hypertension: Gender (nominal), NYHA class (ordinal), Temperature in °C (interval), Systolic BP in mmHg (ratio, since 0 mmHg represents true absence of pressure).

★ Points to Remember

- Data type dictates the correct summary statistic and the correct test — get this classification right first.
- Hierarchy: Nominal < Ordinal < Interval < Ratio (in terms of information content).
- Ratio scale is the most informative and permits every arithmetic operation, including meaningful ratios.

5.3 Presentation of Data

Definition

Methods used to organise raw, unsorted data into a comprehensible form using tables, diagrams and graphs, making patterns and trends easier to identify and communicate.

Detailed Explanation

Good data presentation is not merely decorative — the choice of chart itself signals the type of data being shown, and an incorrect choice (e.g., using a pie chart for continuous data, or joining bars of a bar diagram) is a common and easily-avoidable error in thesis figures.

A frequency distribution table is usually the first step: raw data are grouped into class intervals with a tally of how many observations fall into each interval, from which histograms and other graphs are constructed.

Key Points

- Tabulation: frequency distribution table with class intervals, frequency, relative frequency (%), and cumulative frequency.
- Diagrams for qualitative/discrete data: Simple bar diagram (single variable), Multiple bar diagram (comparing subgroups), Component/stacked bar diagram (parts of a whole within categories), Pie chart (proportions of a whole).
- Graphs for quantitative continuous data: Histogram (bars touching, area proportional to frequency), Frequency polygon (line joining midpoints of histogram bars), Frequency curve (smoothed polygon), Ogive/cumulative frequency curve.
- Line diagram: used for time-trend data (e.g., malaria incidence over 10 years) — X-axis is usually time.
- Scatter diagram: plots paired continuous observations from two variables to visualise a relationship — the visual basis for correlation and regression.

Which Chart for Which Data

Data Type	Recommended Chart
Categorical (nominal/ordinal)	Bar diagram, Pie chart
Continuous, single variable distribution	Histogram, Frequency polygon
Cumulative distribution / percentiles	Ogive
Trend over time	Line diagram
Relationship between 2 continuous variables	Scatter diagram

When to Use

- Histogram — continuous data; bars touch each other (no gaps), unlike a bar diagram.
- Pie chart — proportions of a whole with a small number of categories (ideally ≤ 6).
- Ogive — used to read off the median and quartiles graphically without calculation.

Solved Example — Constructing a Frequency Distribution

Raw data (Hb g/dL, $n=20$): 9.1, 9.8, 10.2, 10.5, 10.9, 11.0, 11.2, 11.4, 11.6, 11.8, 12.0, 12.1, 12.3, 12.5, 12.8, 13.0, 13.2, 13.5, 13.9, 14.2.

Step 1 — Range = Max - Min = $14.2 - 9.1 = 5.1$.

Step 2 — Choose class width ≈ 1.0 g/dL, giving 6 class intervals (9–10, 10–11, 11–12, 12–13, 13–14, 14–15).

Step 3 — Tally observations into each class: 9–10: 2, 10–11: 4, 11–12: 5, 12–13: 5, 13–14: 3, 14–15: 1 (total = 20).

Step 4 — This frequency distribution table is now used directly to draw a histogram or calculate mean/SD using the mid-point method.

★ Points to Remember

- Match the chart type to the data type — bar/pie for categorical, histogram/polygon for continuous.
- A frequency distribution table is the foundation for most graphical presentation and for grouped-data calculations.

5.4 Measures of Central Tendency

Definition

A single value that represents the centre or 'typical' value of a data set. The three main measures are Mean, Median and Mode.

Detailed Explanation

The choice between mean and median in a thesis result table is one of the most frequently scrutinised decisions in a viva — it must be justified by the underlying distribution of the data (checked using Shapiro-Wilk test or a histogram/Q-Q plot), not chosen arbitrarily.

For grouped/class-interval data, the mean is calculated using the mid-point of each class multiplied by its frequency; median and mode for grouped data use interpolation formulas within the class containing the middle value or the highest frequency.

Key Points

- Mean uses every data value in its calculation but is heavily influenced by outliers/extreme values and by skewed distributions.
- Median is a positional average — unaffected by extreme values — and is the preferred measure for skewed data (e.g., hospital stay duration, income).
- Mode is the most frequently occurring value; useful mainly for nominal data (e.g., most common presenting complaint) but can also apply to continuous data grouped into classes (modal class).
- A distribution may be unimodal (one mode), bimodal (two modes) or multimodal.
- For symmetric, normally distributed data, Mean = Median = Mode.

Formula / Notes

Mean ($\bar{y}$) = $\Sigma x / n$

Median = middle value of data arranged in ascending order; for even n , average of the two middle values

Mode = most frequently occurring value

Empirical relation (moderately skewed data): Mean – Mode = 3 (Mean – Median)

When to Use

- Mean — symmetric, interval/ratio data without significant outliers (e.g., average Hb level in a homogeneous group); reported as Mean $\pm$ SD.
- Median — skewed data or presence of outliers (e.g., duration of ICU stay); reported as Median (IQR).
- Mode — nominal data (e.g., most common blood group in a population).

Solved Example — Calculating Mean, Median, Mode

Data (systolic BP, mmHg, $n=9$): 118, 122, 124, 126, 128, 130, 130, 134, 150.

Mean = $(118+122+124+126+128+130+130+134+150) / 9 = 1162 / 9 = 129.1$ mmHg.

Median = middle (5th) value of the ordered data = 128 mmHg.

Mode = most frequent value = 130 mmHg (appears twice).

Note: The single outlier (150) pulls the Mean (129.1) above the Median (128) — with a larger or more extreme outlier, Median would be the more representative/robust measure to report.

★ Points to Remember

→ Mean is sensitive to outliers; Median is robust to outliers; Mode identifies the most common category/value.

→ Report Mean±SD for normally distributed data; Median (IQR) for skewed data — this choice must match the normality-testing result.

5.5 Measures of Dispersion

Definition

Statistics that indicate the spread or variability of data around the central value — the main measures are Range, Standard Deviation (SD), Variance, Coefficient of Variation (CV), and Interquartile Range (IQR).

Detailed Explanation

Central tendency alone can be misleading — two data sets can have identical means but very different spreads, which has direct clinical relevance (e.g., a drug producing a consistent moderate BP drop in everyone is often preferable to one producing a similar average drop but with wildly variable individual responses).

SD and Mean go together, and Median and IQR go together — mixing them (e.g., reporting Mean with IQR) is an inconsistency examiners frequently flag in thesis result tables.

Key Points

- SD is the most widely used measure of dispersion for data with a normal/near-normal distribution; it has the same units as the original data.
- Variance is the square of SD — used internally in many statistical formulas (e.g., ANOVA) though rarely reported directly in a results table.
- CV is unitless (expressed as %) — used to compare the relative variability of two datasets measured in different units or with very different means (e.g., comparing variability of height in cm vs weight in kg).
- IQR (with median) is the correct dispersion measure for skewed data, and is less influenced by outliers than the range.
- Range is the simplest but crudest measure — based only on the two extreme values, highly sensitive to outliers.

Formula / Notes

Range = Maximum – Minimum

Variance (s^2) = $\Sigma(x - \bar{y})^2 / (n - 1)$ [sample formula]

SD (s) = $\sqrt{\text{Variance}}$

Coefficient of Variation (CV %) = $(SD / \text{Mean}) \times 100$

IQR = Q3 (75th percentile) – Q1 (25th percentile)

When to Use

- Report SD with Mean for approximately normal data; report IQR with Median for skewed data.
- Use CV when comparing variability between two variables with different units (e.g., birth weight in kg vs gestational age in weeks).

Solved Example — Calculating SD

Data (Hb g/dL, n=5): 10, 11, 12, 13, 14. Mean = $(10+11+12+13+14)/5 = 12$.

Deviations from mean ($x - \bar{y}$): -2, -1, 0, +1, +2.

Squared deviations: 4, 1, 0, 1, 4. Sum = 10.

Variance = $\sum(x-\bar{y})^2 / (n-1) = 10 / 4 = 2.5$.

SD = $\sqrt{2.5} = 1.58$ g/dL.

Result reported as: Hb = 12.0 $\pm$ 1.58 g/dL (Mean $\pm$ SD).

★ Points to Remember

- Dispersion measures complete the picture that central tendency alone cannot provide — always report both together.
- SD pairs with Mean; IQR pairs with Median — never mix the pairing in a results table.

5.6 Normal Distribution & Other Probability Distributions

Definition

The Normal (Gaussian) distribution is a symmetric, bell-shaped continuous probability distribution in which mean = median = mode, and which underlies most parametric statistical tests.

Detailed Explanation

Testing whether a continuous variable is normally distributed is a mandatory step before choosing between a parametric and a non-parametric test — done visually (histogram, Q-Q plot) or formally (Shapiro-Wilk test for $n < 50$, Kolmogorov-Smirnov test for larger samples).

The Central Limit Theorem states that, regardless of the shape of the population distribution, the distribution of sample means approaches a normal distribution as sample size increases (usually $n \geq 30$) — this is the theoretical justification for using parametric tests even when individual data points are not perfectly normal, provided the sample is reasonably large.

Key Points

- Normal distribution is defined completely by two parameters: mean (μ) and SD (σ).
- Empirical (68-95-99.7) rule: Mean $\pm$ 1 SD contains $\approx$ 68% of observations; Mean $\pm$ 2 SD $\approx$ 95%; Mean $\pm$ 3 SD $\approx$ 99.7%.
- Standard Normal Distribution: a normal distribution with mean = 0 and SD = 1; any raw value x is converted to a Z-score using $Z = (x - \mu) / \sigma$, allowing use of standard Z-tables.
- Skewness: Positive/right skew — tail extends right, Mean $>$ Median $>$ Mode (e.g., hospital bills, income). Negative/left skew — tail extends left, Mean $<$ Median $<$ Mode.
- Binomial distribution: discrete distribution for a fixed number of independent trials, each with two possible outcomes (success/failure) and constant probability of success — e.g., number of patients responding to treatment out of 20.
- Poisson distribution: discrete distribution for the number of rare/random events occurring in a fixed interval of time or space, when the average rate is known and constant — e.g., number of new cases of a rare disease per year in a district.

When to Use

- Parametric tests (t-test, ANOVA, Pearson correlation) assume the outcome variable follows (or reasonably approximates) a normal distribution.
- Binomial — fixed number of independent yes/no trials.
- Poisson — count of rare, independent, randomly occurring events over time/space.

Solved Example — Using the Z-score

A population of adult males has Mean SBP = 120 mmHg, SD = 10 mmHg (approximately normal).

Question: What proportion of men have SBP above 140 mmHg?

$$Z = (x - \mu)/\sigma = (140 - 120)/10 = 2.0.$$

From the standard normal (Z) table, area beyond $Z=2.0 \approx 0.0228$, i.e., about 2.3% of the population has SBP above 140 mmHg.

★ Points to Remember

- Normal distribution: symmetric, Mean=Median=Mode, fully described by μ and σ .
- 68-95-99.7 rule lets you quickly estimate what proportion of data falls within 1/2/3 SD of the mean.
- Central Limit Theorem justifies parametric tests on sample means even for non-normal populations, given adequate sample size.

5.7 Sampling

Definition

Sampling is the process of selecting a representative subset (sample) of individuals from a larger population, so that conclusions drawn from the sample can be validly generalised to that population.

Detailed Explanation

The overarching goal of any sampling method is to minimise both sampling error (which shrinks with larger sample size) and bias/non-sampling error (which does not shrink with sample size and can only be reduced by a better study design).

The choice of sampling method should be decided and justified at the protocol stage, based on the availability of a sampling frame, the geographic spread of the population, and whether specific subgroups need guaranteed representation.

Key Points

- Probability sampling (every unit has a known, non-zero chance of selection — allows valid statistical inference): Simple random sampling, Systematic sampling, Stratified sampling, Cluster sampling, Multistage sampling.
- Non-probability sampling (selection is not by chance — inference to the wider population is limited): Convenience sampling, Purposive/Judgmental sampling, Quota sampling, Snowball sampling.
- Simple random sampling: every individual has an equal chance of selection, typically using a random number table/generator; needs a complete sampling frame (list of the population).
- Systematic sampling: units selected at a fixed interval (every k^{th} unit) from a randomly chosen starting point in the sampling frame.
- Stratified sampling: population divided into homogeneous subgroups (strata, e.g., age groups), then random sampling done within each stratum — ensures adequate representation of each subgroup.

- Cluster sampling: population divided into naturally occurring clusters (e.g., villages, wards); entire clusters are randomly selected and all/some individuals within chosen clusters are studied — economical for large, geographically dispersed populations.
- Multistage sampling: combines two or more of the above methods in stages (e.g., randomly select districts, then villages within districts, then households within villages) — commonly used in large national health surveys.
- Sampling error: the difference between a sample statistic and the true population parameter, arising purely from chance — decreases as sample size increases.
- Non-sampling error (bias): errors arising from faulty study design, measurement error, or non-response — does NOT decrease with increasing sample size, and can even get worse in poorly conducted large studies.

When to Use

- Stratified sampling — when the population has distinct sub-groups and representation of each is essential for the study objectives.
- Cluster sampling — when the population is large and geographically spread, and a complete individual-level sampling frame is unavailable or impractical.
- Systematic sampling — when a sampling frame (e.g., an OPD register) is available and a simple, quick method is needed.
- Multistage sampling — large-scale national/state health surveys (e.g., NFHS).

Example

Selecting every 10th patient from a serially numbered OPD register, starting from a random point between 1–10, is Systematic sampling.

★ Points to Remember

- Probability sampling allows valid statistical inference to the population; non-probability sampling does not.
- Sampling error shrinks with bigger samples; bias does not — a bigger sample cannot fix a biased design.
- Match the sampling method to the population structure: stratified for known subgroups, cluster for dispersed populations without an individual list.

Practice Problems — Section A (Foundations)

1. Classify the following variables by scale of measurement: (a) ABO blood group, (b) APGAR score, (c) Body temperature in °F, (d) Serum creatinine (mg/dL).

Answer: (a) Nominal — categories, no order. (b) Ordinal — ordered score, unequal intervals. (c) Interval — ordered, equal intervals, no true zero. (d) Ratio — ordered, equal intervals, true zero (0 mg/dL = true absence).

2. A dataset of 11 patients' waiting time in OPD (minutes): 5, 8, 8, 10, 12, 12, 12, 15, 18, 20, 60. Which measure of central tendency best represents this data, and why?

Answer: Median (12 minutes) is most appropriate — the value 60 is a clear outlier that would inflate the Mean (Mean=180/11≈16.4) to an unrepresentative figure; the Median is robust to this outlier.

3. Calculate the Range and note one limitation of using it as a measure of dispersion for the data: 22, 24, 25, 25, 26, 90.

Answer: Range = 90–22 = 68. Limitation: Range depends only on the two extreme values (22 and 90) and

ignores the distribution of all other data points — a single outlier (90) makes the Range highly misleading here; IQR or SD (after outlier review) would better describe the typical spread.

4. A study wants to survey diabetic patients from all 14 districts of Kerala, ensuring every district is proportionately represented. Which sampling method is most appropriate?

Answer: Stratified random sampling, with each district treated as a stratum, and proportionate random sampling done within each stratum according to district population/prevalence.

Amrita School of Medicine

Section B — Inferential Statistics

5.8 Standard Error & Confidence Intervals

Definition

Standard Error (SE) measures how much a sample statistic (e.g., mean) is expected to vary from the true population parameter purely due to sampling variation. A Confidence Interval (CI) is a range of values within which the true population parameter is likely to lie, with a stated level of confidence (usually 95%).

Detailed Explanation

SE and SD are frequently confused, but they answer different questions: SD describes how spread out individual observations are around the sample mean, while SE describes how precise the sample mean itself is as an estimate of the (unknown) population mean.

A 95% CI is one of the most important outputs to report in a thesis, because it conveys both statistical significance and clinical/practical importance in a single range — a p-value alone tells you 'significant or not', while a CI additionally tells you the plausible size of the effect.

Key Points

- SE decreases as sample size (n) increases (SE is inversely proportional to $\sqrt{n}$) — larger samples give more precise estimates of the population parameter.
- A 95% CI means: if the same study were repeated many times using new samples from the same population, 95% of the calculated intervals would contain the true population parameter.
- A narrower CI indicates a more precise estimate; a wide CI indicates less precision, often reflecting a small sample size.
- If a 95% CI for a difference between two groups (or for RR/OR) includes the 'null value' (0 for a difference, 1 for RR/OR), the result is NOT statistically significant at $p < 0.05$.

Formula / Notes

$$SE \text{ of mean} = SD / \sqrt{n}$$

$$95\% \text{ CI of mean} = \text{Mean} \pm (1.96 \times SE)$$

$$SE \text{ of proportion} = \sqrt{p(1-p)/n}$$

$$95\% \text{ CI of proportion} = p \pm (1.96 \times SE \text{ of proportion})$$

Solved Example — Calculating a 95% CI for a Mean

A sample of 25 patients has Mean fasting glucose = 100 mg/dL, SD = 15 mg/dL.

$$SE = SD/\sqrt{n} = 15/\sqrt{25} = 15/5 = 3.0 \text{ mg/dL.}$$

$$95\% \text{ CI} = \text{Mean} \pm 1.96 \times SE = 100 \pm 1.96 \times 3.0 = 100 \pm 5.88.$$

$$95\% \text{ CI} = 94.1 \text{ to } 105.9 \text{ mg/dL.}$$

Interpretation: We are 95% confident that the true population mean fasting glucose lies between 94.1 and 105.9 mg/dL.

★ Points to Remember

→ SD = spread of individual data; SE = precision of the sample mean as an estimate of the population mean.

→ SE shrinks as sample size grows; a larger study gives a narrower, more informative CI.

→ Always report 95% CI alongside p-values in thesis results — it shows both significance and the plausible

range of the true effect.

5.9 Hypothesis Testing

Definition

A structured statistical procedure to decide, based on sample data, whether to accept or reject an assumption (hypothesis) about a population parameter.

Detailed Explanation

Every inferential test in this book — from the simple t-test to Cox regression — is, at its core, a hypothesis test: a null hypothesis is set up, a test statistic is calculated from the sample data, and a p-value is derived to decide whether the observed data are compatible with the null hypothesis or not.

Sample size and power are directly linked to Type II error: an underpowered study (too few subjects) may fail to detect a real difference, wrongly concluding 'no significant difference' — this is one of the most common weaknesses examiners probe for in a thesis viva.

Key Points

- Null hypothesis (H_0): the default assumption of no difference/no association/no effect between groups.
- Alternative hypothesis (H_1): assumes a difference/association/effect exists; may be two-tailed (difference in either direction) or one-tailed (difference in a specified direction only).
- Type I error (α , false positive): rejecting a true H_0 — concluding there is a difference when actually there is none. Conventionally set at 5% ($\alpha=0.05$).
- Type II error (β , false negative): failing to reject a false H_0 — concluding there is no difference when one actually exists. Conventionally kept $\leq 20\%$ ($\beta=0.2$).
- Power of a study ($1 - \beta$): the probability of correctly detecting a real difference/effect if one truly exists; conventionally required to be $\geq 80\%$.
- p-value: the probability of obtaining a result as extreme as (or more extreme than) the one observed, assuming H_0 is true. Conventionally, $p < 0.05$ is taken as statistically significant, leading to rejection of H_0 .

Type I vs Type II Error

	H_0 is actually True	H_0 is actually False
Test rejects H_0	Type I error (α) — False Positive	Correct decision (Power, $1-\beta$)
Test fails to reject H_0	Correct decision	Type II error (β) — False Negative

When to Use

- State H_0 and H_1 explicitly for every objective before performing any statistical test — a standard requirement in thesis protocols and a common viva question.

Example

H_0 : New drug produces no difference in mean BP reduction compared to placebo. Result: $p=0.02$ (<0.05)
→ H_0 is rejected; the drug shows a statistically significant BP-lowering effect compared to placebo.

★ Points to Remember

→ α (Type I error) is fixed by the researcher, usually at 5%; β (Type II error) is minimised by adequate sample size.

→ Power = $1 - \beta$, and should be $\geq 80\%$ — this is a key justification needed in the sample-size section of a protocol.
→ $p < 0.05$ → reject H_0 (statistically significant); $p \geq 0.05$ → fail to reject H_0 (not statistically significant, not proof of 'no effect').

5.10 Tests of Significance — Parametric Tests

Definition

Tests that assume the study data follow a known distribution (usually the normal distribution), and are generally used for interval/ratio-scale continuous data.

Detailed Explanation

Parametric tests are generally preferred over their non-parametric counterparts when their assumptions (normality, adequate sample size, similar variance between groups) are met, because they have greater statistical power to detect a true difference for the same sample size.

The choice between paired and unpaired (independent) versions of the t-test depends entirely on the study design — whether the two sets of measurements come from the same subjects (paired) or from two different, independent groups of subjects (unpaired).

Key Points

- Student's t-test compares means of continuous data.
- • Unpaired/Independent t-test: compares means between two different, independent groups of subjects (e.g., Drug A group vs Drug B group).
- • Paired t-test: compares two measurements taken from the same subjects at two time points (e.g., BP before vs after treatment in the same patients).
- • One-sample t-test: compares a sample mean against a known/hypothesised population value.
- ANOVA (Analysis of Variance) compares means across three or more groups simultaneously in a single test.
- • One-way ANOVA: tests the effect of one independent factor with ≥ 3 levels (e.g., three different drug doses).
- • Two-way ANOVA: tests the effects of two independent factors together, including any interaction between them.
- Post-hoc tests (e.g., Tukey's HSD, Bonferroni correction) are performed AFTER a significant ANOVA result, to identify exactly which pairs of groups differ significantly.

When to Use

- t-test — comparing means between exactly 2 groups (or 2 time points), continuous & approximately normally distributed data.
- ANOVA — comparing means among 3 or more groups; avoids the inflated Type I (false positive) error that would result from doing multiple separate t-tests.

Solved Example — Unpaired t-test (conceptual walkthrough)

Group A (Drug, $n=15$): Mean SBP fall = 12 mmHg, SD = 4.

Group B (Placebo, $n=15$): Mean SBP fall = 6 mmHg, SD = 5.

t-test compares the difference in means ($12 - 6 = 6$ mmHg) relative to the combined/pooled variability (SE of the difference) between the two independent groups.

Suppose this yields $t = 3.45$, $df = 28$, $p = 0.002$.

Since $p < 0.05$, H_0 (no difference between drug and placebo) is rejected — the drug produces a statistically significantly greater fall in SBP than placebo.

★ Points to Remember

- t-test for 2 groups; ANOVA for ≥ 3 groups — never run multiple t-tests instead of ANOVA.
- Match paired vs unpaired t-test strictly to the study design (same subjects twice = paired; different subjects = unpaired).
- A significant ANOVA only tells you 'a difference exists somewhere' — a post-hoc test is required to identify which specific groups differ.

5.11 Tests of Significance — Non-Parametric Tests

Definition

Tests used when the data do not follow a normal distribution, are ordinal in nature, or when the sample size is too small to reliably assess normality — these tests do not assume any particular underlying distribution and often work on ranks rather than raw values.

Detailed Explanation

Non-parametric tests are generally 'distribution-free' and more robust to outliers, but are usually somewhat less statistically powerful than their parametric equivalents when the parametric assumptions actually do hold — hence parametric tests are preferred whenever their assumptions are genuinely met.

Most commonly-used non-parametric tests have a direct parametric 'equivalent', and knowing this pairing is essential for quickly identifying the correct choice in a viva or MCQ setting.

Key Points

- Chi-square (χ^2) test — tests for an association between two categorical variables, using a contingency table of observed vs expected frequencies.
- Mann-Whitney U test — non-parametric alternative to the unpaired t-test, for comparing 2 independent groups.
- Wilcoxon signed-rank test — non-parametric alternative to the paired t-test, for comparing 2 related/paired measurements.
- Kruskal-Wallis test — non-parametric alternative to one-way ANOVA, for comparing ≥ 3 independent groups.
- Friedman test — non-parametric alternative to repeated-measures/two-way ANOVA, for ≥ 3 related measurements.
- Fisher's Exact test — used instead of Chi-square specifically when the expected frequency in any cell of a 2×2 table is less than 5, or overall sample size is small.

Formula / Notes

$$\chi^2 = \sum [(O - E)^2 / E] \text{ where } O = \text{observed frequency, } E = \text{expected frequency in each cell}$$

Parametric – Non-Parametric Equivalents

Situation	Parametric Test	Non-Parametric Equivalent
2 independent groups	Unpaired t-test	Mann-Whitney U test
2 paired/related groups	Paired t-test	Wilcoxon signed-rank test
≥ 3 independent groups	One-way ANOVA	Kruskal-Wallis test
≥ 3 related measurements	Repeated-measures ANOVA	Friedman test

Situation	Parametric Test	Non-Parametric Equivalent
Correlation	Pearson correlation	Spearman correlation

When to Use

- Use non-parametric tests for ordinal data, clearly skewed continuous data, or small samples that fail a normality test.
- Chi-square — association between two categorical/nominal variables (e.g., smoking status vs disease presence) with adequate cell counts.
- Fisher's Exact — small sample, 2×2 table, any expected cell count <5.

Solved Example — Chi-square test

Question: Is there an association between smoking (yes/no) and COPD (yes/no) in 200 subjects?

2×2 table — Smokers with COPD (O=40, E=30); Smokers without COPD (O=60, E=70); Non-smokers with COPD (O=20, E=30); Non-smokers without COPD (O=80, E=70).

$$\chi^2 = \sum (O-E)^2/E = (10^2/30) + (10^2/70) + (10^2/30) + (10^2/70) = 3.33 + 1.43 + 3.33 + 1.43 = 9.52.$$

With df=1, $\chi^2=9.52$ corresponds to $p<0.01$.

Since $p<0.05$, H_0 (no association) is rejected — smoking is significantly associated with COPD in this sample.

★ Points to Remember

- Every common parametric test has a non-parametric equivalent — memorise the pairing (t-test ↔ Mann-Whitney, paired t-test ↔ Wilcoxon, ANOVA ↔ Kruskal-Wallis).
- Fisher's Exact replaces Chi-square specifically when expected cell counts are small (<5).

5.12 Correlation & Regression

Definition

Correlation measures the strength and direction of a linear relationship between two continuous variables. Regression goes a step further, allowing prediction of the value of one variable based on the value of another.

Detailed Explanation

It is essential to remember that correlation only quantifies association — a strong correlation between two variables does not prove that one causes the other; a third (confounding) variable may be responsible for both, or the relationship may simply be coincidental.

Regression is directional: it produces an equation ($Y = a + bX$) that lets you predict/estimate an outcome (Y) from a predictor (X); correlation, in contrast, is symmetric and simply quantifies how strongly two variables move together, without implying which one predicts the other.

Key Points

- Pearson correlation — used when both variables are continuous and approximately normally distributed.
- Spearman's rank correlation — the non-parametric alternative, used for ordinal data or non-normally distributed continuous data (calculated on ranks rather than raw values).
- Correlation does not imply causation — always consider confounding and reverse causality before drawing a causal conclusion.

- Multiple linear regression extends simple regression to predict Y from several independent variables (X1, X2, X3...) simultaneously, while adjusting for their mutual effects.

Formula / Notes

Pearson's correlation coefficient (r): ranges from -1 to $+1$

$r = +1 \rightarrow$ perfect positive correlation; $r = -1 \rightarrow$ perfect negative correlation; $r = 0 \rightarrow$ no linear correlation

$|r|$ $0-0.3 =$ weak; $0.3-0.6 =$ moderate; $0.6-1.0 =$ strong (rough interpretive guide)

Simple linear regression equation: $Y = a + bX$ ($a =$ intercept, $b =$ slope/regression coefficient)

Coefficient of determination $= r^2$ (proportion of variability in Y explained by X)

When to Use

- Correlation — to assess whether/how strongly two variables move together (e.g., BMI and systolic BP).
- Simple/Multiple regression — to predict or estimate one variable's value from one or more others, or to statistically adjust for confounding variables.

Solved Example — Interpreting a correlation coefficient

A study finds $r = 0.85$ between BMI and systolic BP ($n=100$, $p<0.001$).

$r^2 = 0.85^2 = 0.72$, meaning about 72% of the variability in systolic BP is statistically explained by BMI in this sample.

Interpretation: There is a strong, statistically significant positive correlation between BMI and systolic BP — as BMI increases, systolic BP tends to increase.

Caution: This does NOT by itself prove BMI causes the BP rise — confounders like age, salt intake, or physical activity could contribute to both.

★ Points to Remember

- r ranges -1 to $+1$; sign shows direction, magnitude shows strength.
- r^2 tells you the proportion of variance in Y explained by X — more informative than r alone for judging practical importance.
- Correlation $\neq$ causation; use regression (ideally multiple regression) when prediction or confounder-adjustment is the goal.

5.13 Multivariate Analysis (Brief)

Definition

Statistical techniques that examine the simultaneous effect of two or more independent (predictor) variables on an outcome, while statistically adjusting for confounders — essential for most modern clinical research and thesis analyses.

Detailed Explanation

Simple/univariate analyses (like a single t-test or chi-square) look at one predictor and one outcome at a time and cannot account for confounding; multivariate analysis allows several predictors to be entered into a single model, producing an 'adjusted' effect estimate for each predictor after accounting for the others.

The choice of multivariate technique depends on the type of outcome variable — continuous, binary/categorical, or time-to-event — exactly parallel to how the choice of a simple bivariate test depends on data type.

Key Points

- Multiple linear regression — outcome is continuous (e.g., predicting haemoglobin level from age, diet score, and BMI together).
- Logistic regression — outcome is binary/categorical (e.g., disease present/absent); the model produces an Adjusted Odds Ratio (OR) with 95% CI for each predictor.
- Cox proportional hazards regression — used for time-to-event (survival) outcomes with multiple predictors; the model produces a Hazard Ratio (HR) with 95% CI for each predictor.
- Purpose in an MD/DM thesis: to control for known confounding variables and to identify independent predictors of an outcome that remain significant even after adjustment.

When to Use

- Logistic regression — binary outcome with multiple candidate predictors (extremely commonly used in MD/DM thesis analysis, e.g., predictors of ICU mortality).
- Cox regression — survival/time-to-event data (e.g., time to death or relapse) with multiple predictors to adjust for.

Example

A logistic regression model for in-hospital mortality reports Age (Adjusted OR 1.08, 95% CI 1.02–1.15) as an independent predictor, even after adjusting for comorbidities and severity score — meaning each additional year of age independently raises the odds of mortality by about 8%, holding the other variables constant.

★ Points to Remember

- Multivariate analysis adjusts for confounders simultaneously — essential whenever more than one predictor could plausibly affect the outcome.
- Match the technique to the outcome type: continuous → multiple linear regression; binary → logistic regression; time-to-event → Cox regression.

Practice Problems — Section B (Inferential Statistics)

1. A sample of 36 patients has Mean LDL = 150 mg/dL, SD = 24 mg/dL. Calculate the SE of the mean and the 95% CI.

Answer: $SE = SD/\sqrt{n} = 24/\sqrt{36} = 24/6 = 4.0$ mg/dL. $95\% \text{ CI} = 150 \pm (1.96 \times 4.0) = 150 \pm 7.84 = 142.2 \text{ to } 157.8$ mg/dL.

2. A researcher compares mean pain scores (0–10 scale, ordinal) between 2 independent treatment groups. The data are clearly skewed. Which test should be used, and why?

Answer: Mann-Whitney U test — the data are ordinal/skewed (not normally distributed continuous data), and the 2 groups are independent, so the non-parametric alternative to the unpaired t-test is appropriate rather than the t-test itself.

3. An RCT compares mean weight loss among 4 different diet plans (independent groups), with approximately normally distributed data. Which test is correct, and what should follow if the result is significant?

Answer: One-way ANOVA, since there are ≥ 3 independent groups with normally distributed continuous data. If the overall ANOVA is significant, a post-hoc test (e.g., Tukey's HSD or Bonferroni) should follow to identify which specific pairs of diet plans differ significantly.

4. A study finds a Pearson $r = -0.65$ between hours of daily exercise and BMI ($p < 0.001$, $n = 150$). Interpret this finding, including r^2 , and state one caution in interpretation.

Answer: $r = -0.65$ indicates a moderate-to-strong negative correlation — more exercise is associated with lower BMI. $r^2 = 0.42$, meaning about 42% of the variability in BMI is statistically explained by exercise hours. Caution: this is a correlation, not proof of causation — confounders (diet, genetics, socioeconomic status) could contribute to the observed association.

Amrita School of Medicine

Section C — Epidemiology-linked Biostatistics

5.14 Measures of Disease Frequency & Association

Definition

Measures used to quantify how often disease occurs in a population (frequency measures: incidence, prevalence) and how strongly an exposure is linked to a disease outcome (association measures: relative risk, odds ratio, attributable risk).

Detailed Explanation

Incidence and prevalence answer fundamentally different questions and are frequently confused: incidence tracks NEW cases arising over a period of time and reflects the risk/rate of developing disease, while prevalence is a snapshot of ALL existing cases (old + new) at a point or period in time and reflects the overall disease burden on the health system.

The relationship $\text{Prevalence} \approx \text{Incidence} \times \text{Average Duration of disease}$ explains why a disease with high incidence but very short duration (e.g., common cold, which resolves quickly or leads to death quickly) can have a deceptively low prevalence, while a disease with even modest incidence but long duration (e.g., diabetes) can have a high prevalence.

Key Points

- Incidence measures new/fresh cases — the correct measure for studying disease causation and risk.
- Prevalence measures existing cases (new + old) — the correct measure for assessing disease burden and planning health services.
- $RR = 1 \rightarrow$ no association between exposure and disease; $RR > 1 \rightarrow$ exposure increases risk; $RR < 1 \rightarrow$ exposure is protective.
- OR approximates RR reasonably well when the disease being studied is rare (the 'rare disease assumption'), which is usually the case in case-control studies of uncommon conditions.
- Attributable Risk quantifies the excess disease occurrence in the exposed group that can be directly attributed to the exposure itself — useful for public-health impact estimation.

Formula / Notes

Incidence = New cases occurring in a period / Population at risk (over that period)
Prevalence = All existing cases at a point in time / Total population at that time
Relative Risk (RR) = Incidence in exposed group / Incidence in unexposed group (used in cohort studies)
Odds Ratio (OR) = $(a \times d) / (b \times c)$ from a standard 2×2 table (used in case-control studies)
Attributable Risk (AR) = Incidence in exposed – Incidence in unexposed

When to Use

- RR — calculated directly in cohort/prospective studies, where the population at risk in each exposure group is known from the outset.
- OR — used in case-control/retrospective studies, where subjects are selected based on disease status and the true population at risk is not known.

Solved Example — Calculating RR and OR

Cohort study: Among 500 smokers, 40 develop CHD (Incidence = $40/500 = 0.08$). Among 500 non-smokers, 10 develop CHD (Incidence = $10/500 = 0.02$).

$RR = 0.08 / 0.02 = 4.0$ — smokers have 4 times the risk of developing CHD compared to non-smokers.

Case-control study (same scenario, retrospective): 40 CHD cases include 30 smokers (a) and 10 non-

smokers (c); 100 controls include 25 smokers (b) and 75 non-smokers (d).

$OR = (a \times d) / (b \times c) = (30 \times 75) / (25 \times 10) = 2250 / 250 = 9.0$ — the odds of having been a smoker are 9 times higher among CHD cases than controls.

★ Points to Remember

→ Incidence = new cases (risk); Prevalence = all existing cases (burden). $Prevalence \approx Incidence \times Duration$.

→ RR is the direct measure of risk from a cohort study; OR is the case-control equivalent, approximating RR when disease is rare.

5.15 Diagnostic Test Evaluation

Definition

Statistical parameters used to assess the accuracy and clinical usefulness of a diagnostic test, compared against a gold-standard reference test, using a 2×2 table of test result vs true disease status.

Detailed Explanation

A crucial distinction in this topic is between sensitivity/specificity (fixed, inherent properties of the test itself, unaffected by how common the disease is) and predictive values (which DO change depending on the prevalence of disease in the population being tested) — this is one of the most frequently tested concepts in biostatistics vivas.

Two mnemonics are widely used and worth memorising: SnNout (a highly SeNsitive test, when Negative, helps rule OUT disease) and SpPin (a highly SPecific test, when Positive, helps rule IN disease).

Key Points

- Sensitivity and specificity are inherent properties of the test itself — they do NOT change with the prevalence of disease in the tested population.
- PPV and NPV DO change with disease prevalence: as prevalence rises, PPV increases and NPV decreases (and vice versa), even using the exact same test with fixed sensitivity/specificity.
- SnNout: a highly SENSitive test, when its result is Negative, is good for ruling OUT disease (few false negatives).
- SpPin: a highly SPecific test, when its result is Positive, is good for ruling IN/confirming disease (few false positives).
- ROC (Receiver Operating Characteristic) curve: plots Sensitivity (Y-axis) against 1-Specificity (X-axis) across all possible test cut-off values; the Area Under the Curve (AUC) summarises overall test performance — AUC of 1.0 is perfect, 0.5 is no better than chance.

Formula / Notes

Sensitivity = $a / (a+c)$ — proportion of truly diseased people correctly identified as positive by the test

Specificity = $d / (b+d)$ — proportion of truly non-diseased people correctly identified as negative by the test

Positive Predictive Value (PPV) = $a / (a+b)$ — proportion of test-positives who actually have the disease

Negative Predictive Value (NPV) = $d / (c+d)$ — proportion of test-negatives who are actually disease-free

(a=true positive, b=false positive, c=false negative, d=true negative)

When to Use

- Prioritise sensitivity for a screening test (avoid missing true cases — minimise false negatives).
- Prioritise specificity for a confirmatory test (avoid unnecessary treatment of healthy people — minimise false positives).

Solved Example — Calculating Sensitivity, Specificity, PPV, NPV

A new screening test is evaluated against biopsy (gold standard) in 200 patients: True positives (a)=45, False positives (b)=15, False negatives (c)=5, True negatives (d)=135.

Sensitivity = $a/(a+c) = 45/50 = 0.90 = 90\%$.

Specificity = $d/(b+d) = 135/150 = 0.90 = 90\%$.

PPV = $a/(a+b) = 45/60 = 0.75 = 75\%$.

NPV = $d/(c+d) = 135/140 = 0.964 = 96.4\%$.

Interpretation: The test correctly identifies 90% of true cases and 90% of true non-cases; among those testing positive, 75% actually have disease; among those testing negative, 96.4% are truly disease-free.

★ Points to Remember

- Sensitivity/Specificity are test properties, fixed regardless of prevalence; PPV/NPV depend on prevalence.
- SnNout (sensitive-negative-rules out) and SpPin (specific-positive-rules in) are the standard memory aids.
- AUC on an ROC curve summarises overall diagnostic accuracy — closer to 1.0 is better; 0.5 means no discrimination.

5.16 Screening & Bias

Definition

Screening is the presumptive identification of unrecognised disease in apparently healthy individuals, using a test that can be applied rapidly on a large scale. Bias is any systematic (non-random) error in the design, conduct, or analysis of a study that distorts the true association between exposure and outcome.

Detailed Explanation

The WHO/Wilson-Jungner criteria for a good screening programme require that the condition be an important health problem, have a recognisable early/latent stage, have an accurate and acceptable test available, and have an effective treatment available for those detected early — screening for a condition with no available treatment is generally not justified.

Bias, once introduced during study design or data collection, generally CANNOT be corrected by statistical adjustment during analysis — unlike confounding, which can often be adjusted for using stratification or multivariate analysis. This distinction is a frequent examiner question.

Key Points

- Lead-time bias: earlier diagnosis through screening appears to prolong survival time from diagnosis to death, even though the actual date of death (and disease course) is unchanged — survival looks longer only because the clock started earlier.
- Length-time bias: screening programmes preferentially detect slow-growing, less aggressive disease (which stays in a detectable pre-clinical phase longer), giving a falsely favourable impression of screening's effect on survival.

- Selection bias: a systematic difference between those who are selected/enrolled into a study and those who are not (e.g., 'healthy worker effect' — employed people tend to be healthier than the general population).
- Recall bias: differential accuracy or completeness of memory between cases and controls when reporting past exposures — particularly relevant in retrospective/case-control studies, since cases often recall past exposures more vividly than controls.
- Observer/measurement bias: systematic error introduced by the person measuring or recording data (reduced by blinding).
- Confounding: distortion of the true exposure-outcome association caused by a third variable that is independently associated with BOTH the exposure and the outcome (classic example: age confounds the relationship between grey hair and heart disease risk — age causes both).

When to Use

- Always name the specific type of bias when critiquing a study design in a viva or journal club, and explicitly link it to the study's specific design flaw — vague answers like 'there could be bias' score poorly.

Example

A case-control study relying on patients recalling their diet from 10 years ago is vulnerable to recall bias, since cases (who have since developed the disease) may recall/report their past diet differently than healthy controls.

★ Points to Remember

- Lead-time and length-time bias both create a false impression that screening improves survival.
- Bias is a design/conduct flaw and generally cannot be statistically corrected after the fact; confounding, in contrast, often can be adjusted for in analysis.
- Always match the bias name precisely to the specific flaw in the study being discussed.

5.17 Survival Analysis

Definition

A set of statistical methods used to analyse the expected time until a defined event of interest occurs (e.g., death, relapse, recovery), which specifically accounts for 'censored' subjects — those lost to follow-up or for whom the event has not yet occurred by the end of the study.

Detailed Explanation

Survival analysis is uniquely suited to time-to-event data because simple methods (like comparing mean survival time using a t-test) would discard all the partial information contributed by censored subjects; survival methods use every subject's contribution up to their last known time point, whether or not the event ultimately occurred for them.

The Kaplan-Meier method and the log-rank test are almost always used together in an MD/DM thesis: the Kaplan-Meier curve visually displays the survival experience of each group over time, and the log-rank test provides the formal p-value for whether the curves differ significantly.

Key Points

- Kaplan-Meier survival curve: a step-function graph estimating the probability of 'surviving' (remaining event-free) at each successive time point; commonly plotted to compare survival between two or more groups (e.g., treatment vs control).
- Log-rank test: the statistical test used to formally compare two or more Kaplan-Meier survival curves and derive a p-value for whether the survival experience differs significantly between groups.

- Life table method: an alternative approach used for large datasets, which groups survival time into fixed intervals (e.g., yearly) and calculates the probability of surviving each interval.
- Censoring: occurs when the event of interest has not occurred by the end of the study period, or a subject is lost to follow-up before the event occurs or the study ends — such subjects still contribute valid information up to their last observed time point and are not simply discarded.
- Cox proportional hazards regression: used when multiple predictors need to be analysed together while modelling survival/time-to-event outcomes; produces a Hazard Ratio (HR) for each predictor, analogous to how logistic regression produces an OR.

When to Use

- Kaplan-Meier + Log-rank test — comparing survival between two (or more) treatment groups in a thesis or clinical trial with time-to-event data, using a single predictor (group).
- Cox regression — when multiple covariates (e.g., age, stage, treatment) need to be adjusted for simultaneously while analysing survival.

Solved Example — Reading a Kaplan-Meier result

A thesis compares 2-year relapse-free survival between Regimen A (n=50) and Regimen B (n=50) using Kaplan-Meier curves.

Median relapse-free survival: Regimen A = 18 months; Regimen B = 12 months.

Log-rank test comparing the two curves: $\chi^2 = 6.2$, $p = 0.013$.

Interpretation: Since $p < 0.05$, Regimen A shows a statistically significantly longer relapse-free survival compared to Regimen B in this sample.

★ Points to Remember

- Survival analysis correctly incorporates censored subjects rather than discarding them.
- Kaplan-Meier displays the curve; log-rank test gives the p-value comparing curves; Cox regression adjusts for multiple predictors simultaneously.

Practice Problems — Section C (Epidemiology-linked Biostatistics)

1. In a cohort of 1000 exposed and 1000 unexposed workers, 50 exposed and 20 unexposed workers develop occupational asthma over 5 years. Calculate the incidence in each group and the RR.

Answer: Incidence (exposed) = $50/1000 = 0.05$ (5%). Incidence (unexposed) = $20/1000 = 0.02$ (2%). $RR = 0.05/0.02 = 2.5$ — exposed workers have 2.5 times the risk of developing occupational asthma compared to unexposed workers.

2. A new rapid test for a disease has Sensitivity=95%, Specificity=80%. In a low-prevalence screening population, would you expect the PPV to be high or low? Why?

Answer: PPV would be expected to be relatively LOW in a low-prevalence population, even with high sensitivity/specificity — because with few true cases in the population, the (comparatively larger) pool of false positives from the many true-negatives (20% of whom test falsely positive) proportionally outweighs the true positives, pulling PPV down. This illustrates why PPV depends heavily on prevalence.

3. A screening programme for a slow-growing cancer reports much better 5-year survival among screen-detected cases compared to symptom-detected cases. Name two biases that could explain this apparent benefit even if screening has no true effect on mortality.

Answer: Lead-time bias (earlier diagnosis simply starts the survival clock earlier, without changing the actual date of death) and Length-time bias (screening preferentially detects slower-growing, less aggressive tumours, which have inherently better prognosis).

4. A trial follows 80 patients after cardiac surgery for 5-year mortality; 15 patients are lost to follow-up before 5 years and are alive at last contact. How should these 15 patients be handled in a Kaplan-Meier analysis?

Answer: They should be treated as censored observations — included in the analysis and contributing survival time up to their last known follow-up point, rather than being excluded from the analysis altogether.

Amrita School of Medicine

Section D — Research Methodology & Thesis Application

5.18 Study Designs

Definition

The overall structural plan used to investigate a research question — broadly classified as Observational (the researcher only observes, without intervening) or Experimental/Interventional (the researcher actively assigns an intervention).

Detailed Explanation

Choosing the correct study design at the protocol stage is arguably the single most consequential decision in an MD/DM thesis, because it determines which measures of association can be calculated (e.g., a case-control study can never directly yield incidence or RR), and it determines the position of the study on the hierarchy of evidence.

Observational designs are further split into descriptive (which simply describe patterns of disease, without a comparison group — hypothesis-generating) and analytical (which include a comparison group and formally test a hypothesis).

Key Points

- Observational — Descriptive: Case report (single patient), Case series (small group of similar patients), Cross-sectional/prevalence study (a single point-in-time snapshot of a population).
- Observational — Analytical: Case-control (retrospective — starts with the outcome/disease and looks backward for exposure), Cohort (prospective or retrospective — starts with exposure status and follows forward for outcome).
- Experimental/Interventional: Randomised Controlled Trial (RCT) — the gold-standard design for testing the efficacy of an intervention, since randomisation balances both known and unknown confounders between groups.
- Hierarchy of evidence (lowest to highest strength): Case report/series < Cross-sectional study < Case-control study < Cohort study < RCT < Systematic review/Meta-analysis of RCTs.

Study Design Quick Comparison

Design	Direction	Best For	Key Limitation
Cross-sectional	Single time-point	Prevalence estimation	Cannot establish causation/sequence
Case-control	Outcome → Exposure (backward)	Rare diseases	Recall bias; cannot calculate incidence directly
Cohort	Exposure → Outcome (forward)	Rare exposures; multiple outcomes	Time-consuming, expensive, loss to follow-up
RCT	Intervention → Outcome	Testing treatment efficacy	Cost, ethics, generalisability

When to Use

- Cross-sectional — quick, inexpensive estimate of disease prevalence; cannot determine which came first, exposure or disease.
- Case-control — best for rare diseases and conditions with a long latent period; inherently retrospective.
- Cohort — best for rare exposures and when multiple outcomes of a single exposure need to be studied; can calculate incidence and RR directly.

- RCT — the design of choice to establish causation/efficacy of a treatment, since randomisation minimises confounding and bias by design.

★ Points to Remember

- Match study design to the research question: rare disease → case-control; rare exposure → cohort; testing treatment efficacy → RCT.
- Only cohort studies and RCTs can directly calculate incidence; case-control studies cannot.
- RCT sits at (near) the top of the evidence hierarchy specifically because randomisation controls confounding by design, not merely by statistical adjustment.

5.19 Sample Size Calculation

Definition

The pre-specified process of determining the minimum number of subjects required in a study to detect a clinically meaningful effect with adequate statistical power, while using resources efficiently and avoiding an unnecessarily large (or too small) study.

Detailed Explanation

Sample size calculation must always be done a priori (before data collection begins), using the best available estimates of variability/proportion from pilot data or previously published studies — calculating it after the fact ('post-hoc power') to justify a non-significant result is considered poor practice and is a common examiner trap question.

Every sample size formula essentially balances four elements: the significance level (α), the desired power ($1-\beta$), the expected variability of the outcome (SD or proportion), and the smallest effect size considered clinically important to detect — changing any one of these changes the required sample size.

Key Points

- A larger sample size is required when: the effect size to be detected is smaller, higher power is desired, or greater precision (a narrower CI) is required.
- A smaller sample size is sufficient when: the expected effect size is large, or lower power/precision is acceptable (though power below 80% is rarely acceptable for a thesis).
- For any comparative study, always state the source of the assumed values (e.g., 'proportion of 25% based on a previous study by X et al.') in the protocol.
- Commonly used software/tools: G*Power, OpenEpi, nMaster, or standard published nomograms/tables for common scenarios.

Formula / Notes

Comparing two means: n (per group) = $2\sigma^2(Z\alpha/2 + Z\beta)^2 / d^2$, where d = clinically meaningful difference between means, σ = SD

Estimating a single proportion: $n = Z^2 \times p(1-p) / d^2$, where p = expected proportion, d = desired precision (margin of error)

Commonly used Z values: $Z\alpha/2 = 1.96$ (for $\alpha=0.05$, two-tailed); $Z\beta = 0.84$ (for 80% power) or 1.28 (for 90% power)

When to Use

- The sample size formula, all assumed input values, and their literature source must be stated explicitly in the Methodology section of every thesis protocol — this is a mandatory Ethics Committee and university requirement.

Solved Example — Sample size for comparing two proportions

A trial expects response rate of 60% (0.60) with a new drug vs 40% (0.40) with standard treatment; $\alpha=0.05$ (two-tailed), power=80%.

Using a standard two-proportion sample size formula/table for these inputs ($p_1=0.60$, $p_2=0.40$, $\alpha=0.05$, power=80%), the calculated requirement is approximately $n \approx 96$ per group.

Accounting for an anticipated 10% dropout/loss to follow-up: Adjusted $n = 96 / (1-0.10) \approx 107$ per group.

Total sample size to be enrolled across both groups ≈ 214 subjects.

★ Points to Remember

- Sample size must be calculated a priori and justified with cited literature values, never derived after seeing the results.
- Always inflate the calculated sample size to account for expected dropout/loss to follow-up.
- Smaller detectable effect size or higher desired power both increase the required sample size.

5.20 Randomization & Blinding

Definition

Randomisation is the process of allocating study subjects to different groups purely by chance, to ensure the groups are comparable at baseline. Blinding (masking) conceals the group allocation from one or more parties involved in the study, to reduce bias in treatment administration, outcome assessment, or reporting.

Detailed Explanation

Randomisation and allocation concealment are related but distinct concepts that are frequently confused in vivas: randomisation is the method used to assign subjects to groups by chance, while allocation concealment specifically ensures that the person enrolling participants cannot predict or influence which group the next participant will be assigned to — concealment protects the integrity of randomisation itself at the point of enrolment.

The number of parties blinded (single/double/triple) should be maximised as far as ethically and practically feasible, since each additional blinded party removes one further potential source of bias from the trial.

Key Points

- Simple randomisation: pure chance allocation (e.g., coin toss, computer-generated random numbers) for every subject.
- Block randomisation: subjects are randomised in small blocks (e.g., blocks of 4 or 6) to ensure that group sizes remain balanced throughout the enrolment period, which is important in trials with interim analyses.
- Stratified randomisation: randomisation is performed separately within strata of a known important confounder (e.g., age group, disease severity), ensuring balance of that confounder across study groups.
- Cluster randomisation: entire clusters/groups of subjects (e.g., hospitals, villages) are randomised together, rather than individuals — used when individual-level randomisation is impractical or would cause contamination between groups.
- Allocation concealment: a separate safeguard from blinding, ensuring the enroller cannot foresee or manipulate upcoming group assignments (e.g., using sequentially numbered, opaque, sealed envelopes, or a centralised randomisation service).

- Single blind: only the participant is unaware of their group allocation.
- Double blind: both the participant and the investigator/outcome assessor are unaware of group allocation.
- Triple blind: participant, investigator/assessor, AND the data analyst/statistician are all unaware of group allocation until after the primary analysis is complete.

When to Use

- Block randomisation — smaller trials, where balanced group sizes need to be maintained throughout the enrolment period.
- Stratified randomisation — when a specific baseline variable (e.g., disease stage) is known to strongly influence outcome and must be balanced between groups.
- Double blinding — the standard approach for drug trials, to simultaneously eliminate participant-side (placebo effect) and assessor-side (observer/detection) bias.

★ Points to Remember

→ Randomisation = method of chance-based group assignment; Allocation concealment = preventing foreknowledge of the next assignment; Blinding = concealing the assignment after allocation — all three are distinct safeguards.

→ Blind as many parties as ethically/practically possible: participant, assessor, and analyst, in that order of priority.

5.21 Writing the Statistical Methods Section of a Protocol/Thesis

Definition

A structured, prospective description of the exact statistical plan to be used in a research protocol or thesis, written and finalised BEFORE data collection and analysis begin.

Detailed Explanation

A well-written statistical methods section should allow another researcher to exactly replicate the planned analysis without needing to see the actual data first — vague language ('appropriate statistical tests will be applied as necessary') is a very commonly criticised weakness in thesis protocols submitted for Ethics Committee or University approval.

Ideally, each specific objective of the thesis should be mapped to exactly one primary statistical test in this section, making the logical connection between hypothesis, data type, and chosen test completely explicit and defensible at viva.

Key Points

- State the overall study design, the sample size with its full justification/formula and assumed input values (with literature source), and the sampling technique used.
- List all variables (dependent/outcome and independent/predictor) along with their type/scale of measurement (nominal/ordinal/interval/ratio).
- Specify which descriptive statistics will be used for each variable (Mean±SD for normally distributed continuous data; Median with IQR for skewed continuous data; frequency and percentage for categorical data).
- Name the exact inferential statistical test planned for each specific objective/hypothesis, with the justification for that choice based on data type and expected distribution.
- State the statistical software to be used (e.g., SPSS version, R) and the pre-specified level of statistical significance (conventionally $p < 0.05$).
- Describe in advance how missing data, protocol deviations, and subjects lost to follow-up will be handled in the analysis (e.g., intention-to-treat vs per-protocol analysis).

When to Use

- Draft this section objective-by-objective: for each specific aim of the thesis, write out the corresponding data type, the planned descriptive summary, and the planned inferential test — this one-to-one mapping is what Ethics Committees and thesis guides specifically look for.

★ Points to Remember

- The statistical plan must be prospective (written before data collection) — this is both good scientific practice and an Ethics Committee requirement.
- Every objective should map to one clearly justified, named statistical test — avoid vague, generic statements.

5.22 Choosing the Right Statistical Test

Definition

A step-by-step decision framework for selecting the correct statistical test, based sequentially on: (1) the type/scale of the outcome data, (2) whether the data are approximately normally distributed, (3) the number of groups being compared, and (4) whether the compared groups/measurements are paired/related or independent.

Detailed Explanation

This four-step logical sequence — data type, then normality, then number of groups, then paired-vs-independent — is the single most heavily tested reasoning pattern across MD/DM biostatistics vivas and exams, because it is exactly the sequence a researcher must follow when planning the analysis for their own thesis data.

When in doubt between two tests, the safer academic default is usually the non-parametric option, since non-parametric tests make fewer assumptions about the data — however, this comes at some cost in statistical power if the parametric assumptions were actually valid.

Test Selection Decision Chart

Comparison	Data Normal?	Correct Test
2 independent groups, continuous	Yes	Unpaired (independent) t-test
2 independent groups, continuous	No	Mann-Whitney U test
2 paired/related measurements, continuous	Yes	Paired t-test
2 paired/related measurements, continuous	No	Wilcoxon signed-rank test
≥3 independent groups, continuous	Yes	One-way ANOVA
≥3 independent groups, continuous	No	Kruskal-Wallis test
2 categorical variables	—	Chi-square (or Fisher's Exact if small n)
Relationship, 2 continuous variables	Yes / No	Pearson / Spearman correlation
Outcome predicted by multiple variables	—	Multiple / Logistic / Cox regression

When to Use

- Step 1: Is the outcome variable categorical or continuous?
- Step 2 (if continuous): Is the data normally distributed (Shapiro-Wilk/Kolmogorov-Smirnov test, or histogram/Q-Q plot)?
- Step 3: How many groups/time-points are being compared — 2, or ≥ 3 ?
- Step 4: Are the groups/measurements independent (different subjects) or paired/related (same subjects, repeated)?
- Follow these four steps, in this exact order, to arrive at the correct test.

Solved Example — Applying the decision chart

Scenario: Compare haemoglobin levels before and after iron therapy, in the same 30 patients.

Step 1: Outcome (Hb) is continuous.

Step 2: Shapiro-Wilk test shows Hb data are approximately normally distributed.

Step 3: 2 measurements/time-points are being compared.

Step 4: Same 30 patients measured twice — this is a paired/related comparison.

Conclusion: The correct test is the Paired t-test.

★ Points to Remember

→ Always follow the sequence: data type → normality → number of groups → paired or independent → select test.

→ This decision chart should be applied explicitly (and stated out loud) when justifying your chosen test in a viva.

5.23 Common Statistical Software — Basics

Definition

An overview of the statistical software commonly used by MD/DM scholars in India for analysing thesis/research data, and how to correctly read and report their output.

Detailed Explanation

Being able to correctly interpret a standard SPSS or R output table — identifying the test statistic, degrees of freedom, and p-value, and mapping them back to the specific hypothesis being tested — is a frequently examined practical skill, distinct from simply knowing which test to run.

Regardless of the software used, results should always be reported in a standard, consistent format: the descriptive summary (Mean $\pm$ SD or Median [IQR] or n(%)), the test statistic with its degrees of freedom, and the exact p-value (or 95% CI where applicable).

Key Points

- SPSS (Statistical Package for Social Sciences): the most widely used software in Indian medical colleges — menu-driven, does not require coding, and generates output tables directly usable in a thesis.
- R: a free, open-source statistical programming language — highly flexible and powerful, widely used in advanced academic research, meta-analyses, and increasingly taught alongside SPSS.
- Epi Info / OpenEpi: free tools commonly used specifically for epidemiological calculations — sample size estimation, and quick 2 $\times$ 2 table analysis (RR, OR, Chi-square, Fisher's Exact).
- Typical elements to interpret in output: the test statistic value (t, F, or χ^2), degrees of freedom (df), the exact p-value, and — for regression/association measures — the effect estimate (mean difference, OR, RR, or HR) with its 95% CI.

- Reporting convention: report the exact p-value wherever possible (e.g., $p=0.032$) rather than only stating ' $p<0.05$ '; for very small p-values, report as $p<0.001$ rather than an unnecessarily precise figure.

When to Use

- Practice reading and correctly interpreting an SPSS/R output table for each test used in your own thesis before the viva — examiners very commonly present an output table and ask for its interpretation directly.

★ Points to Remember

- SPSS is the most common choice for MD/DM theses in India; R is preferred for advanced/flexible analyses.
- Always report the exact p-value (or $p<0.001$ for very small values) together with the relevant effect estimate and its 95% CI.

5.24 Reading & Critiquing Published Statistics

Definition

The structured skill of critically evaluating the statistical methods and results reported in a published research paper — a core competency assessed in journal clubs and thesis viva examinations.

Detailed Explanation

A systematic critique should always move through the same checklist in order — study design appropriateness, sample size justification, correctness of the statistical test used, and completeness/honesty of results reporting — rather than jumping straight to whether the result was 'significant', since a significant result from a flawed design is not trustworthy.

One of the most important distinctions to apply during critique is statistical significance versus clinical significance: with a sufficiently large sample size, even a tiny, clinically trivial difference can become statistically significant ($p<0.05$) — the actual effect size and its 95% CI, not the p-value alone, should be used to judge real-world importance.

Key Points

- Was the sample size calculated and justified a priori, with a clearly stated formula and literature-based assumptions?
- Was the study design appropriate for the stated research objective (e.g., not using a cross-sectional design to claim causation)?
- Was the correct statistical test used, matching the data type, distribution, and number/relatedness of groups?
- Are results reported with BOTH a p-value AND an effect size/95% CI (not p-value alone) — a p-value alone does not convey the magnitude or clinical importance of an effect.
- Was appropriate adjustment made for confounding variables (via multivariate analysis) where relevant to the research question?
- Were dropouts/losses to follow-up reported and accounted for in the analysis?

When to Use

- Apply this checklist systematically, in this order, whenever critiquing any paper presented in a journal club — examiners specifically look for this structured approach rather than isolated, unconnected comments.

Example

A drug trial with $n=5000$ reports a statistically significant ($p=0.001$) reduction in LDL of 2 mg/dL — while statistically significant due to the very large sample size, a 2 mg/dL reduction is of doubtful clinical importance; the 95% CI around this small effect should be examined before drawing a clinical conclusion.

★ **Points to Remember**

- Critique study design and sample size justification before looking at the results themselves.
- A result can be statistically significant without being clinically meaningful, especially in very large studies — always weigh the effect size and CI, not the p-value alone.

5.25 Common Errors in Medical Statistics

Definition

A list of frequently encountered pitfalls in the design, analysis, or interpretation of medical research — commonly probed in MD/DM thesis viva examinations as a test of genuine statistical understanding rather than rote memorisation.

Detailed Explanation

Most of these errors are not calculation mistakes but reasoning/interpretation mistakes — applying the wrong test for the data type, or drawing an unjustified conclusion from a correctly-calculated result — which is exactly why understanding the underlying logic (not just formulas) is essential for both the thesis and the viva.

Reviewing this list critically against your own thesis methodology before the viva is one of the most effective ways to anticipate and prepare for an examiner's questions about the limitations of your work.

Key Points

- Using a parametric test (t-test/ANOVA) on clearly non-normal or ordinal data, without first formally checking the distribution.
- Performing multiple separate t-tests instead of a single ANOVA when comparing ≥ 3 groups, inflating the overall Type I (false positive) error rate.
- Confusing SD with SE, or inconsistently reporting Mean $\pm$ SD for data that is actually skewed (where Median [IQR] would be correct).
- Misinterpreting a non-significant result ($p>0.05$) as definitive proof of 'no difference exists' — correctly, it only means 'no statistically significant difference was detected', which may simply reflect an underpowered (too small) study rather than a true absence of effect.
- Assuming that correlation implies causation, without considering confounding, reverse causality, or chance.
- Failing to adjust for known confounding variables using multivariate/regression analysis when they are clearly relevant to the research question.
- Post-hoc changing of the hypothesis or statistical test after having already seen the data ('data dredging' or 'p-hacking'), which inflates the risk of spurious/false-positive findings.
- Reporting only p-values without accompanying effect sizes or 95% confidence intervals, obscuring the clinical importance of a finding.

When to Use

- Systematically check your own thesis methodology chapter against this list before your viva — examiners very frequently frame questions around exactly these pitfalls.

★ **Points to Remember**

- ' $p>0.05$ ' means 'no significant difference detected' — NOT proof that no true difference exists; consider

whether the study was adequately powered.

→ P-hacking (testing repeatedly until a significant result appears) is a serious methodological error that inflates false-positive findings and must be avoided by pre-specifying the analysis plan.

Practice Problems — Section D (Research Methodology & Thesis Application)

1. You are planning a case-control study on a rare congenital anomaly (population prevalence <1 per 10,000). Justify your choice of study design over a cohort study.

Answer: A cohort study would require an impractically large sample size and long follow-up to observe a meaningful number of cases of such a rare condition. A case-control design, starting from existing cases and tracing back exposures, is far more efficient for studying rare diseases/outcomes.

2. A pilot study shows a control group event rate of 30%. You want to detect a reduction to 15% with the new intervention, at $\alpha=0.05$ (two-tailed) and 80% power. What kind of sample size formula would you use, and what additional adjustment should be made before finalising the number to enroll?

Answer: A two-proportion (comparison of two independent proportions) sample size formula/software (e.g., OpenEpi, G*Power) would be used with $p_1=0.30$, $p_2=0.15$, $\alpha=0.05$, power=80%. The calculated per-group sample size should then be inflated to account for an anticipated dropout/loss-to-follow-up rate (e.g., 10–15%) before finalising enrollment numbers.

3. In a multi-arm drug trial, the statistician is kept unaware of group allocation until after the primary analysis is locked. What level of blinding does this represent, and why is it valuable?

Answer: This represents triple blinding (participant + investigator/assessor + statistician). It further protects against analytic bias — preventing the analyst from consciously or unconsciously favouring an analytical approach that produces a more 'favourable' result for a particular arm.

4. A published paper reports $p=0.04$ for a difference in mean birth weight between two groups, with no confidence interval or actual mean difference stated. What is the key limitation of this reporting, and what should have been included?

Answer: The key limitation is that a p-value alone does not indicate the size or clinical importance of the difference — the actual mean difference in birth weight (e.g., in grams) and its 95% CI should have been reported alongside the p-value, so readers can judge whether the difference is clinically meaningful, not merely statistically significant.

Appendix I — Quick Formula Reference

Concept	Formula
Mean	$\bar{y} = \Sigma x / n$
Variance (sample)	$s^2 = \Sigma(x - \bar{y})^2 / (n-1)$
Standard Deviation	$SD = \sqrt{\text{Variance}}$
Coefficient of Variation	$CV (\%) = (SD/\text{Mean}) \times 100$
Standard Error of Mean	$SE = SD / \sqrt{n}$
95% Confidence Interval	$\text{Mean} \pm (1.96 \times SE)$
Z-score	$Z = (x - \mu) / \sigma$
Chi-square	$\chi^2 = \Sigma[(O-E)^2 / E]$
Pearson's r range	-1 to +1
Simple linear regression	$Y = a + bX$
Incidence	New cases / Population at risk (per period)
Prevalence	Existing cases / Total population (at a time point)
Relative Risk (RR)	Incidence exposed / Incidence unexposed
Odds Ratio (OR)	$(a \times d) / (b \times c)$
Attributable Risk	Incidence exposed - Incidence unexposed
Sensitivity	$a / (a+c)$
Specificity	$d / (b+d)$
PPV	$a / (a+b)$
NPV	$d / (c+d)$
Sample size (2 means)	$n = 2\sigma^2(Z\alpha/2 + Z\beta)^2 / d^2$
Sample size (1 proportion)	$n = Z^2 \times p(1-p) / d^2$

Appendix II — Glossary of Key Terms

Term	Definition
Population	The entire group of individuals about whom conclusions are to be drawn.
Sample	A subset of the population that is actually studied.
Parameter	A numerical value describing a population characteristic (usually unknown).
Statistic	A numerical value calculated from sample data, used to estimate a parameter.
Variable	Any characteristic that can differ between individuals.
Null hypothesis (H_0)	The default assumption of no difference/association/effect.
Alternative hypothesis (H_1)	The hypothesis that a difference/association/effect exists.
Type I error (α)	Rejecting a true null hypothesis (false positive).
Type II error (β)	Failing to reject a false null hypothesis (false negative).
Power ($1-\beta$)	Probability of correctly detecting a true effect.
p-value	Probability of observing a result as extreme as this, assuming H_0 is true.
Confidence Interval	Range likely to contain the true population parameter.
Confounding	Distortion of an exposure-outcome association by a third variable.
Bias	Systematic (non-random) error in study design or conduct.
Sensitivity	Proportion of true cases correctly identified by a test.
Specificity	Proportion of true non-cases correctly identified by a test.
Incidence	Rate of new cases of disease over a period.
Prevalence	Proportion of existing cases at a point/period in time.
Randomisation	Chance-based allocation of subjects to study groups.
Blinding	Concealing group allocation to reduce bias.
Censoring	When the event of interest has not occurred/is unknown by study end.
Cohort study	Study starting from exposure, following forward for outcome.
Case-control study	Study starting from outcome, tracing backward for exposure.
Skewness	Asymmetry of a distribution (positive/right or negative/left).

Important Questions — Biostatistics

Frequently asked long-answer, short-note and viva questions for the MD/MS examination

1

LONG ANSWER

Describe the measures of central tendency and dispersion. When would you prefer the median to the mean?

Key points: Mean, median, mode • range, IQR, SD, variance, coefficient of variation • skewed data and outliers → median and IQR

2

SHORT NOTE

List the properties of the normal distribution. Differentiate standard deviation from standard error.

Key points: Symmetric, mean = median = mode • 68–95–99.7 rule • SD describes spread of data; SE describes precision of the mean

3

LONG ANSWER

Explain hypothesis testing. Define p value, type I and type II errors and power.

Key points: Null and alternative hypotheses • α and β • power = $1 - \beta$ • p value interpretation • confidence intervals

4

SHORT NOTE

How do you choose an appropriate statistical test? Compare parametric and non-parametric tests with examples.

Key points: Type of variable, number of groups, pairing, distribution • t-test / ANOVA vs Mann-Whitney / Kruskal-Wallis • chi-square for proportions

5

SHORT NOTE

Define sensitivity, specificity, positive and negative predictive values. How does prevalence affect them?

Key points: 2×2 table • predictive values change with prevalence; sensitivity and specificity do not • likelihood ratios

6

VIVA

What is the difference between correlation and regression? What is a Kaplan-Meier curve?

Key points: Strength of association vs prediction • Pearson vs Spearman • survival probability over time with censoring • log-rank test

Tip: answer long questions with a labelled flow chart or table — examiners reward structure.

INDEX

MD/MS Mandatory Essentials — page numbers refer to the printed page numbers of this edition.

A

ACLS Resuscitation Drug Chart, 24
ACLS Systematic Approach, 13
ACLS — Key Changes, 68
Adenosine, 24, 26, 37–38, 64–65
Adverse Event, 83–87, 93, 110, 150–151
Airway Management in ACLS, 42
Amiodarone, 23–27, 30–31, 37–38, 65, 68
ANOVA, 163, 165, 170–172, 175, 186, 189
Appendix A — Glossary of Key GCLP Terms, 120
Appendix B — Key Annexures Referenced in ICMR GCLP Guidelines, 121
Appendix C — Quick-Revision Summary, 122
Appendix D — Examination Preparation Tips, 123
Appendix E — Model Answer Framework, 124
Atropine, 24–27, 33–34, 64–65
Audit, Laboratory/GCP, 74, 85, 89, 92, 94, 99–101, 104, 107, 111, 113, 115, 118–119, 150
Automated External Defibrillator (AED), 9–10, 12–13, 60
AVPU, 15

B

Basic Life Support (BLS) — Key Changes, 68
Belmont Report, 71–74, 148
Beyond Drug Trials — Device, Diagnostic, and Public Health Research, 144
Bias, 73, 93, 103, 107, 112, 126–129, 135–139, 144–147, 151–152, 154–155, 158, 165–166, 178–179, 181–185, 190, 192
Bias and Confounding, 137, 144
Biosafety and Biosecurity, 99, 112
Blinding (Masking), 82, 85, 90, 136–138, 144–145, 154–155, 158, 179, 184–185, 190, 192
BLS Primary Assessment and High-Quality CPR, 10
Bradycardia Algorithm, 31

C

Cardiac Arrest Algorithm, 20
Cardiac Arrest in Pregnancy, 46
Cardiac Arrest Rhythms: Shockable vs Non-Shockable, 16

Case-Control Study, 126, 128, 143–144, 176, 179, 190, 192
Categories of Laboratory SOPs, 102
Chain of Survival, 9–10, 13, 64, 68
Chest Compression Fraction (CCF), 12, 63
Chi-square, 171–173, 186–187, 191
Choosing a Study Design, 143
Choosing the Right Statistical Test, 186
Clinical Trial Lifecycle, 133
Closed-Loop Communication, 62, 64
Cohort Study, 126–128, 141, 143, 176–177, 182, 190, 192
Common Errors in Medical Statistics, 189
Common Statistical Software — Basics, 187
Competency Assessment, Staff, 103
Confidence Interval, 139–140, 142, 146–147, 168, 190–192
Corrective and Preventive Action (CAPA), 93–94, 99, 101–103, 109, 113–115, 117, 120–121, 123
Correlation and Regression, 161
Cox Proportional Hazards Regression, 174, 180
Cross-Sectional Study, 126, 128, 182

D

Data Integrity (ALCOA-C Principles), 88, 90–96, 107, 113, 116–117, 147, 150
Data Management in Clinical Trials, 149
Declaration of Helsinki, 71, 73, 76, 148
Defibrillation, 9–10, 15–17, 19–20, 24, 26, 38, 50, 60–61, 63–66, 68
Defibrillation and Cardioversion (overview), 19
Diagnostic Test Evaluation, 177
Document Control and Record Retention, 99, 122
Documentation and Debriefing After a Resuscitation Event, 63
Dopamine, 25, 33–34

E

ECG Rhythm Recognition Basics for ACLS, 17
Endpoint, 137, 140–141, 144, 152, 154–155
Endpoints in Clinical Trials, 140

Epinephrine, 15–16, 23–28, 30–31, 33–34, 50–51, 60–69

Equipment Qualification and Calibration, 99, 101–104, 109–112, 116–117, 120–121

Essential Components of an SOP, 101

Essential Documents and Trial Master File, 84–85, 88

Essential Requirements for Sample Transport, 108

Ethical Foundations of GCP, 74

Ethics Committee Oversight in Clinical Research, 148

External Quality Assessment (EQA) / Proficiency Testing, 99, 101–104, 109, 111, 115, 120–121, 123–124

F

Foreign-Body Airway Obstruction, 43, 57–58

G

Good Clinical Laboratory Practice (GCLP), 98–101, 105–113, 116–124

Good Clinical Practice (GCP), 71–77, 80–86, 88–89, 91–96, 100, 147–150, 157

H

Hypothermia, 15, 29, 50, 66

Hypothermic Cardiac Arrest, 66

Hypothesis Testing, 158, 169

I

ICH-GCP E6 (Core Principles), 73, 75, 81–82, 84–85, 96, 157

Informed Consent Process, 74, 79, 83

Institutional Review Board (IRB) / Independent Ethics Committee (IEC), 72–73, 76–87, 89, 91, 93–96, 148, 155

Internal Quality Control (IQC), 99, 101–104, 109–112, 115–116, 120–121, 123–124

Intraosseous (IO) Access, 9–10, 14–15, 23–31, 60–65

Introduction and Historical Background, 71

Introduction to Biostatistics, 158

Introduction to Clinical Research and the Evidence Hierarchy, 126

Investigational Product Management, 89

Investigator, Roles and Responsibilities, 74–78, 80–84, 86–87, 89, 94–96, 108–109, 116–117, 129–130, 136–137, 148, 150, 185, 190

K

Kaplan-Meier, 179–181

L

Landmark Clinical Trials That Shaped Modern Practice, 152

Lidocaine, 23–24, 26–27, 68

Logistic Regression, 174, 180

LVAD, 47

M

Magnesium sulfate, 38

Mann-Whitney, 171–172, 174, 186

Measures of Central Tendency, 158

Measures of Disease Frequency & Association, 176

Measures of Dispersion, 158

Meta-Analysis, 126, 138, 145–147, 154–155, 182

Method Validation and Verification, 99, 101, 103, 114, 118

Multivariate Analysis (Brief), 173

N

Naloxone, 25, 27, 29, 50, 68

Non-conformance (Laboratory), 99, 104–105, 109, 113–115, 117–118, 120, 122–123

Normal Distribution, 158, 163–165, 170–171

Normal Distribution & Other Probability Distributions, 158

Nuremberg Code, 71, 73, 148

O

Observational versus Experimental Studies, 129

Odds Ratio, 128, 139, 174, 176, 191

P

p-value, 139–140, 154–155, 168–169, 179–180, 187–190, 192

Paediatric Advanced Life Support (PALS) — Key Changes, 69

Pediatric and Neonatal Resuscitation — Key Differences, 51

Pharmacovigilance, 82, 133, 150, 155

Pharmacovigilance Basics, 150

Phases of Clinical Trials, 131

Post-Cardiac Arrest Care, 39

Pre-analytical Phase (Errors and Minimisation), 99, 106–107

Predictive Value, 177

Presentation of Data, 158

Primary Survey in Detail, 14

Procainamide, 25, 37–38, 68

Protocol Deviations vs Protocol Violations, 93

Q

Quality Assurance, 88–89, 99, 101–103

Quality Assurance vs Quality Control, 88–89, 99, 101–103

Quality Control, 88, 99, 101–103, 120, 159

Quality Management System (QMS), 76, 99–101, 104, 108–109, 112, 120

R

Randomization, 126, 128–129, 131, 135–138, 143, 153–154, 158, 184

Randomized Controlled Trial (RCT), 126–130, 135, 143, 153, 155, 174, 182–183

Reading & Critiquing Published Statistics, 188

Regulatory Framework for Clinical Research, 147

Relative Risk, 126, 128, 142, 176, 191

Reporting and Publication Standards, 151

Reversible Causes (H's and T's), 9, 13, 15, 23, 28, 31, 33, 60–62, 66

ROC Curve, 178

Role and Responsibilities of the Laboratory Director, 100

Role and Responsibilities of the Quality Assurance Department, 101

ROSC, 9–10, 18, 23–25, 27–31, 41–42, 44–45, 50, 64–65

S

Sample Size Calculation, 140–142, 158, 183

Sampling, 139, 142, 158, 165–168, 185

Screening & Bias, 178

Sensitivity, 114, 144, 147, 177–178, 180, 191–192

Serious Adverse Event (SAE), 85–87, 96

Skewed Distribution, 162

Sodium bicarbonate, 24, 29, 50

Special Resuscitation Situations, 45

Specificity, 114, 144, 177–178, 180, 191–192

Specimen Management, Workflow of, 99, 109

Specimen Rejection Criteria, 99, 107, 116

Standard Deviation, 103–104, 121, 140, 163, 191

Standard Error, 158, 168, 191

Standard Error & Confidence Intervals, 158

Standard Operating Procedure (SOP), 94, 99, 101–102, 104, 109–110, 112, 115–117, 119–120

Study Designs, 182

Study Protocol, 130

Survival Analysis, 158, 179–180

Synchronized Cardioversion, 19, 37–38, 64, 68

Systematic Review, 127, 145, 182

Systematic Reviews and Meta-Analysis Basics, 145

T

t-test, 160, 165, 169–174, 179, 186–187, 189

Tachycardia Algorithm, 34

Targeted temperature management, 9, 23, 31, 41

Team Dynamics and Communication, 61

Team Roles and Responsibilities, 62

Tests of Significance — Non-Parametric Tests, 171

Tests of Significance — Parametric Tests, 170

Torsades de Pointes, 24

Trial Registration and Transparency, 92

Tuskegee, 71, 73, 75

Types of Data & Scales of Measurement, 158

Types of Study Designs, 127

V

Vascular Access in Resuscitation, 26

Vasopressin, 25, 68

Vulnerable Populations in Research, 80

W

Waveform capnography, 14, 44, 62–64

Worked Case Scenario: VF Arrest Walkthrough, 30

Worked Case Study: A Documented GCP Violation and Its Consequences, 95

Worked Example: Designing a Simple Cohort Study, 141

Writing the Statistical Methods Section of a Protocol/Thesis, 185

MD/MS Mandatory Essentials

NMC-ALIGNED POSTGRADUATE REVISION RESOURCE

A focused companion for Amrita postgraduate medical students, bringing together the common certified learning requirements that complement specialty training and support eligibility for the final MD/MS examination.

ESSENTIAL AREAS

- Basic Cardiac Life Support
- Advanced Cardiac Life Support
- Good Clinical Practice
- Good Laboratory Practice
- Research Methodology
- Biostatistics

DESIGNED FOR RAPID REVISION

Clear explanations, examination-focused tables, clinical algorithms, process charts, common pitfalls and quick-reference summaries for theory, practical and viva preparation.



Mandatory learning • Confident practice • Safer care